<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults - Edwards Mayhew, RG - 2022 | Cochrane Library</title> <meta content="Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults - Edwards Mayhew, RG - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014831.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults - Edwards Mayhew, RG - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014831.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD014831.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults" name="citation_title"/> <meta content="Rebecca G Edwards Mayhew" name="citation_author"/> <meta content="University of Colorado Anschutz Medical Campus" name="citation_author_institution"/> <meta content="becca.edwards@cuanschutz.edu" name="citation_author_email"/> <meta content="Tianjing Li" name="citation_author"/> <meta content="University of Colorado Anschutz Medical Campus" name="citation_author_institution"/> <meta content="Paul McCann" name="citation_author"/> <meta content="University of Colorado Anschutz Medical Campus" name="citation_author_institution"/> <meta content="Louis Leslie" name="citation_author"/> <meta content="University of Colorado Anschutz Medical Campus" name="citation_author_institution"/> <meta content="Anne Strong Caldwell" name="citation_author"/> <meta content="University of Colorado Anschutz Medical Campus" name="citation_author_institution"/> <meta content="Alan G Palestine" name="citation_author"/> <meta content="University of Colorado Anschutz Medical Campus" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD014831.pub2" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/10/31" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014831.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014831.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014831.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Antirheumatic Agents [therapeutic use]; Azathioprine [therapeutic use]; Cyclosporine [therapeutic use]; Immunosuppressive Agents [therapeutic use]; Inflammation; *Macular Edema [etiology]; Methotrexate [therapeutic use]; Mycophenolic Acid [therapeutic use]; *Panuveitis [complications, drug therapy]; Steroids [therapeutic use]; Tacrolimus [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014831.pub2&amp;doi=10.1002/14651858.CD014831.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014831.pub2&amp;doi=10.1002/14651858.CD014831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014831.pub2&amp;doi=10.1002/14651858.CD014831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014831.pub2&amp;doi=10.1002/14651858.CD014831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014831.pub2&amp;doi=10.1002/14651858.CD014831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014831.pub2&amp;doi=10.1002/14651858.CD014831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014831.pub2&amp;doi=10.1002/14651858.CD014831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014831.pub2&amp;doi=10.1002/14651858.CD014831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014831.pub2&amp;doi=10.1002/14651858.CD014831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014831.pub2&amp;doi=10.1002/14651858.CD014831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014831.pub2&amp;doi=10.1002/14651858.CD014831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014831.pub2&amp;doi=10.1002/14651858.CD014831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014831.pub2&amp;doi=10.1002/14651858.CD014831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014831.pub2&amp;doi=10.1002/14651858.CD014831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014831.pub2&amp;doi=10.1002/14651858.CD014831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014831.pub2&amp;doi=10.1002/14651858.CD014831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014831.pub2&amp;doi=10.1002/14651858.CD014831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014831.pub2&amp;doi=10.1002/14651858.CD014831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014831.pub2&amp;doi=10.1002/14651858.CD014831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014831.pub2&amp;doi=10.1002/14651858.CD014831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014831.pub2&amp;doi=10.1002/14651858.CD014831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014831.pub2&amp;doi=10.1002/14651858.CD014831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014831.pub2&amp;doi=10.1002/14651858.CD014831.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="PMzGcYGP";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD014831\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD014831\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014831\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014831\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","fa","ko","fr","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD014831.pub2",title:"Non\\u2010biologic, steroid\\u2010sparing therapies for non\\u2010infectious intermediate, posterior, and panuveitis in adults",firstPublishedDate:"Oct 31, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Eyes and Vision Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PMzGcYGP&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014831.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD014831.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD014831.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD014831.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014831.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD014831.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;riskOfBias2&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Risk of Bias&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD014831.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD014831.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD014831.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD014831.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1541 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD014831.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014831.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014831.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014831.pub2/full#CD014831-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014831.pub2/full#CD014831-sec-0135"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014831.pub2/full#CD014831-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014831.pub2/full#CD014831-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014831.pub2/full#CD014831-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014831.pub2/full#CD014831-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014831.pub2/full#CD014831-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014831.pub2/full#CD014831-sec-0129"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014831.pub2/appendices#CD014831-sec-0140"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references#riskOfBias2"> Risk of bias </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/supinfo/CD014831StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/supinfo/CD014831StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014831.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014831.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014831.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD014831.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD014831.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD014831.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014831.pub2/information#CD014831-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Rebecca G Edwards Mayhew</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014831.pub2/information#CD014831-cr-0005">Tianjing Li</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014831.pub2/information#CD014831-cr-0006">Paul McCann</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014831.pub2/information#CD014831-cr-0007">Louis Leslie</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014831.pub2/information#CD014831-cr-0008">Anne Strong Caldwell</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014831.pub2/information#CD014831-cr-0009">Alan G Palestine</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/information/en#CD014831-sec-0151">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 31 October 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD014831.pub2">https://doi.org/10.1002/14651858.CD014831.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD014831-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD014831-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD014831-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD014831-abs-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD014831-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD014831-abs-0006">한국어</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD014831-abs-0001" lang="en"> <section id="CD014831-sec-0001"> <h3 class="title" id="CD014831-sec-0001">Background</h3> <p>Non‐infectious intermediate, posterior, and panuveitis (NIIPPU) represent a heterogenous collection of autoimmune and inflammatory disorders isolated to or concentrated in the posterior structures of the eye. Because NIIPPU is typically a chronic condition, people with NIIPPU frequently require treatment with steroid‐sparing immunosuppressive therapy. Methotrexate, mycophenolate, cyclosporine, azathioprine, and tacrolimus are non‐biologic, disease‐modifying antirheumatic drugs (DMARDs) which have been used to treat people with NIIPPU. </p> </section> <section id="CD014831-sec-0002"> <h3 class="title" id="CD014831-sec-0002">Objectives</h3> <p>To compare the effectiveness and safety of selected DMARDs (methotrexate, mycophenolate mofetil, tacrolimus, cyclosporine, and azathioprine) in the treatment of NIIPPU in adults. </p> </section> <section id="CD014831-sec-0003"> <h3 class="title" id="CD014831-sec-0003">Search methods</h3> <p>We searched CENTRAL (which contains the Cochrane Eyes and Vision Trials Register), MEDLINE, Embase, the Latin American and Caribbean Health Sciences database, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform, most recently on 16 April 2021. </p> </section> <section id="CD014831-sec-0004"> <h3 class="title" id="CD014831-sec-0004">Selection criteria</h3> <p>We included randomized controlled trials (RCTs) comparing selected DMARDs (methotrexate, mycophenolate, tacrolimus, cyclosporine, and azathioprine) with placebo, standard of care (topical steroids, with or without oral steroids), or with each other. </p> </section> <section id="CD014831-sec-0005"> <h3 class="title" id="CD014831-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane.</p> </section> <section id="CD014831-sec-0006"> <h3 class="title" id="CD014831-sec-0006">Main results</h3> <p>We included 11 RCTs with a total of 601 participants in this review.</p> <p><b>DMARDs versus control</b> </p> <p>Two studies compared an experimental DMARD (cyclosporine A or enteric‐coated mycophenolate [EC‐MPS]) plus oral steroid with steroid monotherapy. We did not pool these results into a meta‐analysis because the dose of cyclosporine used was much higher than that used in current clinical practice. The evidence is very uncertain about whether EC‐MPS plus low‐dose oral steroid results in a higher proportion of participants achieving control of inflammation over steroid monotherapy (risk ratio [RR] 2.81, 95% confidence interval [CI] 1.10 to 7.17; 1 study, 41 participants; very low‐certainty evidence). The change in best‐corrected visual acuity (BCVA) was reported separately for right and left eyes. The evidence for improvement (lower logarithm of the minimum angle of resolution (logMAR) indicates better vision) between the groups is very uncertain (mean difference [MD] ‐0.03 and ‐0.10, 95% CI ‐0.96 to 0.90 and ‐0.27 to 0.07 for right and left, respectively; 1 study, 82 eyes; very low‐certainty evidence). No data were available for the following outcomes: proportion of participants achieving a 2‐line improvement in visual acuity, with confirmed macular edema, or achieving steroid‐sparing control. The evidence for the proportion of participants requiring cessation of medication in the DMARD versus control group is very uncertain (RR 2.61, 95% CI 0.11 to 60.51; 1 study, 41 participants; very low‐certainty evidence). </p> <p><b>Methotrexate versus mycophenolate</b> </p> <p>We were able to combine two studies into a meta‐analysis comparing methotrexate versus mycophenolate mofetil. Methotrexate probably results in a slight increase in the proportion of participants achieving control of inflammation, including steroid‐sparing control, compared to mycophenolate at six months (RR 1.23, 95% CI 1.01 to 1.50; 2 studies, 261 participants; moderate‐certainty evidence). Change in BCVA was reported per eye and the treatments likely result in little to no difference in change in vision (MD 0.01 logMAR higher [worse] for methotrexate versus mycophenolate; 2 studies, 490 eyes; moderate‐certainty evidence). No data were available for the proportion of participants achieving a 2‐line improvement in visual acuity. The evidence is very uncertain regarding the proportion of participants with confirmed macular edema between methotrexate versus mycophenolate (RR 0.49, 95% CI 0.19 to 1.30; 2 studies, 35 eyes; very low‐certainty). Methotrexate versus mycophenolate may result in little to no difference in the proportion of participants requiring cessation of medication (RR 0.99, 95% CI 0.43 to 2.27; 2 studies, 296 participants; low‐certainty evidence). </p> <p><b>Steroids with or without azathioprine versus cyclosporine A</b> </p> <p>Four studies compared steroids with or without azathioprine (oral steroids, intravenous [IV] steroids, or azathioprine) to cyclosporine A. We excluded two studies from the meta‐analysis because the participants were treated with 8 mg to 15 mg/kg/day of cyclosporine A, a significantly higher dose than is utilized today because of concerns for nephrotoxicity. </p> <p>The remaining two studies were conducted in all Vogt‐Koyanagi‐Harada disease (VKH) populations and compared cyclosporine A to azathioprine or IV pulse‐dose steroids. The evidence is very uncertain for whether the steroids with or without azathioprine or cyclosporine A influenced the proportion of participants achieving control of inflammation (RR 0.84, 95% CI 0.70 to 1.02; 2 studies, 112 participants; very low‐certainty evidence), achieving steroid‐sparing control (RR 0.64, 95% CI 0.33 to 1.25; 1 study, 21 participants; very low‐certainty evidence), or requiring cessation of medication (RR 0.85, 95% 0.21 to 3.45; 2 studies, 91 participants; very low‐certainty evidence). The evidence is uncertain for improvement in BCVA (MD 0.04 logMAR lower [better] with the steroids with or without azathioprine versus cyclosporine A; 2 studies, 91 eyes; very low‐certainty evidence). There were no data available (with current cyclosporine A dosing) for the proportion of participants achieving a 2‐line improvement in visual acuity or with confirmed macular edema. </p> <p><b>Studies not included in synthesis</b> </p> <p>We were unable to include three studies in any of the comparisons (in addition to the aforementioned studies excluded based on historic doses of cyclosporine A). One was a dose‐response study comparing cyclosporine A to cyclosporine G, a formulation which was never licensed and is not clinically available. We excluded another study from meta‐analysis because it compared cyclosporine A and tacrolimus, considered to be of the same class (calcineurin inhibitors). We were unable to combine the third study, which examined tacrolimus monotherapy versus tacrolimus plus oral steroid, with any group. </p> </section> <section id="CD014831-sec-0007"> <h3 class="title" id="CD014831-sec-0007">Authors' conclusions</h3> <p>There is a paucity of data regarding which DMARD is most effective or safe in NIIPPU. Studies in general were small, heterogenous in terms of their design and outcome measures, and often did not compare different classes of DMARD with each other. Methotrexate is probably slightly more efficacious than mycophenolate in achieving control of inflammation, including steroid‐sparing control (moderate‐certainty evidence), although there was insufficient evidence to prefer one medication over the other in the VKH subgroup (very low‐certainty evidence). Methotrexate may result in little to no difference in safety outcomes compared to mycophenolate. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD014831-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD014831-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD014831-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD014831-abs-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD014831-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD014831-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD014831-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD014831-abs-0003">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD014831-abs-0002" lang="en"> <h3>Treatment of inflammatory conditions of the eye with medications</h3> <p><b>What was the aim of this review?</b> </p> <p>In this systematic review, we studied the available evidence on the effectiveness and safety of several medications used to treat a specific subset of inflammatory conditions of the back part of the eye. </p> <p><b>Key message</b> </p> <p>We found that the medication methotrexate may be slightly more effective than mycophenolate. Otherwise, there was no strong evidence to suggest one medication is more effective or safe than the others. </p> <p><b>What did we study in this review?</b> </p> <p>Non‐infectious intermediate, posterior, and panuveitis (NIIPPU) are a collection of several diseases which cause inflammation restricted to or including the back part of the eye. NIIPPU is not caused by an infection. NIIPPU is usually treated first with oral steroids, which tamp down the overactive immune system. However, because steroids have many other side effects when used over the long term, people with NIIPPU often require other immunosuppressive medications to control their disease. Several medications have been developed, but it is not clear which is most effective or safest for NIIPPU. This systematic review attempted to answer how safe and effective the medications methotrexate, mycophenolate, azathioprine, tacrolimus, and cyclosporine are for NIIPPU. </p> <p><b>What were the main results of this review?</b> </p> <p>The main result of this review is that the medication methotrexate may be slightly more effective than mycophenolate for the treatment of NIIPPU in terms of how many people had their disease controlled and were able to be weaned from (taken off) steroid medications. The two medications are likely similar in terms of their safety, but this evidence is not strong. There were not many other instances in which we could combine evidence from different studies. There is a general lack of data in this area, and we cannot draw any other conclusions regarding the superiority of one medication over the others in terms of safety or efficacy. </p> <p><b>What are the limitations of this review?</b> </p> <p>This review does not include biologic therapies, which are increasingly becoming the class of medications preferred by most doctors for treating inflammatory rheumatologic conditions such as NIIPPU. This review is also limited by the lack of large, randomized controlled trials (RCTs) in the field, wide differences in the available studies' design, and absence of studies comparing multiple medications head‐to‐head. </p> <p><b>How up to date is the review?</b> </p> <p>This study is up to date as of 16 April 2021.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD014831-sec-0135" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD014831-sec-0135"></div> <h3 class="title" id="CD014831-sec-0136">Implications for practice</h3> <section id="CD014831-sec-0136"> <p> <ul id="CD014831-list-0010"> <li> <p>Methotrexate may be more effective than mycophenolate in control of inflammation, including achievement of steroid‐sparing control, in non‐infectious intermediate, posterior, and panuveitis (NIIPPU). Otherwise, there is insufficient evidence to consider one non‐biologic, disease‐modifying antirheumatic drug (DMARD) more effective or safe than the others, or more effective or safe compared to systemic steroid therapy, in the treatment of NIIPPU. </p> </li> <li> <p>DMARDs are generally well‐tolerated and few patients require cessation of medication while on these therapies. </p> </li> </ul> </p> </section> <h3 class="title" id="CD014831-sec-0137">Implications for research</h3> <section id="CD014831-sec-0137"> <p> <ul id="CD014831-list-0011"> <li> <p>Significant heterogeneity exists in the NIIPPU literature in virtually every aspect of randomized controlled trials (RCTs): study design (active to control design versus remission to relapse design), study population (dependent on geographic location, with significant alterations in the proportion of people with Vogt‐Koyanagi‐Harada [VKH] disease included), length of follow‐up, outcome definition (control of inflammation, relapse), reporting of adverse events, and so on. Because studies of this relatively rare condition tend to be small, it would be useful to combine results into meta‐analyses. </p> </li> <li> <p>Standardization of outcome definitions would make synthesizing all evidence more feasible and valid. A core outcome set published in 2021 identified 16 outcomes of importance for studies of NIIPPU covering four domains: visual function, health‐related quality of life, treatment side effects, and disease control (<a href="./references#CD014831-bbs2-0055" title="TallouziMO , MathersJM , MooreDJ , BucknallN , CalvertMJ , COSUMO Working Group. Development of a Core Outcome Set for clinical trials in non-infectious uveitis of the posterior segment. Ophthalmology2021;128(8):1209-21. [DOI: 10.1016/j.ophtha.2021.01.022]">Tallouzi 2021</a>). This provides an important framework for future study design, but the authors acknowledge that many of the outcomes identified remain based on somewhat subjective clinician estimates. The optimal timing and method of measurement of these outcomes are also not codified. Furthermore, the issue of which outcomes to measure when comparing clinical activity between different conditions within NIIPPU (i.e. serous retinal detachments in VKH, retinal vasculitis in vasculitis subtypes) remains to be dealt with. </p> </li> <li> <p>Because diseases within NIIPPU have a wide variety of clinical presentations, with different features (vitreous cell, serous retinal detachment, enlargement of lesion size) indicating disease activity, it would be useful going forward to develop standardized, widely‐adopted definitions of clinical activity and inflammation control for various NIIPPU subtypes. </p> </li> <li> <p>There are significant gaps in the literature: there are few RCTs testing the same comparators or testing different DMARDs head‐to‐head. Clinical practice, therefore, is currently being based on small, single studies. Larger, multicenter studies testing DMARDs head‐to‐head are needed. </p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD014831-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD014831-sec-0008"></div> <div class="table" id="CD014831-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Non‐biologic disease‐modifying antirheumatic drugs (DMARDs) versus steroid for NIIPPU</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Non‐biologic disease‐modifying antirheumatic drugs (DMARDs) versus steroid for NIIPPU</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> NIIPPU </p> <p><b>Setting:</b> ophthalmology clinics (Netherlands, Germany) </p> <p><b>Intervention:</b> DMARDs (CsA, EC‐MPS plus steroid) </p> <p><b>Comparison:</b> control (placebo plus steroid or steroid alone) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Anticipated absolute effect (95% CI)</b><sup>*</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Relative effect (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Assumed risk with control</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Assumed risk with DMARDs</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants achieving control of inflammation</b> </p> <p>(higher number of events is better)</p> <p>Follow‐up: 0 to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 events per 100 participants</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 events per 100 participants</b> </p> <p>(2 to 100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.81</b> (95% CI 1.10 to 7.17) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>⊕⊝⊝⊝</b> </p> <p><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One study comparing CsA plus steroid with placebo plus steroid also reported this outcome but used CsA doses no longer in practice (<a href="./references#CD014831-bbs2-0003" title="De VriesJ , BaarsmaG , ZaalM , Boen-TanT , RothovaA , BuitenhuisH , et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. British Journal of Ophthalmology1990;74(6):344‐9. [CENTRAL: CN-00069296] [DOI: 10.1136/bjo.74.6.344]">De Vries 1990</a>); thus, we did not include it in meta‐analysis. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in BCVA</b> </p> <p>(lower logMAR indicate better vision)</p> <p>Follow‐up: 0 to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Right eyes MD ‐0.03 logMAR (95% CI ‐0.96 logMAR to 0.90 logMAR); Left eyes MD ‐0.10 logMAR (95% CI ‐0.27 logMAR to 0.07 logMAR) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82 eyes (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>⊕⊝⊝⊝</b> </p> <p><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants achieving a 2‐line improvement in visual acuity (Snellen chart)</b> </p> <p>(higher scores indicate better vision)</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No data were reported for this outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with confirmed macular edema</b> </p> <p>(lower number of events is better)</p> <p>Follow‐up: 0 to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No data were reported for this outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants achieving steroid‐sparing control</b> </p> <p>(higher number of events is better)</p> <p>Follow‐up: 0 to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No data were reported for this outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants experiencing complications or requiring cessation of medication</b> </p> <p>(lower number of events is better)</p> <p>Follow‐up: 0 to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>⊕⊝⊝⊝</b> </p> <p><b>Very low</b><sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One event reported in DMARDs group (RR 2.61, 95% CI 0.11 to 60.51). Another study reported this outcome but used CsA doses no longer in practice (<a href="./references#CD014831-bbs2-0003" title="De VriesJ , BaarsmaG , ZaalM , Boen-TanT , RothovaA , BuitenhuisH , et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. British Journal of Ophthalmology1990;74(6):344‐9. [CENTRAL: CN-00069296] [DOI: 10.1136/bjo.74.6.344]">De Vries 1990</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).</b> </p> <p><b>BCVA:</b> best‐corrected visual acuity; <b>CI:</b> confidence interval; <b>CsA:</b> cyclosporin A; <b>DMARD</b> : disease‐modifying antirheumatic drug;<b>EC‐MPS:</b> enteric‐coated mycophenolate sodium; <b>logMAR:</b> logarithm of the minimum angle of resolution;<b>MD:</b> mean difference; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SD:</b> standard deviation </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>The Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group grades of evidence:</b> <br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/><b>Very low certainty:</b> we are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded (‐2) for risk of bias (unclear risk of bias for the randomization process, deviations from intended interventions, and high risk of bias overall)<br/><sup>b</sup>Downgraded (‐1) for imprecision (small sample size)<br/><sup>c</sup>Downgraded (‐2) for risk of bias (unclear risk of bias for the randomization process and missing outcome data, and high risk of bias for measurement of outcome, selection of the reported result, and high risk of bias overall) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD014831-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Methotrexate versus mycophenolate for NIIPPU</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Mycophenolate versus methotrexate for NIIPPU</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> NIIPPU </p> <p><b>Setting:</b> ophthalmology clinics (India, United States, Australia, India, Mexico, Saudi Arabia) </p> <p><b>Intervention:</b> methotrexate </p> <p><b>Comparison:</b> mycophenolate </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="bottom"> <p><b>Anticipated absolute effect (95% CI)</b><sup>*</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Relative effect (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Assumed risk with mycophenolate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Assumed risk with methotrexate</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants achieving control of inflammation</b><sup>§</sup> </p> <p>(higher number of events is better)</p> <p>Follow‐up: 0 to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>55 events per 100 participants</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 events per 100 participants</b> (55 to 88) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.23</b> (1.01 to 1.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>261 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in BCVA</b> </p> <p>(lower logMAR indicate better vision)</p> <p>Follow‐up: 0 to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean BCVA score across the control group ranged from ‐0.12 to ‐0.19 logMAR</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>The mean logMAR was 0.01 higher (worse) on average</b><br/>(0.04 lower to 0.05 higher logMAR) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>490 eyes (2 RCTs)<sup>ɸ</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants achieving a 2‐line improvement in visual acuity (Snellen chart)</b> </p> <p>(higher scores indicate better vision)</p> <p>Follow‐up: 0 to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No data were reported for this outcome</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with confirmed macular edema</b> </p> <p>(lower number of events is better)</p> <p>Follow‐up: 0 to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>46 events per 100 participant eyes</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 events per 100 participant eyes</b> (9 to 60) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR</b> 0.49 (0.19 to 1.30) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 eyes (1 RCT)<sup>†</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>b,c</sup> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p> </p> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants achieving steroid‐sparing control</b><sup>§</sup> </p> <p>(higher number of events is better)</p> <p>Follow‐up: 0 to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>55 events per 100 participants</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 events per 100 participants</b> (55 to 88) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.23</b> (1.01 to 1.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>261 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants experiencing complications or requiring cessation of medication</b> </p> <p>(lower number of events is better)</p> <p>Follow‐up: 0 to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 events per 100 participants</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 events per 100 participants</b> (3 to 17) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.99</b> (0.43 to 2.27) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>296 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>a,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).</b> </p> <p><b>BCVA:</b> best‐corrected visual acuity; <b>CI:</b> confidence interval; <b>logMAR:</b> logarithm of the minimum angle of resolution;<b>MD:</b> mean difference; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SD:</b> standard deviation; <b>VKH:</b> Vogt‐Koyanagi‐Harada </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>The Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group grades of evidence:</b> <br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/><b>Very low certainty:</b> we are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>§</sup>Study primary outcome of steroid sparing control of inflammation defined as ≤ 0.5 + anterior chamber cells, ≤ 0.5 + vitreous cells, ≤ 0.5 + vitreous haze, and no active retinal or choroidal lesions; ≤ 2 drops of prednisolone acetate 1% a day in both studies and daily prednisolone ≤ 10 mg in one study and ≤ 7.5 mg/day in the other study<br/><sup>ɸ</sup>Visual acuity of uveitic eyes only<br/><sup>†</sup>Subgroup of VKH participants' eyes with macular edema at baseline<br/><br/><sup>a</sup>Downgraded (‐1) for imprecision (small sample size)<br/><sup>b</sup>Downgraded (‐1) for indirectness (single study subgroup of VKH in India)<br/><sup>c</sup>Downgraded (‐2) for serious imprecision (small sample size)<br/><sup>d</sup>Downgraded (‐1) for risk of bias (both studies have some concern for risk of bias in outcome measurement) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD014831-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Steroids with or without azathioprine versus cyclosporine A for NIIPPU</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Steroids with or without azathioprine versus cyclosporine A for NIIPPU</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> NIIPPU </p> <p><b>Setting:</b> ophthalmology clinics (Germany, Japan, Chile, USA) </p> <p><b>Intervention:</b> Steroids with or without azathioprine (oral steroids, IV steroids, or azathioprine) </p> <p><b>Comparison:</b> cyclosporine A (CsA) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="bottom"> <p><b>Anticipated absolute effect (95% CI)</b><sup>*</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Relative effect (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Assumed risk with cyclosporine A</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Assumed risk with steroids ± azathioprine</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants achieving control of inflammation</b> </p> <p>(higher number of events is better)</p> <p>Follow‐up: 0 to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>87 events per 100 participants</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>73 events per 100 participants</b> (61 to 88) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.84</b> (0.70 to 1.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112 (2 RCTs)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two other studies reported this outcome but used CsA doses no longer in practice (<a href="./references#CD014831-bbs2-0006" title="NussenblattRB , PalestineA , ChanCC , FujikawaLS , StevensG , GreenSB . A randomised, double-masked trial of sandimmune vs. prednisolone for endogenous uveitis. American Academy of Ophthalmology1990;112:105. [CENTRAL: CN-00485269] NussenblattRB , PalestineAG , ChanCC , StevensG , MellowSD , GreenSB . Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. American Journal of Ophthalmology1991;112(2):138‐46. [CENTRAL: CN-00077346] [DOI: 10.1016/s0002-9394(14)76692-9]">Nussenblatt 1991</a>; <a href="./references#CD014831-bbs2-0011" title="WiederholtM , KämpeC , HansenLL , HövenerG . Treatment of posterior uveitis with cyclosporin or prednisolone--one-year report of a randomized prospective study [Behandlung der uveitis posterior mit cyclosporin oder prednisolon--jahresbericht über eine randomisierte prospektive studie]. Fortschritte der Ophthalmologie1986;83(3):348‐52. [CENTRAL: CN-00044224] [EMBASE: 1986247564] [PMID: 3527903]">Wiederholt 1986</a>).  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in BCVA</b> </p> <p>(lower logMAR indicate better vision)</p> <p>Follow‐up: 0 to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean BCVA score across the CsA group ranged from ‐0.32 to ‐0.21 logMAR</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>The mean logMAR was 0.04 lower (better) on average</b><br/>(‐0.14 to 0.07 logMAR) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91 eyes (2 RCTs)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants achieving a 2‐line improvement in visual acuity (Snellen chart)</b> </p> <p>(higher scores indicate better vision)</p> <p>Follow‐up: 0 to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One study reported this outcome but used CsA doses no longer in practice (<a href="./references#CD014831-bbs2-0011" title="WiederholtM , KämpeC , HansenLL , HövenerG . Treatment of posterior uveitis with cyclosporin or prednisolone--one-year report of a randomized prospective study [Behandlung der uveitis posterior mit cyclosporin oder prednisolon--jahresbericht über eine randomisierte prospektive studie]. Fortschritte der Ophthalmologie1986;83(3):348‐52. [CENTRAL: CN-00044224] [EMBASE: 1986247564] [PMID: 3527903]">Wiederholt 1986</a>).  </p> <p> </p> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with confirmed macular edema</b> </p> <p>(lower number of events is better)</p> <p>Follow‐up: 0 to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One study reported this outcome but used CsA doses no longer in practice</p> <p> (<a href="./references#CD014831-bbs2-0006" title="NussenblattRB , PalestineA , ChanCC , FujikawaLS , StevensG , GreenSB . A randomised, double-masked trial of sandimmune vs. prednisolone for endogenous uveitis. American Academy of Ophthalmology1990;112:105. [CENTRAL: CN-00485269] NussenblattRB , PalestineAG , ChanCC , StevensG , MellowSD , GreenSB . Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. American Journal of Ophthalmology1991;112(2):138‐46. [CENTRAL: CN-00077346] [DOI: 10.1016/s0002-9394(14)76692-9]">Nussenblatt 1991</a>).  </p> <p> </p> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants achieving steroid‐sparing control</b> </p> <p>(higher number of events is better)</p> <p>Follow‐up: 0 to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>78 events per 100 participants</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 events per 100 participants</b> (26 to 97) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.64</b> (0.33 to 1.25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 (1 RCT)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants experiencing complications or requiring cessation of medication</b> </p> <p>(lower number of events is better)</p> <p>Follow‐up: 0 to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 events per 100 participants</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 events per 100 participants</b> (1 to 24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.85</b><br/>(0.21 to 3.45) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91 participants (2 RCTs)<sup>§</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One other study reported this outcome but used CsA doses no longer in practice (<a href="./references#CD014831-bbs2-0006" title="NussenblattRB , PalestineA , ChanCC , FujikawaLS , StevensG , GreenSB . A randomised, double-masked trial of sandimmune vs. prednisolone for endogenous uveitis. American Academy of Ophthalmology1990;112:105. [CENTRAL: CN-00485269] NussenblattRB , PalestineAG , ChanCC , StevensG , MellowSD , GreenSB . Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. American Journal of Ophthalmology1991;112(2):138‐46. [CENTRAL: CN-00077346] [DOI: 10.1016/s0002-9394(14)76692-9]">Nussenblatt 1991</a>).  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).</b> </p> <p><b>BCVA:</b> best‐corrected visual acuity; <b>CI:</b> confidence interval; <b>CsA</b> : cyclosporin A; <b>IV:</b> intravenous<b>logMAR:</b> logarithm of the minimum angle of resolution;<b>MD:</b> mean difference; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SD:</b> standard deviation; <b>VKH:</b> Vogt‐Koyanagi‐Harada </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>The Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group grades of evidence:</b> <br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/><b>Very low certainty:</b> we are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded (‐2) for risk of bias (one or more studies with unclear or high risk of bias overall, randomization process, deviations from intended interventions)<br/><sup>b</sup>Downgraded (‐1) for imprecision (small sample size)<br/><sup>c</sup>Downgraded (‐1) for indirectness (VKH not representative of all NIIPPU) </p> <p><sup>§</sup>Only VKH participants </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD014831-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD014831-sec-0009"></div> <section id="CD014831-sec-0010"> <h3 class="title" id="CD014831-sec-0010">Description of the condition</h3> <p>Uveitis (inflammation of the middle layer of the eye) is one of the main causes of visual morbidity, specifically in the working‐age population (<a href="./references#CD014831-bbs2-0030" title="DurraniOM , TehraniNN , MarrJE , MoradiP , StavrouP , MurrayPI . Degree, duration, and causes of visual loss in uveitis. British Journal of Ophthalmology2004;88(9):1159-62. [DOI: 10.1136/bjo.2003.037226]">Durrani 2004</a>). The incidence of uveitis in high‐income countries is estimated to be between 17 and 52 per 100,000 people per year, and the prevalence is estimated to be between 38 and 714 cases per 100,000 people (<a href="./references#CD014831-bbs2-0056" title="TsiroukiT , DastiridouA , SymeonidisC , TounakakiO , BrazitikouI , KalogeropoulosC , et al. A focus on the epidemiology of uveitis. Ocular Immunology and Inflammation2018;26(1):2-16. [DOI: 10.1080/09273948.2016.1196713]">Tsirouki 2018</a>). Uveitis involves inflammation of the vascularized uveal tissues of the eye — the iris, ciliary body, and choroid — along with neighboring tissues, including the retina, vitreous, and optic nerve. As its name suggests, non‐infectious intermediate, posterior, and panuveitis (NIIPPU) represent a collection of anatomically‐defined, heterogeneous inflammatory conditions, rather than a single clinical entity. NIIPPU includes inflammation secondary to isolated, well‐described uveitic conditions; inflammation associated with systemic autoimmune conditions such as Behçet’s disease, the spondyloarthropathies, and sarcoidosis; and idiopathic disease. The heterogeneity of these conditions and uncertainty about their pathophysiologic causes present a challenge for both treatment and research. Although these diseases are classified by phenotype and anatomic location, it is not clear that they are truly separate entities. Even well‐defined clinical entities, such as sarcoidosis, are probably heterogeneous responses to a variety of unknown processes, rather than a single disease. </p> <p>According to the Standardization of Uveitis Nomenclature (SUN) Working Group, intermediate uveitis is defined by primary inflammation of the vitreous, including inflammation of the vitreous also involving the peripheral retina (<a href="./references#CD014831-bbs2-0039" title="JabsDA , NussenblattRB , RosenbaumJT . Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. American Journal of Ophthalmology2005;140(3):509-16. [DOI: 10.1016/j.ajo.2005.03.057]">Jabs 2005</a>). Globally, intermediate uveitis is estimated to comprise approximately 15% of all uveitides (<a href="./references#CD014831-bbs2-0056" title="TsiroukiT , DastiridouA , SymeonidisC , TounakakiO , BrazitikouI , KalogeropoulosC , et al. A focus on the epidemiology of uveitis. Ocular Immunology and Inflammation2018;26(1):2-16. [DOI: 10.1080/09273948.2016.1196713]">Tsirouki 2018</a>). Pars planitis, posterior cyclitis, and hyalitis are all described variants of intermediate uveitis, according to this definition. Non‐infectious intermediate uveitis is associated with a variety of systemic conditions, including sarcoidosis, multiple sclerosis, and inflammatory bowel disease, although the vast majority of intermediate uveitis is idiopathic, at least in high‐income countries (<a href="./references#CD014831-bbs2-0056" title="TsiroukiT , DastiridouA , SymeonidisC , TounakakiO , BrazitikouI , KalogeropoulosC , et al. A focus on the epidemiology of uveitis. Ocular Immunology and Inflammation2018;26(1):2-16. [DOI: 10.1080/09273948.2016.1196713]">Tsirouki 2018</a>). People with intermediate uveitis are typically aged 15 to 40 and may present with floaters and decreased or blurry vision. Inflammatory cells, typically T cells, localized in the anterior vitreous are a characteristic finding, along with vitreous condensations and focal collections of inflammatory cells ('snowballs'), fibrovascular peripheral plaques ('snowbanks'), and peripheral periphlebitis. </p> <p>Like intermediate uveitis, the majority of non‐infectious posterior uveitis, which primarily affects the retina and choroid, is idiopathic: that is, it is not found in conjunction with a systemic disease. Posterior uveitis can primarily affect the retina (retinitis), the choroid (choroiditis), some combination of the two (chorioretinitis or retinochoroiditis), and may variably involve inflammation of the optic nerve as well (neuroretinitis). Common non‐infectious associations with posterior uveitis include sarcoidosis, birdshot chorioretinopathy, and Behçet's disease. Panuveitis, in which people develop inflammation of the anterior chamber, vitreous, and retina or choroid, is also frequently seen in Behçet’s disease, sarcoidosis, and Vogt‐Koyanagi‐Harada (VKH) disease. As many of these conditions are associated with specific human leukocyte antigen haplotypes, it is not surprising that their incidence varies dramatically between countries: for instance, VKH panuveitis is rare in Europe and common in Asia (<a href="./references#CD014831-bbs2-0056" title="TsiroukiT , DastiridouA , SymeonidisC , TounakakiO , BrazitikouI , KalogeropoulosC , et al. A focus on the epidemiology of uveitis. Ocular Immunology and Inflammation2018;26(1):2-16. [DOI: 10.1080/09273948.2016.1196713]">Tsirouki 2018</a>). A wide spectrum of clinical signs may be seen in the posterior pole in posterior and panuveitis, including cystoid macular edema, choroidal and retinal exudates, retinal hemorrhages, periphlebitis, disc edema, and choroidal neovascularization. People with posterior and panuveitis may present with decreased vision, eye pain or redness, floaters, flashes, and photophobia. </p> <p>To date, our understanding of the pathophysiology of NIIPPU remains incomplete. It is likely that both autoinflammatory and autoimmune processes play a role. Some of these diseases are thought to be driven by autoinflammation, caused by unwarranted activation of effectors of the innate immune system, namely myeloid cells, with or without the influence of the cytokine interleukin‐1 (IL‐1) (<a href="./references#CD014831-bbs2-0045" title="LeeRW , NicholsonLB , SenHN , ChanCC , WeiL , NussenblattRB , et al. Autoimmune and autoinflammatory mechanisms in uveitis. Seminars in Immunopathology2014;36(5):581-94. [DOI: 10.1007/s00281-014-0433-9]">Lee 2014</a>). Other subtypes of NIIPPU, including VKH syndrome, seem to be autoimmune in nature, arising from a dysregulated cellular or humoral response to autoantigens found in ocular tissues themselves (<a href="./references#CD014831-bbs2-0054" title="SugitaS , TakaseH , TaguchiC , ImaiY , KamoiK , KawaguchiT , et al. Ocular infiltrating CD4+ T cells from patients with Vogt-Koyanagi-Harada disease recognize human melanocyte antigens. Investigative Ophthalmology and Visual Science2006;47(6):2547-54. [DOI: 10.1167/iovs.05-1547]">Sugita 2006</a>). It is likely that infectious agents, in certain situations, act as the spark that ignites a susceptible host into a dysregulated immune response, further complicating the question of who develops uveitis, and why. A variety of cytokines and immune mediators has been identified in the eye during intermediate and posterior uveitis, including IL‐1, IL‐2, IL‐6, tumor necrosis factor (TNF‐α), interferon gamma (IFN‐γ), as well as CD4<sup>+</sup> and CD8<sup>+</sup> T cells, natural killer (NK) cells, B cells, and myeloid lineage cells (<a href="./references#CD014831-bbs2-0023" title="BoydSR , YoungS , LightmanS . Immunopathology of the noninfectious posterior and intermediate uveitides. Survey of Ophthalmology2001;46(3):209-33. [DOI: 10.1016/s0039-6257(01)00275-2]">Boyd 2001</a>). Elevated levels of IL‐17A have been identified in the serum of people with uveitis and sarcoidosis (<a href="./references#CD014831-bbs2-0040" title="JawadS , LiuB , AgronE , NussenblattRB , SenHN . Elevated serum levels of interleukin-17A in uveitis patients. Ocular Immunology and Inflammation2013;21(6):434-9. [DOI: 10.3109/09273948.2013.815786]">Jawad 2013</a>), and animal models of uveitis supported a role for this cytokine in disease (<a href="./references#CD014831-bbs2-0024" title="ChiW , ZhouS , YangP , ChenL . CD4⁺ T cells from behcet patients produce high levels of IL-17. Eye Science2011;26(2):65-9. [DOI: 10.3969/j.issn.1000-4432.2011.02.013]">Chi 2011</a>; <a href="./references#CD014831-bbs2-0058" title="ZhangR , QianJ , GuoJ , YuanYF , XueK . Suppression of experimental autoimmune uveoretinitis by Anti-IL-17 antibody. Current Eye Research2009;34(4):297-303. [DOI: 10.1080/02713680902741696]">Zhang 2009</a>). However, secukinumab, a human monoclonal anti‐IL‐17 antibody, failed in three randomized controlled trials (RCTs) in people with NIIPPU (<a href="./references#CD014831-bbs2-0028" title="DickAD , Tugal-TutkunI , FosterS , ZierhutM , Melissa LiewSH , BezlyakV , et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology2013;120(4):777-87. [DOI: 10.1016/j.ophtha.2012.09.040]">Dick 2013</a>), underscoring the tenuous connection that observational and animal data have to this complex human disease. </p> <p>In general, people with NIIPPU suffer vision‐limiting sequelae, including cataracts, glaucoma, and retinopathy, that often necessitate surgical management. Some of these problems are caused by recurrent episodes of inflammation, but many are secondary to long‐term steroid use, the traditional mainstay of treatment. Uveitic eyes are often more surgically complex and have been shown to have higher rates of postoperative complications than non‐uveitic eyes (<a href="./references#CD014831-bbs2-0025" title="ChuCJ , DickAD , JohnstonRL , YangYC , DennistonAK , UK Pseudophakic Macular Edema Study Group. Cataract surgery in uveitis: a multicentre database study. British Journal of Ophthalmology2017;101(8):1132. [DOI: 10.1136/bjophthalmol-2016-309047]">Chu 2017</a>). Steroids are powerful, broad‐spectrum immunosuppressants — in some ways, an ideal choice for a group of diseases with a poorly understood pathophysiology and likely disparate etiologies. Because steroids effectively suppress both the innate and adaptive immune system, are reasonably well‐tolerated (at least in the short term), and are inexpensive and widely available, they will likely always be first‐line therapy for people with uveitis. However, given the chronicity of many forms of uveitis, it is necessary to find other treatment modalities that spare people the side effects of steroids. Monoclonal antibody treatments, including anti‐TNF and anti‐IL‐6 agents, have been studied in several RCTs. A non‐Cochrane meta‐analysis assessed three RCTs of anti‐TNF agents in people with NIIPPU, finding high‐quality evidence that adalimumab reduces the risk of decreased best‐corrected visual acuity (<a href="./references#CD014831-bbs2-0044" title="LealI , RodriguesFB , SousaDC , DuarteGS , RomãoVC , Marques-NevesC , et al. Anti-TNF drugs for chronic uveitis in adults - a systematic review and meta-analysis of randomized controlled trials. Frontiers in Medicine2019;6:104. [DOI: 10.3389/fmed.2019.00104]">Leal 2019</a>). However, non‐biologic, immune‐modifying therapies, such as methotrexate, mycophenolate, cyclosporine, tacrolimus, and azathioprine, are often used as first‐line, steroid‐sparing agents. In many resource‐limited countries, these may be the only medications available as an alternative to chronic steroids, as biologics as a class remain expensive. </p> </section> <section id="CD014831-sec-0011"> <h3 class="title" id="CD014831-sec-0011">Description of the intervention</h3> <p>This review focused on the following non‐biologic, immune‐modifying therapies: methotrexate, mycophenolate, cyclosporine, tacrolimus, and azathioprine. We selected these non‐biologic, disease‐modifying antirheumatic drugs (DMARDs) for review because they are the agents most utilized in clinical practice due to their cost and perceived efficacy. None of these medications are approved by the US Food and Drug Administration for usage in NIIPPU. </p> <p>Methotrexate, a folate antimetabolite, has a long history of use in cancer treatment. At high doses, it inhibits multiple enzymes involved in DNA synthesis, specifically those involved in critical steps in the production of purines and pyrimidines. However, at lower doses, methotrexate is efficacious for a number of inflammatory diseases, including psoriasis, rheumatoid arthritis, and inflammatory bowel disease. This may be due to suppression of lymphoproliferation by the drug, although alternate immunomodulatory functions are also likely, given that co‐administration of folate to people on methotrexate often ameliorates side effects without decreasing the drug’s efficacy (<a href="./references#CD014831-bbs2-0049" title="OrtizZ , SheaB , Suarez-AlmazorME , MoherD , WellsGA , TugwellP . The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A meta-analysis of randomized controlled trials. Journal of Rheumatology1998;25(1):36-43. [PMID: 9458200]">Ortiz 1998</a>), a finding further supported by animal models (<a href="./references#CD014831-bbs2-0035" title="Graffner-NordbergM , FyfeM , BrattsandR , MellgårdB , HallbergA . Design and synthesis of dihydrofolate reductase inhibitors encompassing a bridging ester group. Evaluation in a mouse colitis model. Journal of Medicinal Chemistry2003;46(16):3455-62. [DOI: 10.1021/jm021062y]">Graffner‐Nordberg 2003</a>). The most common side effects of low‐dose methotrexate include gastrointestinal upset, stomatitis, headache, and fatigue. Hepatotoxicity and, more rarely, severe myelosuppression, may also occur. </p> <p>Mycophenolate mofetil is another antimetabolite, inhibiting synthesis of the purine guanosine, required for the production of DNA and RNA. Lymphocytes are unable to generate guanosine‐derived nucleotides from alternate pathways, requiring de novo synthesis of these molecules in order to proliferate. Therefore, mycophenolate mofetil is a potent and selective inhibitor of B cells, CD4<sup>+</sup> and CD8<sup>+</sup> lymphocytes, and dendritic cells (<a href="./references#CD014831-bbs2-0021" title="AllisonAC . Mechanisms of action of mycophenolate mofetil in preventing chronic rejection. Transplantation Proceedings2002;34(7):2863-6. [DOI: 10.1016/s0041-1345(02)03538-8]">Allison 2002</a>). The most common adverse effect of mycophenolate mofetil is persistent diarrhea; the most serious is cytopenia, for which people must undergo regular monitoring of blood counts. </p> <p>Azathioprine, a prodrug converted to its active form by glutathione in red blood cells, also inhibits purine synthesis. Inhibition of DNA and RNA synthesis in B and T cells reduces the number of circulating lymphocytes, the production of immunoglobulins, and the secretion of IL‐2 (<a href="./references#CD014831-bbs2-0022" title="BaconPA , SalmonM . Modes of action of second-line agents. Scandinavian Journal of Rheumatology1987;16(Suppl 64):17-24. [DOI: 10.3109/03009748709096717]">Bacon 1987</a>). Common adverse effects of azathioprine include anorexia, nausea, and vomiting. A small increase in the risk of malignancy, particularly lymphoma, has been reported in people with inflammatory bowel disease treated with azathioprine (<a href="./references#CD014831-bbs2-0041" title="KandielA , FraserAG , KorelitzBI , BrensingerC , LewisJD . Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut2005;54(8):1121-5. [DOI: 10.1136/gut.2004.049460]">Kandiel 2005</a>). </p> <p>Tacrolimus and cyclosporine are fungally‐derived calcineurin receptor inhibitors. By forming complexes with other receptors, these molecules block calcineurin signaling, preventing T cell activation, and limiting their proliferation and production of IL‐2, IL‐6, IFN‐γ, and TNF‐α, among others. Both of these agents were previously thought to lack any clinically significant myelosuppressive activity (<a href="./references#CD014831-bbs2-0038" title="IshidaY , MatsudaH , KidaK . Effect of cyclosporin A on human bone marrow granulocyte-macrophage progenitors with anti-cancer agents. Acta Paediatrica Japonica : Overseas Edition1995;37(5):610-3. [DOI: 10.1111/j.1442-200x.1995.tb03386.x]">Ishida 1995</a>), although there is evidence that tacrolimus also inhibits B cells, dendritic cells, and macrophages (<a href="./references#CD014831-bbs2-0057" title="Van DierenJM , KuipersEJ , SamsomJN , NieuwenhuisEE , Van der WoudeCJ . Revisiting the immunomodulators tacrolimus, methotrexate, and mycophenolate mofetil: their mechanisms of action and role in the treatment of IBD. Inflammatory Bowel Diseases2006;12(4):311-27. [DOI: 10.1097/01.MIB.0000209787.19952.53]">van Dieren 2006</a>). The most serious adverse effect of calcineurin inhibitors is nephrotoxicity: both reversible, acute kidney injury and irreversible chronic, progressive renal damage may occur. </p> </section> <section id="CD014831-sec-0012"> <h3 class="title" id="CD014831-sec-0012">How the intervention might work</h3> <p>Given the importance of both cellular and humoral immunity in the pathogenesis of NIIPPU, non‐biologic, steroid‐sparing therapies are thought to suppress the lymphocytes, myeloid cells, and cytokines responsible for the aberrant immune response central to these diseases. </p> </section> <section id="CD014831-sec-0013"> <h3 class="title" id="CD014831-sec-0013">Why it is important to do this review</h3> <p>Although there have been several RCTs studying non‐biologic, steroid‐sparing therapies in NIIPPU, heterogeneity in outcomes, study design, and participants has made it difficult to draw comparisons between publications. A rigorous systematic review of these agents may provide insights into which medication is most efficacious or best tolerated, providing a useful resource for both clinicians and people with uveitis. Gaps in the data which are identified through this review could be equally informative, providing guidance on experimental design or outcomes that should be taken into consideration in future studies. By selecting agents which are widely accessible and inexpensive, this review aims to be relevant to ophthalmologists globally. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD014831-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD014831-sec-0014"></div> <p>To compare the effectiveness and safety of selected DMARDs (methotrexate, mycophenolate mofetil, tacrolimus, cyclosporine, and azathioprine) in the treatment of NIIPPU in adults. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD014831-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD014831-sec-0015"></div> <section id="CD014831-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD014831-sec-0017"> <h4 class="title">Types of studies</h4> <p>This review included only RCTs.</p> </section> <section id="CD014831-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included trials in which the investigators enrolled individuals with NIIPPU, as defined by the SUN criteria (<a href="./references#CD014831-bbs2-0039" title="JabsDA , NussenblattRB , RosenbaumJT . Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. American Journal of Ophthalmology2005;140(3):509-16. [DOI: 10.1016/j.ajo.2005.03.057]">Jabs 2005</a>). We planned on including trials with adult participants only (age 18 and over) (<a href="./references#CD014831-bbs2-0059" title="Edwards MayhewR , KhachatryanN , LiT , PalestineA . Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults. Cochrane Database of Systematic Reviews2021, Issue 3. Art. No: CD014831. [DOI: 10.1002/14651858.CD014831]">Edwards Mayhew 2021</a>). We changed this to include trials with a mix of adults, adolescents, and children but excluded trials where all participants were under 18 years old (<a href="#CD014831-sec-0155">Differences between protocol and review</a>). We excluded trials in which: (i) participants had uveitis of infectious origin; (ii) participants were on combination therapy with multiple steroid‐sparing agents, or (iii) participants were either currently on biologic therapy or had been within the past six months. </p> </section> <section id="CD014831-sec-0019"> <h4 class="title">Types of interventions</h4> <p>The original pharmacologic interventions included the following DMARDs, alone or in combination with topical or oral steroid therapy: </p> <p> <ul id="CD014831-list-0001"> <li> <p>methotrexate, a folate antimetabolite;</p> </li> <li> <p>mycophenolate mofetil, an inhibitor of purine synthesis;</p> </li> <li> <p>azathioprine, a purine antimetabolite;</p> </li> <li> <p>cyclosporine, a fungally‐derived calcineurin inhibitor; and</p> </li> <li> <p>tacrolimus, a macrolide inhibitor of T cells.</p> </li> </ul> </p> <p>We compared each steroid‐sparing therapy described above with placebo or with standard of care (e.g. topical steroids, with or without systemic steroids), or with each other. We decided comparisons of the same DMARD (tacrolimus versus tacrolimus) or overlapping mechanism of action (tacrolimus versus cyclosporine) were not of interest for this review (<a href="#CD014831-sec-0155">Differences between protocol and review</a>). </p> </section> <section id="CD014831-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD014831-sec-0021"> <h5 class="title">Critical outcomes</h5> <p> <ul id="CD014831-list-0002"> <li> <p>Proportion of participants achieving control of inflammation, defined as a two‐step reduction in vitreous haze grade/score or decrease to grade 0 (<a href="./references#CD014831-bbs2-0039" title="JabsDA , NussenblattRB , RosenbaumJT . Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. American Journal of Ophthalmology2005;140(3):509-16. [DOI: 10.1016/j.ajo.2005.03.057]">Jabs 2005</a>; <a href="./references#CD014831-bbs2-0048" title="NussenblattRB , PalestineAG , ChanCC , RobergeF . Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology1985;92(4):467-71. [DOI: 10.1016/s0161-6420(85)34001-0] [PMID: 4000641]">Nussenblatt 1985</a>); or clinically comparable study definition </p> </li> <li> <p>Change in best corrected visual acuity (BCVA), measured as a continuous outcome on a logMAR (logarithm of the minimum angle of resolution) chart (or equivalent) </p> </li> <li> <p>Proportion of participants achieving a 2‐line improvement in visual acuity (Snellen chart) </p> </li> <li> <p>Proportion of participants with macular edema, confirmed by optical coherence tomography (OCT) (macular thickness, at the center point ≥ 240 μm) or by fluorescein angiogram (macular leakage ≥ 0.44 disc areas) or by slit‐lamp biomicroscopy through a dilated pupil </p> </li> </ul> </p> <p>Key time points for these outcomes include follow‐up at six and 12 months.</p> </section> <section id="CD014831-sec-0022"> <h5 class="title">Important outcomes</h5> <p> <ul id="CD014831-list-0003"> <li> <p>Mean time to relapse</p> </li> <li> <p>Reduction in cumulative hazard of disease relapse</p> </li> <li> <p>Proportion of participants with change in anterior chamber flare and cells, as defined by the SUN Working Group (<a href="./references#CD014831-bbs2-0039" title="JabsDA , NussenblattRB , RosenbaumJT . Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. American Journal of Ophthalmology2005;140(3):509-16. [DOI: 10.1016/j.ajo.2005.03.057]">Jabs 2005</a>) </p> </li> <li> <p>Mean change in central macular thickness (CMT), measured in microns on OCT imaging</p> </li> <li> <p>Change (resolution, yes/no) in other activity domains, including vitreous cells; vitreous 'snow‐balls'; chorioretinal inflammatory lesions; and retinovascular inflammation </p> </li> <li> <p>Proportion of participants to achieve steroid‐sparing control</p> </li> <li> <p>Proportion of participants to achieve reduction in oral steroid dose (to &lt; 10 mg/day)</p> </li> <li> <p>Cost‐effectiveness, e.g. the incremental cost‐effectiveness ratio (ICER)</p> </li> <li> <p>Mean change in vision‐related quality of life, measured using the Visual Function Questionnaire 25 (VFQ‐25), or other validated questionnaire (<a href="./references#CD014831-bbs2-0046" title="MangioneCM , LeePP , GutierrezPR , SpritzerK , BerryS , HaysRD . Development of the 25-item National Eye Institute Visual Function Questionnaire. Archives of Ophthalmology (Chicago, Ill. : 1960)2001;119(7):1050-8. [PMID: 11448327]">Mangione 2001</a>) </p> </li> <li> <p>Mean change in general health‐related quality of life (HRQoL), measured using the EuroQoL five dimensions questionnaire (EQ‐5D), or other validated questionnaire </p> </li> <li> <p>Adverse events:</p> <ul id="CD014831-list-0004"> <li> <p>Proportion of participants experiencing any adverse effects, including ocular and systemic complications </p> </li> <li> <p>Proportion of participants experiencing complications or requiring cessation of medication, such as bone marrow suppression (absolute neutrophil count [ANC] &lt; 1500 cells/μL), hepatotoxicity (elevation in liver enzyme alanine transaminase [ALT] &gt; 45 IU/L in men and ALT &gt; 35 IU/L in women), as well as severe allergic reaction </p> </li> <li> <p>Proportion of participants experiencing ocular complications, including elevated eye pressure (≥ 21 mmHg), lens opacity, hypotony, choroidal neovascular membrane </p> </li> </ul> </li> </ul> </p> <p>We used the same time points as above for the critical outcomes (six and 12 months).</p> </section> </section> </section> <section id="CD014831-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD014831-sec-0024"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Eyes and Vision (CEV) Information Specialist searched the following electronic databases for RCTs on 16 April 2021. There were no restrictions by language or year of publication. </p> <p> <ul id="CD014831-list-0005"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register) in the Cochrane Library (Issue 4) (<a href="./appendices#CD014831-sec-0141">Appendix 1</a>) </p> </li> <li> <p>MEDLINE Ovid (1946 to 16 April 2021) (<a href="./appendices#CD014831-sec-0142">Appendix 2</a>) </p> </li> <li> <p>Embase.com (1947 to 16 April 2021) (<a href="./appendices#CD014831-sec-0143">Appendix 3</a>) </p> </li> <li> <p>PubMed (1946 to 16 April 2021) (<a href="./appendices#CD014831-sec-0144">Appendix 4</a>) </p> </li> <li> <p>Latin American and Caribbean Health Sciences Literature Database (LILACS) (1982 to 16 April 2021) (<a href="./appendices#CD014831-sec-0145">Appendix 5</a>) </p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>) (<a href="./appendices#CD014831-sec-0146">Appendix 6</a>) </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="http://www.who.int/ictrp" target="_blank">www.who.int/ictrp</a>) (<a href="./appendices#CD014831-sec-0147">Appendix 7</a>) </p> </li> </ul> </p> </section> <section id="CD014831-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We handsearched the references of included studies, review articles, and guidelines for additional trials. We did not search conference abstracts as many eyes and vision conference abstracts are included in Embase, which was searched as part of our electronic search. </p> </section> </section> <section id="CD014831-sec-0026"> <h3 class="title" id="CD014831-sec-0026">Data collection and analysis</h3> <section id="CD014831-sec-0027"> <h4 class="title">Selection of studies</h4> <p>The Information Specialist removed duplicate references and imported the search results into the web‐based review management software <a href="./references#CD014831-bbs2-0026" title="Covidence. Version accessed 13 March 2022. Melbourne, Australia: Veritas Health Innovation. Available at covidence.org.">Covidence</a>. Review authors (REM, PMcC, LL, ASC) worked in pairs to independently screen titles and abstracts using <a href="./references#CD014831-bbs2-0026" title="Covidence. Version accessed 13 March 2022. Melbourne, Australia: Veritas Health Innovation. Available at covidence.org.">Covidence</a>. Based on the eligibility criteria, we classified each record as 'relevant', 'possibly relevant', and 'not relevant' for further full‐text review. We then retrieved the full‐text articles for records considered 'relevant' or 'possibly relevant'. Review authors (REM, PMcC, LL) worked in pairs to independently screen the full‐text articles for eligibility and classified articles as 'to be included' or 'to be excluded'. When there were questions regarding the eligibility of the studies, we contacted the authors of the studies to obtain additional information. If the authors did not respond within two weeks, we used information available from publications and trial registries to determine eligibility. For non‐English studies, we used GoogleTranslate. We recorded reasons for exclusion of full‐text reports in the <a href="./references#CD014831-sec-0163" title="">Characteristics of excluded studies</a> table. We also classified eligible studies that had not yet been completed as 'ongoing'. In contrast, we classified eligible studies whose results were unavailable as 'awaiting classification'. In case of any disagreement or discrepancies regarding the classification of the studies, we adjudicated via discussion with the senior authors (AP or TL). We did not exclude studies on the basis of outcomes reported or study status. </p> </section> <section id="CD014831-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>We used <a href="./references#CD014831-bbs2-0026" title="Covidence. Version accessed 13 March 2022. Melbourne, Australia: Veritas Health Innovation. Available at covidence.org.">Covidence</a> for data extraction. Review authors (REM, PMcC, LL) independently extracted data from the selected full‐text articles, including the following information: study setting, countries where participant recruitment took place, study design, sample size, study duration (planned and actual), participants, interventions, comparators, outcomes, sources of funding, and potential conflicts of interests (<a href="./appendices#CD014831-sec-0148">Appendix 8</a>). Where data were only available in graphical displays, two review authors independently extracted the data using <a href="./references#CD014831-bbs2-0031" title="GetData Graph Digitizer 2.24. S. Fedorov, accessed 17 August 2020. Available at getdata-graph-digitizer.com.">GetData Graph Digitizer 2.24</a>. One review author (LL) exported data from <a href="./references#CD014831-bbs2-0026" title="Covidence. Version accessed 13 March 2022. Melbourne, Australia: Veritas Health Innovation. Available at covidence.org.">Covidence</a> into RevMan Web (<a href="./references#CD014831-bbs2-0052" title="Review Manager Web (RevMan Web). Version 1.22.0. The Cochrane Collaboration, 2020. Available at revman.cochrane.org.">Review Manager Web 2020</a>) and a second review author (PMcC) verified all data entries to ensure that data were consistent and free of errors. Any discrepancies in data extraction were resolved through discussion. </p> </section> <section id="CD014831-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Review authors (REM, PMcC, LL) worked in pairs to independently apply the Risk of Bias tool 2 (RoB 2) to assess the risk of bias for the effect of assignment to interventions according to Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD014831-bbs2-0036" title="HigginsJP , SavovićJ , PageMJ , ElbersRG , SterneJA . Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from handbook.cochrane.org.">Higgins 2022a</a>). In case of authors' disagreement, we resolved the conflicts via discussion with the senior authors (AP or TL). We assessed the risk of bias for the 'proportion of participants achieving control of inflammation' efficacy outcome and the 'proportion of participants experiencing complications or requiring cessation of medication' safety outcome. We used RoB2 Excel tool and 2019 guidance to implement RoB 2 (available on the riskofbiasinfo.org website).We considered the following domains of bias: </p> <p> <ul id="CD014831-list-0006"> <li> <p>bias arising from the randomization process;</p> </li> <li> <p>bias due to deviations from intended interventions;</p> </li> <li> <p>bias due to missing outcome data;</p> </li> <li> <p>bias in measurement of the outcome; and</p> </li> <li> <p>bias in selection of the reported result.</p> </li> </ul> </p> <p>We assessed each domain as guided by domain‐specific signaling questions. For an overall 'risk of bias' judgement, we considered each study to have: </p> <p> <ul id="CD014831-list-0007"> <li> <p>'low risk of bias' if it was at low risk of bias for all domains for this result;</p> </li> <li> <p>'some concerns' if the trial raised some concerns in at least one domain for this result, but we did not consider it to be at high risk of bias for any domain; and </p> </li> <li> <p>'high risk of bias' if we judged the trial to be at high risk of bias in at least one domain, or to have some concerns for multiple domains in a way that substantially lowers confidence in the result. </p> </li> </ul> </p> </section> <section id="CD014831-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We conducted data analysis using guidance from Chapter 9 and Chapter 10 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD014831-bbs2-0027" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Deeks 2022</a>; <a href="./references#CD014831-bbs2-0047" title="McKenzieJE , BrennanSE , RyanRE , ThomsonHJ , JohnstonRV . Chapter 9: Summarizing study characteristics and preparing for synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">McKenzie 2022</a>). We calculated the mean difference (MD) with 95% confidence intervals (CIs) for continuous outcomes. We calculated the standardized mean difference (SMD) for quality of life scores. We used risk ratios (RR) with 95% CIs for dichotomous outcomes. There were no time‐to‐event data reported, so we did not calculate hazard ratios. </p> </section> <section id="CD014831-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>For the purpose of this review, the unit of analysis was the study participant. When a study randomized both eyes of participants (to the same or different interventions), we extracted the results that accounted for the correlation between eyes. If the included studies failed to consider the correlation between two eyes, we planned to exclude those studies in the sensitivity analysis. We followed the guidance in Chapter 23 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> regarding including variants on randomized trials (<a href="./references#CD014831-bbs2-0037" title="HigginsJP , EldridgeS , LiT , editor(s). Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Higgins 2022b</a>). </p> </section> <section id="CD014831-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>While dealing with missing data, we followed recommendations in Chapter 10 of the <i>Cochrane Handbook for Systematic Reviews of Intervention</i>s (<a href="./references#CD014831-bbs2-0027" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Deeks 2022</a>). If there were missing data (e.g. missing full‐text report from a trial, missing information regarding study methods, missing summary data for an outcome, or individual participants missing from the summary data), we contacted the authors of the primary trials to request the information of interest. As prespecified in the protocol, we planned to assess the impact of missing data by excluding studies at high risk of bias of missing outcome data in a sensitivity analysis. However, there were only trials at 'low' or 'some concern' for this domain. </p> </section> <section id="CD014831-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed clinical and methodological heterogeneity among studies by evaluating the potential differences in participants, interventions, and outcomes, as well as differences in study design, outcome measurement tools, and risk of bias. We evaluated the statistical heterogeneity by assessing if CIs for the results of individual studies showed poor overlap. We also considered the I<sup>2</sup> statistic, which described the percentage of the variability in effect estimates that was due to heterogeneity rather than sampling error (chance). As described in Chapter 10 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD014831-bbs2-0027" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Deeks 2022</a>), we consider the following ranges while interpreting the I<sup>2</sup> statistics: </p> <p> <ul id="CD014831-list-0008"> <li> <p>0% to 40%: might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity; and</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> </section> <section id="CD014831-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We evaluated selective outcome reporting for each study by comparing the outcomes specified in the protocol or clinical trial registry with those in study reports. Where trial protocols or trial registry records were unavailable or inaccessible, we compared outcomes specified in the Methods section with outcomes reported in the Results section of the study reports. Because we did not include more than 10 trials in a meta‐analysis, we did not use funnel plots to assess small‐study effects. </p> </section> <section id="CD014831-sec-0035"> <h4 class="title">Data synthesis</h4> <p>For data synthesis and analysis, we followed the guidelines in Chapter 9 and Chapter 10 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD014831-bbs2-0027" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Deeks 2022</a>; <a href="./references#CD014831-bbs2-0047" title="McKenzieJE , BrennanSE , RyanRE , ThomsonHJ , JohnstonRV . Chapter 9: Summarizing study characteristics and preparing for synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">McKenzie 2022</a>). We analyzed data using a random‐effects model whenever feasible; we used fixed‐effects models when fewer than three studies contributed data in a given meta‐analysis. If the direction of treatment effects was inconsistent across studies or there was evidence of considerable statistical heterogeneity (I<sup>2</sup> &gt; 75%), we did not combine results in a meta‐analysis and presented a narrative summary of results instead. The primary analysis included all eligible studies and did not restrict them based on risk of bias. </p> </section> <section id="CD014831-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Given the limited number of trials included, we did not perform subgroup analyses by study design or by uveitis subtype. We only performed subgroup analysis by uveitis etiology when there was sufficient information reported by trials that enrolled mainly participants with Vogt‐Koyanagi‐Harada (VKH) disease versus trials that enrolled participants with non‐VKH uveitis (<a href="#CD014831-sec-0155">Differences between protocol and review</a>). </p> </section> <section id="CD014831-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>There were too few studies included in analyses to perform meaningful sensitivity analysis. </p> </section> <section id="CD014831-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We created summary of findings tables to present the main findings of the review, including key information concerning the certainty of evidence, the magnitude of effect of the interventions examined, and the summary of available data on the main outcomes, following guidelines in Chapter 14 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD014831-bbs2-0053" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Schünemann 2022</a>). </p> <p>We included the following outcomes at six and 12 months' follow‐up in the summary of findings tables: </p> <p> <ul id="CD014831-list-0009"> <li> <p>control of inflammation;</p> </li> <li> <p>change in BCVA;</p> </li> <li> <p>proportion of participants achieving a 2‐line improvement in visual acuity (Snellen chart); </p> </li> <li> <p>proportion of participants with confirmed macular edema;</p> </li> <li> <p>proportion of participants achieving steroid‐sparing control; and</p> </li> <li> <p>proportion of participants experiencing complications or requiring cessation of medication.</p> </li> </ul> </p> <p>Authors (REM, PMcC, LL) worked in pairs and each independently performed the GRADE assessment to evaluate the certainty of the review findings by grading the certainty of evidence as 'high', 'moderate', 'low', or 'very low' (<a href="./references#CD014831-bbs2-0034" title="GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), version accessed 3 March 2022. Available at gradepro.org.">GRADEpro GDT</a>), based on (i) high risk of bias among included studies, (ii) indirectness of evidence, (iii) unexplained heterogeneity or inconsistency of results, (iv) imprecision of results, and (v) high probability of publication bias. When there was any disagreement or discrepancy between the two review authors, a third review author (AP or TL) adjudicated the grading. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD014831-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD014831-sec-0039"></div> <section id="CD014831-sec-0040"> <h3 class="title">Description of studies</h3> <section id="CD014831-sec-0041"> <h4 class="title">Results of the search</h4> <p>We identified 5070 records through electronic database searches and two additional records through supplemental search methods. After the removal of duplicates, 4299 records remained. Fifty of these records underwent full‐text screening. We excluded six studies (11 records) and listed three studies (8 records) as 'awaiting classification.' We included 11 studies (31 records) in this review (<a href="#CD014831-fig-0001">Figure 1</a>). Because some studies included a mixture of children and adults, we made a post hoc decision to include studies with children and adults, but no studies with only children (<a href="#CD014831-sec-0155">Differences between protocol and review</a>). </p> <div class="figure" id="CD014831-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD014831-fig-0001" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD014831-sec-0042"> <h4 class="title">Included studies</h4> <p>For a detailed description of the included studies, please see the <a href="./references#CD014831-sec-0162" title="">Characteristics of included studies</a> table. </p> <p>We included 11 studies with a total of 601 participants. The majority of the included studies were small: all but one had fewer than 100 participants, and seven of the 11 had fewer than 50 participants (<a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a>; <a href="./references#CD014831-bbs2-0002" title="DeuterC , EngelmannK , HeiligenhausA , LanzlI , MackensenF , NessT , et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. British Journal of Ophthalmology2018;102(5):647‐53. [CENTRAL: CN-00781196] [DOI: 10.1136/bjophthalmol-2017-310156]EUCTR2009-009998-10-DE. Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009998-10 (first received 2 December 2009). NCT01092533. Myfortic for the treatment of non-infectious intermediate uveitis (MYCUV-IIT02) [Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectious intermediate uveitis - a prospective, controlled randomized multicenter trial]. clinicaltrials.gov/ct2/show/study/NCT01092533 (first received 25 March 2010). ">Deuter 2018</a>; <a href="./references#CD014831-bbs2-0003" title="De VriesJ , BaarsmaG , ZaalM , Boen-TanT , RothovaA , BuitenhuisH , et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. British Journal of Ophthalmology1990;74(6):344‐9. [CENTRAL: CN-00069296] [DOI: 10.1136/bjo.74.6.344]">De Vries 1990</a>; <a href="./references#CD014831-bbs2-0004" title="ISRCTN46576063. Tacrolimus monotherapy for uveitis [Dual steroid and tacrolimus therapy versus steroid withdrawal and tacrolimus therapy in the treatment of posterior segment intraocular inflammation (uveitis)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN46576063 (first received 16 April 2008). [DOI: https://doi.org/10.1186/ISRCTN46576063]LeeR , GreenwoodR , TaylorH , AmerR , BiesterS , HeissigerovaJ , et al. A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. Ophthalmology2012;119(6):1223‐30. [DOI: 10.1016/j.ophtha.2011.12.030]LeeRW , GreenwoodR , AmerR , BiesterS , PlskovaJ , ForresterJV , et al. Tacrolimus monotherapy versus tacrolimus and prednisone for the maintenance of disease remission in non-infectious posterior segment intraocular inflammation. Investigative Ophthalmology and Visual Science2009;50(13):2024. ">Lee 2012</a>; <a href="./references#CD014831-bbs2-0005" title="MurphyC , GreinerK , PlskovaJ , DuncanL , FrostN , ForresterJ , et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Archives of Ophthalmology2005;123(5):634‐41. [CENTRAL: CN-00511918] [DOI: 10.1001/archopht.123.5.634]">Murphy 2005</a>; <a href="./references#CD014831-bbs2-0007" title="NussenblattRB , De SmetMD , RubinB , FreidlinV , WhitcupSM , DavisJ , et al. A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin. American Journal of Ophthalmology1993;115(5):583‐91. [CENTRAL: CN-00093004] [DOI: 10.1016/s0002-9394(14)71454-0]">Nussenblatt 1993</a>; <a href="./references#CD014831-bbs2-0011" title="WiederholtM , KämpeC , HansenLL , HövenerG . Treatment of posterior uveitis with cyclosporin or prednisolone--one-year report of a randomized prospective study [Behandlung der uveitis posterior mit cyclosporin oder prednisolon--jahresbericht über eine randomisierte prospektive studie]. Fortschritte der Ophthalmologie1986;83(3):348‐52. [CENTRAL: CN-00044224] [EMBASE: 1986247564] [PMID: 3527903]">Wiederholt 1986</a>). The First‐line Antimetabolites as Steroid‐sparing Treatment (FAST) uveitis trials enrolled 46% (274 of 601) of the total participants included (<a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a>; <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a>). Trials conducted after 2005 incorporated the Standardization of Uveitis Nomenclature (SUN) working group definition of NIIPPU; studies conducted prior to this generally had similar eligibility criteria (<a href="./references#CD014831-bbs2-0003" title="De VriesJ , BaarsmaG , ZaalM , Boen-TanT , RothovaA , BuitenhuisH , et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. British Journal of Ophthalmology1990;74(6):344‐9. [CENTRAL: CN-00069296] [DOI: 10.1136/bjo.74.6.344]">De Vries 1990</a>; <a href="./references#CD014831-bbs2-0006" title="NussenblattRB , PalestineA , ChanCC , FujikawaLS , StevensG , GreenSB . A randomised, double-masked trial of sandimmune vs. prednisolone for endogenous uveitis. American Academy of Ophthalmology1990;112:105. [CENTRAL: CN-00485269] NussenblattRB , PalestineAG , ChanCC , StevensG , MellowSD , GreenSB . Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. American Journal of Ophthalmology1991;112(2):138‐46. [CENTRAL: CN-00077346] [DOI: 10.1016/s0002-9394(14)76692-9]">Nussenblatt 1991</a>; <a href="./references#CD014831-bbs2-0007" title="NussenblattRB , De SmetMD , RubinB , FreidlinV , WhitcupSM , DavisJ , et al. A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin. American Journal of Ophthalmology1993;115(5):583‐91. [CENTRAL: CN-00093004] [DOI: 10.1016/s0002-9394(14)71454-0]">Nussenblatt 1993</a>; <a href="./references#CD014831-bbs2-0011" title="WiederholtM , KämpeC , HansenLL , HövenerG . Treatment of posterior uveitis with cyclosporin or prednisolone--one-year report of a randomized prospective study [Behandlung der uveitis posterior mit cyclosporin oder prednisolon--jahresbericht über eine randomisierte prospektive studie]. Fortschritte der Ophthalmologie1986;83(3):348‐52. [CENTRAL: CN-00044224] [EMBASE: 1986247564] [PMID: 3527903]">Wiederholt 1986</a>). Most studies included only adults; four studies also included children and teenagers (<a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a>; <a href="./references#CD014831-bbs2-0006" title="NussenblattRB , PalestineA , ChanCC , FujikawaLS , StevensG , GreenSB . A randomised, double-masked trial of sandimmune vs. prednisolone for endogenous uveitis. American Academy of Ophthalmology1990;112:105. [CENTRAL: CN-00485269] NussenblattRB , PalestineAG , ChanCC , StevensG , MellowSD , GreenSB . Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. American Journal of Ophthalmology1991;112(2):138‐46. [CENTRAL: CN-00077346] [DOI: 10.1016/s0002-9394(14)76692-9]">Nussenblatt 1991</a>; <a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a>; <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a>). </p> <p>There was a broad global distribution of studies, with representation from the United Kingdom, USA, Germany, the Netherlands, Chile, Japan, India, Australia, Saudi Arabia, and Mexico. Given the wide range of clinical entities making up NIIPPU, many of which have strong geographic or ethnic associations, or both, it is not surprising that the specific uveitis diagnoses varied greatly between studies. For example, studies conducted in the UK, the Netherlands, and Germany (<a href="./references#CD014831-bbs2-0002" title="DeuterC , EngelmannK , HeiligenhausA , LanzlI , MackensenF , NessT , et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. British Journal of Ophthalmology2018;102(5):647‐53. [CENTRAL: CN-00781196] [DOI: 10.1136/bjophthalmol-2017-310156]EUCTR2009-009998-10-DE. Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009998-10 (first received 2 December 2009). NCT01092533. Myfortic for the treatment of non-infectious intermediate uveitis (MYCUV-IIT02) [Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectious intermediate uveitis - a prospective, controlled randomized multicenter trial]. clinicaltrials.gov/ct2/show/study/NCT01092533 (first received 25 March 2010). ">Deuter 2018</a>; <a href="./references#CD014831-bbs2-0003" title="De VriesJ , BaarsmaG , ZaalM , Boen-TanT , RothovaA , BuitenhuisH , et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. British Journal of Ophthalmology1990;74(6):344‐9. [CENTRAL: CN-00069296] [DOI: 10.1136/bjo.74.6.344]">De Vries 1990</a>; <a href="./references#CD014831-bbs2-0004" title="ISRCTN46576063. Tacrolimus monotherapy for uveitis [Dual steroid and tacrolimus therapy versus steroid withdrawal and tacrolimus therapy in the treatment of posterior segment intraocular inflammation (uveitis)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN46576063 (first received 16 April 2008). [DOI: https://doi.org/10.1186/ISRCTN46576063]LeeR , GreenwoodR , TaylorH , AmerR , BiesterS , HeissigerovaJ , et al. A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. Ophthalmology2012;119(6):1223‐30. [DOI: 10.1016/j.ophtha.2011.12.030]LeeRW , GreenwoodR , AmerR , BiesterS , PlskovaJ , ForresterJV , et al. Tacrolimus monotherapy versus tacrolimus and prednisone for the maintenance of disease remission in non-infectious posterior segment intraocular inflammation. Investigative Ophthalmology and Visual Science2009;50(13):2024. ">Lee 2012</a>; <a href="./references#CD014831-bbs2-0005" title="MurphyC , GreinerK , PlskovaJ , DuncanL , FrostN , ForresterJ , et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Archives of Ophthalmology2005;123(5):634‐41. [CENTRAL: CN-00511918] [DOI: 10.1001/archopht.123.5.634]">Murphy 2005</a>), composed of largely white populations, contained no VKH patients, while studies with large Asian or South American populations had high rates of VKH, or were entirely composed of VKH patients (<a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a>; <a href="./references#CD014831-bbs2-0008" title="JPRN-UMIN000014387. A prospective multicenter comparative clinical trial between corticosteroid pulse therapy vs. combination therapy of oral corticosteroid and cyclosporine on Vogt-Koyanagi-Harada disease. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000014387 (first received 27 June 2014). [CENTRAL: CN-01827271] OnoT , GotoH , SakaiT , NittaF , MizukiN , TakaseH , et al. Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt–Koyanagi–Harada disease. Japanese Journal of Ophthalmology 2021 Oct 24 [Epub ahead of print]. [DOI: 10.1007/s10384-021-00878-w]OnoT , MochizukiM , GotoH , SakaiT , NittaF , MizukiN , et al. A prospective multi-center randomized clinical study comparing steroid-pulse therapy and a combined therapy with oral prednisolone and cyclosporine for new-onset acute Vogt-Koyanagi-Harada disease. Investigative Ophthalmology and Visual Science2020;61(7):3169. [CENTRAL: CN-02179109] [EMBASE: 632697033]">Ono 2021</a>; <a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a>; <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a>). </p> <p>There was also significant heterogeneity between studies in the clinical interventions and definitions of clinical outcomes (see below). </p> <section id="CD014831-sec-0043"> <h5 class="title">Types of interventions</h5> <p>The included studies evaluated a variety of treatments, dosages, and regimens.</p> <section id="CD014831-sec-0044"> <h6 class="title"><i>Non‐biologic disease‐modifying antirheumatic drugs (DMARDs) versus steroids</i> </h6> <p>Two studies compared a DMARD plus steroid to steroid monotherapy. <a href="./references#CD014831-bbs2-0003" title="De VriesJ , BaarsmaG , ZaalM , Boen-TanT , RothovaA , BuitenhuisH , et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. British Journal of Ophthalmology1990;74(6):344‐9. [CENTRAL: CN-00069296] [DOI: 10.1136/bjo.74.6.344]">De Vries 1990</a> compared CsA plus oral steroid with steroid monotherapy plus placebo whereas <a href="./references#CD014831-bbs2-0002" title="DeuterC , EngelmannK , HeiligenhausA , LanzlI , MackensenF , NessT , et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. British Journal of Ophthalmology2018;102(5):647‐53. [CENTRAL: CN-00781196] [DOI: 10.1136/bjophthalmol-2017-310156]EUCTR2009-009998-10-DE. Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009998-10 (first received 2 December 2009). NCT01092533. Myfortic for the treatment of non-infectious intermediate uveitis (MYCUV-IIT02) [Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectious intermediate uveitis - a prospective, controlled randomized multicenter trial]. clinicaltrials.gov/ct2/show/study/NCT01092533 (first received 25 March 2010). ">Deuter 2018</a> compared enteric‐coated mycophenolate sodium (1440 mg/day) in combination with a steroid to steroid monotherapy. </p> </section> <section id="CD014831-sec-0045"> <h6 class="title"><i>Mycophenolate versus methotrexate</i> </h6> <p>Two studies compared mycophenolate to methotrexate. The FAST pilot study and main study both compared a higher dose of mycophenolate (2000 mg/day) and a slightly different formulation (oral mycophenolate mofetil) with methotrexate (<a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a>; <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a>). </p> </section> <section id="CD014831-sec-0046"> <h6 class="title"><i>Steroids with or without azathioprine versus cyclosporine A</i> </h6> <p>Four studies compared other steroids with or without azathioprine (oral steroid, IV steroid, or azathioprine) to cyclosporine A. <a href="./references#CD014831-bbs2-0006" title="NussenblattRB , PalestineA , ChanCC , FujikawaLS , StevensG , GreenSB . A randomised, double-masked trial of sandimmune vs. prednisolone for endogenous uveitis. American Academy of Ophthalmology1990;112:105. [CENTRAL: CN-00485269] NussenblattRB , PalestineAG , ChanCC , StevensG , MellowSD , GreenSB . Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. American Journal of Ophthalmology1991;112(2):138‐46. [CENTRAL: CN-00077346] [DOI: 10.1016/s0002-9394(14)76692-9]">Nussenblatt 1991</a> and <a href="./references#CD014831-bbs2-0011" title="WiederholtM , KämpeC , HansenLL , HövenerG . Treatment of posterior uveitis with cyclosporin or prednisolone--one-year report of a randomized prospective study [Behandlung der uveitis posterior mit cyclosporin oder prednisolon--jahresbericht über eine randomisierte prospektive studie]. Fortschritte der Ophthalmologie1986;83(3):348‐52. [CENTRAL: CN-00044224] [EMBASE: 1986247564] [PMID: 3527903]">Wiederholt 1986</a> used oral steroids while <a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a> compared oral steroid and azathioprine to oral steroid and cyclosporine A at a dosage of 3 to 5 mg/kg/day. <a href="./references#CD014831-bbs2-0008" title="JPRN-UMIN000014387. A prospective multicenter comparative clinical trial between corticosteroid pulse therapy vs. combination therapy of oral corticosteroid and cyclosporine on Vogt-Koyanagi-Harada disease. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000014387 (first received 27 June 2014). [CENTRAL: CN-01827271] OnoT , GotoH , SakaiT , NittaF , MizukiN , TakaseH , et al. Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt–Koyanagi–Harada disease. Japanese Journal of Ophthalmology 2021 Oct 24 [Epub ahead of print]. [DOI: 10.1007/s10384-021-00878-w]OnoT , MochizukiM , GotoH , SakaiT , NittaF , MizukiN , et al. A prospective multi-center randomized clinical study comparing steroid-pulse therapy and a combined therapy with oral prednisolone and cyclosporine for new-onset acute Vogt-Koyanagi-Harada disease. Investigative Ophthalmology and Visual Science2020;61(7):3169. [CENTRAL: CN-02179109] [EMBASE: 632697033]">Ono 2021</a> compared a 3‐day pulse‐dose of IV methylprednisolone to a 3 mg/kg/day dose of cyclosporine A, both in combination with a gradually tapered dose of oral steroid. </p> <p>Three studies included comparisons outside the scope of this review (see <a href="#CD014831-sec-0155">Differences between protocol and review</a>). Two studies used tacrolimus: <a href="./references#CD014831-bbs2-0005" title="MurphyC , GreinerK , PlskovaJ , DuncanL , FrostN , ForresterJ , et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Archives of Ophthalmology2005;123(5):634‐41. [CENTRAL: CN-00511918] [DOI: 10.1001/archopht.123.5.634]">Murphy 2005</a> compared tacrolimus plus oral steroid with cyclosporine A, but was not included in the synthesis as these two medications were considered to be of the same class (both are calcineurin inhibitors); <a href="./references#CD014831-bbs2-0004" title="ISRCTN46576063. Tacrolimus monotherapy for uveitis [Dual steroid and tacrolimus therapy versus steroid withdrawal and tacrolimus therapy in the treatment of posterior segment intraocular inflammation (uveitis)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN46576063 (first received 16 April 2008). [DOI: https://doi.org/10.1186/ISRCTN46576063]LeeR , GreenwoodR , TaylorH , AmerR , BiesterS , HeissigerovaJ , et al. A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. Ophthalmology2012;119(6):1223‐30. [DOI: 10.1016/j.ophtha.2011.12.030]LeeRW , GreenwoodR , AmerR , BiesterS , PlskovaJ , ForresterJV , et al. Tacrolimus monotherapy versus tacrolimus and prednisone for the maintenance of disease remission in non-infectious posterior segment intraocular inflammation. Investigative Ophthalmology and Visual Science2009;50(13):2024. ">Lee 2012</a> compared tacrolimus monotherapy with tacrolimus in combination with oral steroids, with the same target tacrolimus trough level as used in <a href="./references#CD014831-bbs2-0005" title="MurphyC , GreinerK , PlskovaJ , DuncanL , FrostN , ForresterJ , et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Archives of Ophthalmology2005;123(5):634‐41. [CENTRAL: CN-00511918] [DOI: 10.1001/archopht.123.5.634]">Murphy 2005</a> (8 to 12 ng/L). <a href="./references#CD014831-bbs2-0007" title="NussenblattRB , De SmetMD , RubinB , FreidlinV , WhitcupSM , DavisJ , et al. A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin. American Journal of Ophthalmology1993;115(5):583‐91. [CENTRAL: CN-00093004] [DOI: 10.1016/s0002-9394(14)71454-0]">Nussenblatt 1993</a> was designed as a dose‐escalation trial with four different doses of cyclosporine A to cyclosporine G. Because the formulation of cyclosporine G is not clinically available, we have omitted this study as well. </p> </section> </section> <section id="CD014831-sec-0047"> <h5 class="title"><i>Dosing of cyclosporine A</i> </h5> <p>The dosages of cyclosporine A ranged from 2.5 mg to 15 mg/kg/day. Three studies published from 1986 to 1991 used dosages of 8 mg to 15 mg/kg/day (<a href="./references#CD014831-bbs2-0003" title="De VriesJ , BaarsmaG , ZaalM , Boen-TanT , RothovaA , BuitenhuisH , et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. British Journal of Ophthalmology1990;74(6):344‐9. [CENTRAL: CN-00069296] [DOI: 10.1136/bjo.74.6.344]">De Vries 1990</a>; <a href="./references#CD014831-bbs2-0006" title="NussenblattRB , PalestineA , ChanCC , FujikawaLS , StevensG , GreenSB . A randomised, double-masked trial of sandimmune vs. prednisolone for endogenous uveitis. American Academy of Ophthalmology1990;112:105. [CENTRAL: CN-00485269] NussenblattRB , PalestineAG , ChanCC , StevensG , MellowSD , GreenSB . Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. American Journal of Ophthalmology1991;112(2):138‐46. [CENTRAL: CN-00077346] [DOI: 10.1016/s0002-9394(14)76692-9]">Nussenblatt 1991</a>; <a href="./references#CD014831-bbs2-0011" title="WiederholtM , KämpeC , HansenLL , HövenerG . Treatment of posterior uveitis with cyclosporin or prednisolone--one-year report of a randomized prospective study [Behandlung der uveitis posterior mit cyclosporin oder prednisolon--jahresbericht über eine randomisierte prospektive studie]. Fortschritte der Ophthalmologie1986;83(3):348‐52. [CENTRAL: CN-00044224] [EMBASE: 1986247564] [PMID: 3527903]">Wiederholt 1986</a>). Around that time, dose‐response and tolerability studies revealed that chronic use of cyclosporine at high doses was associated with the development of interstitial fibrosis, glomerular atrophy, decreased glomerular filtration rate, and increased risk of hypertension (<a href="./references#CD014831-bbs2-0050" title="PalestineAG , Austin HA 3rd, BalowJE , AntonovychTT , SabnisSG , PreussHG , et al. Renal histopathologic alterations in patients treated with cyclosporine for uveitis. New England Journal of Medicine1986;314(20):1293-8. [DOI: 10.1056/NEJM198605153142005]">Palestine 1986</a>; <a href="./references#CD014831-bbs2-0007" title="NussenblattRB , De SmetMD , RubinB , FreidlinV , WhitcupSM , DavisJ , et al. A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin. American Journal of Ophthalmology1993;115(5):583‐91. [CENTRAL: CN-00093004] [DOI: 10.1016/s0002-9394(14)71454-0]">Nussenblatt 1993</a>). Two studies published more recently used modern dosing of 3 mg to 5 mg/kg/day of cyclosporine A (<a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a>; <a href="./references#CD014831-bbs2-0008" title="JPRN-UMIN000014387. A prospective multicenter comparative clinical trial between corticosteroid pulse therapy vs. combination therapy of oral corticosteroid and cyclosporine on Vogt-Koyanagi-Harada disease. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000014387 (first received 27 June 2014). [CENTRAL: CN-01827271] OnoT , GotoH , SakaiT , NittaF , MizukiN , TakaseH , et al. Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt–Koyanagi–Harada disease. Japanese Journal of Ophthalmology 2021 Oct 24 [Epub ahead of print]. [DOI: 10.1007/s10384-021-00878-w]OnoT , MochizukiM , GotoH , SakaiT , NittaF , MizukiN , et al. A prospective multi-center randomized clinical study comparing steroid-pulse therapy and a combined therapy with oral prednisolone and cyclosporine for new-onset acute Vogt-Koyanagi-Harada disease. Investigative Ophthalmology and Visual Science2020;61(7):3169. [CENTRAL: CN-02179109] [EMBASE: 632697033]">Ono 2021</a>). We excluded the studies using the higher, outdated dosing of cyclosporine from our primary analyses as these data are not informative to current clinical practice. However, we have included a description of their results. </p> </section> <section id="CD014831-sec-0048"> <h5 class="title"><i>Steroid regimens</i> </h5> <p>Steroid regimens varied considerably across included studies. All studies either explicitly allowed the use of topical steroids or did not comment on the use of topical drops (<a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a>; <a href="./references#CD014831-bbs2-0002" title="DeuterC , EngelmannK , HeiligenhausA , LanzlI , MackensenF , NessT , et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. British Journal of Ophthalmology2018;102(5):647‐53. [CENTRAL: CN-00781196] [DOI: 10.1136/bjophthalmol-2017-310156]EUCTR2009-009998-10-DE. Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009998-10 (first received 2 December 2009). NCT01092533. Myfortic for the treatment of non-infectious intermediate uveitis (MYCUV-IIT02) [Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectious intermediate uveitis - a prospective, controlled randomized multicenter trial]. clinicaltrials.gov/ct2/show/study/NCT01092533 (first received 25 March 2010). ">Deuter 2018</a>; <a href="./references#CD014831-bbs2-0005" title="MurphyC , GreinerK , PlskovaJ , DuncanL , FrostN , ForresterJ , et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Archives of Ophthalmology2005;123(5):634‐41. [CENTRAL: CN-00511918] [DOI: 10.1001/archopht.123.5.634]">Murphy 2005</a>; <a href="./references#CD014831-bbs2-0007" title="NussenblattRB , De SmetMD , RubinB , FreidlinV , WhitcupSM , DavisJ , et al. A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin. American Journal of Ophthalmology1993;115(5):583‐91. [CENTRAL: CN-00093004] [DOI: 10.1016/s0002-9394(14)71454-0]">Nussenblatt 1993</a>); no studies explicitly prohibited the use of topical steroid drops. Regimens for oral steroids and steroid tapers ranged widely among the studies. Four studies started at relatively low doses of oral steroids (10 mg to 15 mg/day or 0.3 mg/kg/day to a maximum of 20 mg) with subsequent tapers (<a href="./references#CD014831-bbs2-0003" title="De VriesJ , BaarsmaG , ZaalM , Boen-TanT , RothovaA , BuitenhuisH , et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. British Journal of Ophthalmology1990;74(6):344‐9. [CENTRAL: CN-00069296] [DOI: 10.1136/bjo.74.6.344]">De Vries 1990</a>; <a href="./references#CD014831-bbs2-0004" title="ISRCTN46576063. Tacrolimus monotherapy for uveitis [Dual steroid and tacrolimus therapy versus steroid withdrawal and tacrolimus therapy in the treatment of posterior segment intraocular inflammation (uveitis)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN46576063 (first received 16 April 2008). [DOI: https://doi.org/10.1186/ISRCTN46576063]LeeR , GreenwoodR , TaylorH , AmerR , BiesterS , HeissigerovaJ , et al. A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. Ophthalmology2012;119(6):1223‐30. [DOI: 10.1016/j.ophtha.2011.12.030]LeeRW , GreenwoodR , AmerR , BiesterS , PlskovaJ , ForresterJV , et al. Tacrolimus monotherapy versus tacrolimus and prednisone for the maintenance of disease remission in non-infectious posterior segment intraocular inflammation. Investigative Ophthalmology and Visual Science2009;50(13):2024. ">Lee 2012</a>; <a href="./references#CD014831-bbs2-0007" title="NussenblattRB , De SmetMD , RubinB , FreidlinV , WhitcupSM , DavisJ , et al. A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin. American Journal of Ophthalmology1993;115(5):583‐91. [CENTRAL: CN-00093004] [DOI: 10.1016/s0002-9394(14)71454-0]">Nussenblatt 1993</a>; <a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a>). Six studies started at a high dose of oral steroid (60 mg to 100 mg/day) for a variable time period, usually one to four weeks, although this was not always explicitly stated, followed by a taper (<a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a>; <a href="./references#CD014831-bbs2-0002" title="DeuterC , EngelmannK , HeiligenhausA , LanzlI , MackensenF , NessT , et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. British Journal of Ophthalmology2018;102(5):647‐53. [CENTRAL: CN-00781196] [DOI: 10.1136/bjophthalmol-2017-310156]EUCTR2009-009998-10-DE. Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009998-10 (first received 2 December 2009). NCT01092533. Myfortic for the treatment of non-infectious intermediate uveitis (MYCUV-IIT02) [Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectious intermediate uveitis - a prospective, controlled randomized multicenter trial]. clinicaltrials.gov/ct2/show/study/NCT01092533 (first received 25 March 2010). ">Deuter 2018</a>; <a href="./references#CD014831-bbs2-0006" title="NussenblattRB , PalestineA , ChanCC , FujikawaLS , StevensG , GreenSB . A randomised, double-masked trial of sandimmune vs. prednisolone for endogenous uveitis. American Academy of Ophthalmology1990;112:105. [CENTRAL: CN-00485269] NussenblattRB , PalestineAG , ChanCC , StevensG , MellowSD , GreenSB . Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. American Journal of Ophthalmology1991;112(2):138‐46. [CENTRAL: CN-00077346] [DOI: 10.1016/s0002-9394(14)76692-9]">Nussenblatt 1991</a>; <a href="./references#CD014831-bbs2-0008" title="JPRN-UMIN000014387. A prospective multicenter comparative clinical trial between corticosteroid pulse therapy vs. combination therapy of oral corticosteroid and cyclosporine on Vogt-Koyanagi-Harada disease. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000014387 (first received 27 June 2014). [CENTRAL: CN-01827271] OnoT , GotoH , SakaiT , NittaF , MizukiN , TakaseH , et al. Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt–Koyanagi–Harada disease. Japanese Journal of Ophthalmology 2021 Oct 24 [Epub ahead of print]. [DOI: 10.1007/s10384-021-00878-w]OnoT , MochizukiM , GotoH , SakaiT , NittaF , MizukiN , et al. A prospective multi-center randomized clinical study comparing steroid-pulse therapy and a combined therapy with oral prednisolone and cyclosporine for new-onset acute Vogt-Koyanagi-Harada disease. Investigative Ophthalmology and Visual Science2020;61(7):3169. [CENTRAL: CN-02179109] [EMBASE: 632697033]">Ono 2021</a>; <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a>; <a href="./references#CD014831-bbs2-0011" title="WiederholtM , KämpeC , HansenLL , HövenerG . Treatment of posterior uveitis with cyclosporin or prednisolone--one-year report of a randomized prospective study [Behandlung der uveitis posterior mit cyclosporin oder prednisolon--jahresbericht über eine randomisierte prospektive studie]. Fortschritte der Ophthalmologie1986;83(3):348‐52. [CENTRAL: CN-00044224] [EMBASE: 1986247564] [PMID: 3527903]">Wiederholt 1986</a>). Participants in the <a href="./references#CD014831-bbs2-0005" title="MurphyC , GreinerK , PlskovaJ , DuncanL , FrostN , ForresterJ , et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Archives of Ophthalmology2005;123(5):634‐41. [CENTRAL: CN-00511918] [DOI: 10.1001/archopht.123.5.634]">Murphy 2005</a> study were allowed to be taking anywhere from 14 mg to 51 mg/day of oral steroids at the start of the trial. Participants in two studies received an IV pulse‐dose of steroids at the start of the trial (1.0 g to 3.0 g over one to three days in <a href="./references#CD014831-bbs2-0004" title="ISRCTN46576063. Tacrolimus monotherapy for uveitis [Dual steroid and tacrolimus therapy versus steroid withdrawal and tacrolimus therapy in the treatment of posterior segment intraocular inflammation (uveitis)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN46576063 (first received 16 April 2008). [DOI: https://doi.org/10.1186/ISRCTN46576063]LeeR , GreenwoodR , TaylorH , AmerR , BiesterS , HeissigerovaJ , et al. A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. Ophthalmology2012;119(6):1223‐30. [DOI: 10.1016/j.ophtha.2011.12.030]LeeRW , GreenwoodR , AmerR , BiesterS , PlskovaJ , ForresterJV , et al. Tacrolimus monotherapy versus tacrolimus and prednisone for the maintenance of disease remission in non-infectious posterior segment intraocular inflammation. Investigative Ophthalmology and Visual Science2009;50(13):2024. ">Lee 2012</a>, and 1.5 g to 3.0 g over three days in <a href="./references#CD014831-bbs2-0008" title="JPRN-UMIN000014387. A prospective multicenter comparative clinical trial between corticosteroid pulse therapy vs. combination therapy of oral corticosteroid and cyclosporine on Vogt-Koyanagi-Harada disease. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000014387 (first received 27 June 2014). [CENTRAL: CN-01827271] OnoT , GotoH , SakaiT , NittaF , MizukiN , TakaseH , et al. Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt–Koyanagi–Harada disease. Japanese Journal of Ophthalmology 2021 Oct 24 [Epub ahead of print]. [DOI: 10.1007/s10384-021-00878-w]OnoT , MochizukiM , GotoH , SakaiT , NittaF , MizukiN , et al. A prospective multi-center randomized clinical study comparing steroid-pulse therapy and a combined therapy with oral prednisolone and cyclosporine for new-onset acute Vogt-Koyanagi-Harada disease. Investigative Ophthalmology and Visual Science2020;61(7):3169. [CENTRAL: CN-02179109] [EMBASE: 632697033]">Ono 2021</a>). Steroid tapers were generally aimed to achieve a dose of 5 mg to 10 mg/day, but the time period over which the taper occurred varied from two to six months, and the exact tapering regimen was not always explicitly stated by the investigators. The steroid regimens between arms within a study were similar except for the comparisons with one steroid group (<a href="./references#CD014831-bbs2-0004" title="ISRCTN46576063. Tacrolimus monotherapy for uveitis [Dual steroid and tacrolimus therapy versus steroid withdrawal and tacrolimus therapy in the treatment of posterior segment intraocular inflammation (uveitis)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN46576063 (first received 16 April 2008). [DOI: https://doi.org/10.1186/ISRCTN46576063]LeeR , GreenwoodR , TaylorH , AmerR , BiesterS , HeissigerovaJ , et al. A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. Ophthalmology2012;119(6):1223‐30. [DOI: 10.1016/j.ophtha.2011.12.030]LeeRW , GreenwoodR , AmerR , BiesterS , PlskovaJ , ForresterJV , et al. Tacrolimus monotherapy versus tacrolimus and prednisone for the maintenance of disease remission in non-infectious posterior segment intraocular inflammation. Investigative Ophthalmology and Visual Science2009;50(13):2024. ">Lee 2012</a>, <a href="./references#CD014831-bbs2-0006" title="NussenblattRB , PalestineA , ChanCC , FujikawaLS , StevensG , GreenSB . A randomised, double-masked trial of sandimmune vs. prednisolone for endogenous uveitis. American Academy of Ophthalmology1990;112:105. [CENTRAL: CN-00485269] NussenblattRB , PalestineAG , ChanCC , StevensG , MellowSD , GreenSB . Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. American Journal of Ophthalmology1991;112(2):138‐46. [CENTRAL: CN-00077346] [DOI: 10.1016/s0002-9394(14)76692-9]">Nussenblatt 1991</a>; <a href="./references#CD014831-bbs2-0011" title="WiederholtM , KämpeC , HansenLL , HövenerG . Treatment of posterior uveitis with cyclosporin or prednisolone--one-year report of a randomized prospective study [Behandlung der uveitis posterior mit cyclosporin oder prednisolon--jahresbericht über eine randomisierte prospektive studie]. Fortschritte der Ophthalmologie1986;83(3):348‐52. [CENTRAL: CN-00044224] [EMBASE: 1986247564] [PMID: 3527903]">Wiederholt 1986</a>.) </p> <p>The overall length and time points for data collection varied between studies, as detailed below. </p> </section> <section id="CD014831-sec-0049"> <h5 class="title">Types of outcomes</h5> <p>There was a wide variety in the study design and reported outcomes of each study, with variation in how authors defined outcomes such as control of inflammation or treatment success. This made comparisons across studies challenging. </p> <section id="CD014831-sec-0050"> <h6 class="title"><i>Active to improvement versus inactive to relapse</i> </h6> <p>Most studies tested an experimental therapy in participants with active disease, and reported measures such as time to control of inflammation; that is, treatment success. Some of these studies would report a time to relapse after control was achieved, often with a loading dose of oral steroids while the experimental medication was being initiated (<a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a>; <a href="./references#CD014831-bbs2-0005" title="MurphyC , GreinerK , PlskovaJ , DuncanL , FrostN , ForresterJ , et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Archives of Ophthalmology2005;123(5):634‐41. [CENTRAL: CN-00511918] [DOI: 10.1001/archopht.123.5.634]">Murphy 2005</a>; <a href="./references#CD014831-bbs2-0002" title="DeuterC , EngelmannK , HeiligenhausA , LanzlI , MackensenF , NessT , et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. British Journal of Ophthalmology2018;102(5):647‐53. [CENTRAL: CN-00781196] [DOI: 10.1136/bjophthalmol-2017-310156]EUCTR2009-009998-10-DE. Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009998-10 (first received 2 December 2009). NCT01092533. Myfortic for the treatment of non-infectious intermediate uveitis (MYCUV-IIT02) [Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectious intermediate uveitis - a prospective, controlled randomized multicenter trial]. clinicaltrials.gov/ct2/show/study/NCT01092533 (first received 25 March 2010). ">Deuter 2018</a>; <a href="./references#CD014831-bbs2-0008" title="JPRN-UMIN000014387. A prospective multicenter comparative clinical trial between corticosteroid pulse therapy vs. combination therapy of oral corticosteroid and cyclosporine on Vogt-Koyanagi-Harada disease. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000014387 (first received 27 June 2014). [CENTRAL: CN-01827271] OnoT , GotoH , SakaiT , NittaF , MizukiN , TakaseH , et al. Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt–Koyanagi–Harada disease. Japanese Journal of Ophthalmology 2021 Oct 24 [Epub ahead of print]. [DOI: 10.1007/s10384-021-00878-w]OnoT , MochizukiM , GotoH , SakaiT , NittaF , MizukiN , et al. A prospective multi-center randomized clinical study comparing steroid-pulse therapy and a combined therapy with oral prednisolone and cyclosporine for new-onset acute Vogt-Koyanagi-Harada disease. Investigative Ophthalmology and Visual Science2020;61(7):3169. [CENTRAL: CN-02179109] [EMBASE: 632697033]">Ono 2021</a>). However, another study design, utilized by <a href="./references#CD014831-bbs2-0004" title="ISRCTN46576063. Tacrolimus monotherapy for uveitis [Dual steroid and tacrolimus therapy versus steroid withdrawal and tacrolimus therapy in the treatment of posterior segment intraocular inflammation (uveitis)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN46576063 (first received 16 April 2008). [DOI: https://doi.org/10.1186/ISRCTN46576063]LeeR , GreenwoodR , TaylorH , AmerR , BiesterS , HeissigerovaJ , et al. A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. Ophthalmology2012;119(6):1223‐30. [DOI: 10.1016/j.ophtha.2011.12.030]LeeRW , GreenwoodR , AmerR , BiesterS , PlskovaJ , ForresterJV , et al. Tacrolimus monotherapy versus tacrolimus and prednisone for the maintenance of disease remission in non-infectious posterior segment intraocular inflammation. Investigative Ophthalmology and Visual Science2009;50(13):2024. ">Lee 2012</a> and <a href="./references#CD014831-bbs2-0002" title="DeuterC , EngelmannK , HeiligenhausA , LanzlI , MackensenF , NessT , et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. British Journal of Ophthalmology2018;102(5):647‐53. [CENTRAL: CN-00781196] [DOI: 10.1136/bjophthalmol-2017-310156]EUCTR2009-009998-10-DE. Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009998-10 (first received 2 December 2009). NCT01092533. Myfortic for the treatment of non-infectious intermediate uveitis (MYCUV-IIT02) [Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectious intermediate uveitis - a prospective, controlled randomized multicenter trial]. clinicaltrials.gov/ct2/show/study/NCT01092533 (first received 25 March 2010). ">Deuter 2018</a>, instead examined participants with inactive disease and tested how long the experimental therapeutic regimen could prevent a relapse; that is, treatment failure. For example, <a href="./references#CD014831-bbs2-0004" title="ISRCTN46576063. Tacrolimus monotherapy for uveitis [Dual steroid and tacrolimus therapy versus steroid withdrawal and tacrolimus therapy in the treatment of posterior segment intraocular inflammation (uveitis)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN46576063 (first received 16 April 2008). [DOI: https://doi.org/10.1186/ISRCTN46576063]LeeR , GreenwoodR , TaylorH , AmerR , BiesterS , HeissigerovaJ , et al. A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. Ophthalmology2012;119(6):1223‐30. [DOI: 10.1016/j.ophtha.2011.12.030]LeeRW , GreenwoodR , AmerR , BiesterS , PlskovaJ , ForresterJV , et al. Tacrolimus monotherapy versus tacrolimus and prednisone for the maintenance of disease remission in non-infectious posterior segment intraocular inflammation. Investigative Ophthalmology and Visual Science2009;50(13):2024. ">Lee 2012</a> required inactive disease for four weeks with target tacrolimus trough levels on a maximum of 10 mg/day of steroid, and then randomized participants to tacrolimus monotherapy (after a quick steroid taper), or to continue dual therapy. Those with active inflammation on this regimen were excluded from the study. </p> </section> <section id="CD014831-sec-0051"> <h6 class="title"><i>Definitions of control of inflammation or time to relapse/hazard of relapse, or both</i> </h6> <p>All studies used a composite measure of multiple clinical exam findings to define "control of inflammation," many in combination with a visual acuity outcome. These definitions were heterogenous. To define inflammatory activity, <a href="./references#CD014831-bbs2-0011" title="WiederholtM , KämpeC , HansenLL , HövenerG . Treatment of posterior uveitis with cyclosporin or prednisolone--one-year report of a randomized prospective study [Behandlung der uveitis posterior mit cyclosporin oder prednisolon--jahresbericht über eine randomisierte prospektive studie]. Fortschritte der Ophthalmologie1986;83(3):348‐52. [CENTRAL: CN-00044224] [EMBASE: 1986247564] [PMID: 3527903]">Wiederholt 1986</a> used a combination of anterior chamber cell and vitreous opacities grading but did not explicitly define what constituted control of inflammation with these parameters. <a href="./references#CD014831-bbs2-0003" title="De VriesJ , BaarsmaG , ZaalM , Boen-TanT , RothovaA , BuitenhuisH , et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. British Journal of Ophthalmology1990;74(6):344‐9. [CENTRAL: CN-00069296] [DOI: 10.1136/bjo.74.6.344]">De Vries 1990</a> utilized a modified Hogan‐Thygeson‐Kimura scale with a variety of domains in both the anterior and posterior segment (congestion, anterior chamber cell/flare, nerve edema, cystoid macular edema [CME], 'snowballs'), and treatment failure was, in part, defined by worsening of this score. A composite weighted visual morbidity scale was also used by <a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a> and incorporated anterior chamber Tyndall and flare measured from grade 0 to 4 and vitreous haze graded from 0 to 4; an improvement in inflammation was then defined as a two‐step decrease in the level of inflammation or a decrease to 0. <a href="./references#CD014831-bbs2-0005" title="MurphyC , GreinerK , PlskovaJ , DuncanL , FrostN , ForresterJ , et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Archives of Ophthalmology2005;123(5):634‐41. [CENTRAL: CN-00511918] [DOI: 10.1001/archopht.123.5.634]">Murphy 2005</a>, <a href="./references#CD014831-bbs2-0004" title="ISRCTN46576063. Tacrolimus monotherapy for uveitis [Dual steroid and tacrolimus therapy versus steroid withdrawal and tacrolimus therapy in the treatment of posterior segment intraocular inflammation (uveitis)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN46576063 (first received 16 April 2008). [DOI: https://doi.org/10.1186/ISRCTN46576063]LeeR , GreenwoodR , TaylorH , AmerR , BiesterS , HeissigerovaJ , et al. A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. Ophthalmology2012;119(6):1223‐30. [DOI: 10.1016/j.ophtha.2011.12.030]LeeRW , GreenwoodR , AmerR , BiesterS , PlskovaJ , ForresterJV , et al. Tacrolimus monotherapy versus tacrolimus and prednisone for the maintenance of disease remission in non-infectious posterior segment intraocular inflammation. Investigative Ophthalmology and Visual Science2009;50(13):2024. ">Lee 2012</a>, and <a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a> utilized a binocular indirect ophthalmoscopy (BIO) score, along with a visual acuity measure, as their definitions of control of inflammation, treatment failure, or treatment success, respectively. <a href="./references#CD014831-bbs2-0006" title="NussenblattRB , PalestineA , ChanCC , FujikawaLS , StevensG , GreenSB . A randomised, double-masked trial of sandimmune vs. prednisolone for endogenous uveitis. American Academy of Ophthalmology1990;112:105. [CENTRAL: CN-00485269] NussenblattRB , PalestineAG , ChanCC , StevensG , MellowSD , GreenSB . Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. American Journal of Ophthalmology1991;112(2):138‐46. [CENTRAL: CN-00077346] [DOI: 10.1016/s0002-9394(14)76692-9]">Nussenblatt 1991</a> and <a href="./references#CD014831-bbs2-0007" title="NussenblattRB , De SmetMD , RubinB , FreidlinV , WhitcupSM , DavisJ , et al. A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin. American Journal of Ophthalmology1993;115(5):583‐91. [CENTRAL: CN-00093004] [DOI: 10.1016/s0002-9394(14)71454-0]">Nussenblatt 1993</a> utilized a two‐step improvement in vitreous haze as a component, along with a visual acuity measurement, in their definition of treatment success, with the latter reporting at 16 weeks and the former at three months. <a href="./references#CD014831-bbs2-0002" title="DeuterC , EngelmannK , HeiligenhausA , LanzlI , MackensenF , NessT , et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. British Journal of Ophthalmology2018;102(5):647‐53. [CENTRAL: CN-00781196] [DOI: 10.1136/bjophthalmol-2017-310156]EUCTR2009-009998-10-DE. Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009998-10 (first received 2 December 2009). NCT01092533. Myfortic for the treatment of non-infectious intermediate uveitis (MYCUV-IIT02) [Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectious intermediate uveitis - a prospective, controlled randomized multicenter trial]. clinicaltrials.gov/ct2/show/study/NCT01092533 (first received 25 March 2010). ">Deuter 2018</a> used vitreous haze, anterior chamber cells, CME, retinal vasculitis, and a visual acuity outcome in their criteria for relapse. <a href="./references#CD014831-bbs2-0008" title="JPRN-UMIN000014387. A prospective multicenter comparative clinical trial between corticosteroid pulse therapy vs. combination therapy of oral corticosteroid and cyclosporine on Vogt-Koyanagi-Harada disease. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000014387 (first received 27 June 2014). [CENTRAL: CN-01827271] OnoT , GotoH , SakaiT , NittaF , MizukiN , TakaseH , et al. Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt–Koyanagi–Harada disease. Japanese Journal of Ophthalmology 2021 Oct 24 [Epub ahead of print]. [DOI: 10.1007/s10384-021-00878-w]OnoT , MochizukiM , GotoH , SakaiT , NittaF , MizukiN , et al. A prospective multi-center randomized clinical study comparing steroid-pulse therapy and a combined therapy with oral prednisolone and cyclosporine for new-onset acute Vogt-Koyanagi-Harada disease. Investigative Ophthalmology and Visual Science2020;61(7):3169. [CENTRAL: CN-02179109] [EMBASE: 632697033]">Ono 2021</a>, a study in all VKH patients, also used a two‐step increase (or increase from 3+ to 4+) of vitreous haze or anterior chamber cells to define "worsening," while "recurrence" was defined as reappearance of a serous retinal detachment on optical coherence tomography (OCT) that had previously resolved, or a return of systemic symptoms of VKH disease. </p> <p><a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a> and <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a> used similar definitions of control of inflammation, utilizing the 0 to 4 grading scale for anterior chamber cells and vitreous haze, and requiring less than or equal to 0.5 + for each, as part of this outcome. The 2014 study also used vitreous cells, again at a level less than or equal to 0.5 +, as a requirement for control of inflammation, and both required participants to have no active retinal or choroidal lesions (<a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a>). Other features required for control of inflammation in these studies were a limitation on amount of oral and topical steroid and lack of failure due to safety or intolerability concerns (see below). These outcomes were primarily determined at six months of follow‐up, although the 2019 study followed participants for an additional six months after this (<a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a>). </p> <p>Time to relapse, hazard of relapse, or relapse rate were not reported by several studies (<a href="./references#CD014831-bbs2-0006" title="NussenblattRB , PalestineA , ChanCC , FujikawaLS , StevensG , GreenSB . A randomised, double-masked trial of sandimmune vs. prednisolone for endogenous uveitis. American Academy of Ophthalmology1990;112:105. [CENTRAL: CN-00485269] NussenblattRB , PalestineAG , ChanCC , StevensG , MellowSD , GreenSB . Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. American Journal of Ophthalmology1991;112(2):138‐46. [CENTRAL: CN-00077346] [DOI: 10.1016/s0002-9394(14)76692-9]">Nussenblatt 1991</a>; <a href="./references#CD014831-bbs2-0007" title="NussenblattRB , De SmetMD , RubinB , FreidlinV , WhitcupSM , DavisJ , et al. A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin. American Journal of Ophthalmology1993;115(5):583‐91. [CENTRAL: CN-00093004] [DOI: 10.1016/s0002-9394(14)71454-0]">Nussenblatt 1993</a>; <a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a>; <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a>). <a href="./references#CD014831-bbs2-0011" title="WiederholtM , KämpeC , HansenLL , HövenerG . Treatment of posterior uveitis with cyclosporin or prednisolone--one-year report of a randomized prospective study [Behandlung der uveitis posterior mit cyclosporin oder prednisolon--jahresbericht über eine randomisierte prospektive studie]. Fortschritte der Ophthalmologie1986;83(3):348‐52. [CENTRAL: CN-00044224] [EMBASE: 1986247564] [PMID: 3527903]">Wiederholt 1986</a> did not go into detail about parameters for relapse, but did report the number of relapses and timing of these relapses over 12 months. <a href="./references#CD014831-bbs2-0005" title="MurphyC , GreinerK , PlskovaJ , DuncanL , FrostN , ForresterJ , et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Archives of Ophthalmology2005;123(5):634‐41. [CENTRAL: CN-00511918] [DOI: 10.1001/archopht.123.5.634]">Murphy 2005</a> determined relapse as a decrease in visual acuity of two lines or an increase in the BIO score of at least one point after achieving a clinical response, and reported a rate of relapse among responders and average time to first relapse over one year of follow‐up. <a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a> reported a rate of relapse and average time to relapse over one year of follow‐up after one year of steroid treatment; <a href="./references#CD014831-bbs2-0004" title="ISRCTN46576063. Tacrolimus monotherapy for uveitis [Dual steroid and tacrolimus therapy versus steroid withdrawal and tacrolimus therapy in the treatment of posterior segment intraocular inflammation (uveitis)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN46576063 (first received 16 April 2008). [DOI: https://doi.org/10.1186/ISRCTN46576063]LeeR , GreenwoodR , TaylorH , AmerR , BiesterS , HeissigerovaJ , et al. A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. Ophthalmology2012;119(6):1223‐30. [DOI: 10.1016/j.ophtha.2011.12.030]LeeRW , GreenwoodR , AmerR , BiesterS , PlskovaJ , ForresterJV , et al. Tacrolimus monotherapy versus tacrolimus and prednisone for the maintenance of disease remission in non-infectious posterior segment intraocular inflammation. Investigative Ophthalmology and Visual Science2009;50(13):2024. ">Lee 2012</a> reported rates of relapse for nine months of follow‐up in a group with established remission at the start of the trial. Time to relapse was the primary outcome for the <a href="./references#CD014831-bbs2-0002" title="DeuterC , EngelmannK , HeiligenhausA , LanzlI , MackensenF , NessT , et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. British Journal of Ophthalmology2018;102(5):647‐53. [CENTRAL: CN-00781196] [DOI: 10.1136/bjophthalmol-2017-310156]EUCTR2009-009998-10-DE. Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009998-10 (first received 2 December 2009). NCT01092533. Myfortic for the treatment of non-infectious intermediate uveitis (MYCUV-IIT02) [Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectious intermediate uveitis - a prospective, controlled randomized multicenter trial]. clinicaltrials.gov/ct2/show/study/NCT01092533 (first received 25 March 2010). ">Deuter 2018</a> study, and the criteria for relapse involved a visual acuity measure, a two‐step change in vitreous haze or anterior chamber cells using a 0 to 4 grading system, new‐onset or worsening CME on OCT, or new‐onset or worsening of retinal vasculitis on fundus fluorescein angiography in the first six months of treatment. <a href="./references#CD014831-bbs2-0008" title="JPRN-UMIN000014387. A prospective multicenter comparative clinical trial between corticosteroid pulse therapy vs. combination therapy of oral corticosteroid and cyclosporine on Vogt-Koyanagi-Harada disease. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000014387 (first received 27 June 2014). [CENTRAL: CN-01827271] OnoT , GotoH , SakaiT , NittaF , MizukiN , TakaseH , et al. Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt–Koyanagi–Harada disease. Japanese Journal of Ophthalmology 2021 Oct 24 [Epub ahead of print]. [DOI: 10.1007/s10384-021-00878-w]OnoT , MochizukiM , GotoH , SakaiT , NittaF , MizukiN , et al. A prospective multi-center randomized clinical study comparing steroid-pulse therapy and a combined therapy with oral prednisolone and cyclosporine for new-onset acute Vogt-Koyanagi-Harada disease. Investigative Ophthalmology and Visual Science2020;61(7):3169. [CENTRAL: CN-02179109] [EMBASE: 632697033]">Ono 2021</a> reported the risk of relapse (recurrence or worsening) over 12 months of observation. </p> </section> <section id="CD014831-sec-0052"> <h6 class="title"><i>Change in BCVA</i> </h6> <p>All studies reported some visual acuity outcome. A variety of vision tests were used, including Snellen tables (<a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a>; <a href="./references#CD014831-bbs2-0011" title="WiederholtM , KämpeC , HansenLL , HövenerG . Treatment of posterior uveitis with cyclosporin or prednisolone--one-year report of a randomized prospective study [Behandlung der uveitis posterior mit cyclosporin oder prednisolon--jahresbericht über eine randomisierte prospektive studie]. Fortschritte der Ophthalmologie1986;83(3):348‐52. [CENTRAL: CN-00044224] [EMBASE: 1986247564] [PMID: 3527903]">Wiederholt 1986</a>), Landolt C optotypes (<a href="./references#CD014831-bbs2-0003" title="De VriesJ , BaarsmaG , ZaalM , Boen-TanT , RothovaA , BuitenhuisH , et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. British Journal of Ophthalmology1990;74(6):344‐9. [CENTRAL: CN-00069296] [DOI: 10.1136/bjo.74.6.344]">De Vries 1990</a>), the Early Treatment of Diabetic Retinopathy Study (ETDRS) chart (<a href="./references#CD014831-bbs2-0002" title="DeuterC , EngelmannK , HeiligenhausA , LanzlI , MackensenF , NessT , et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. British Journal of Ophthalmology2018;102(5):647‐53. [CENTRAL: CN-00781196] [DOI: 10.1136/bjophthalmol-2017-310156]EUCTR2009-009998-10-DE. Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009998-10 (first received 2 December 2009). NCT01092533. Myfortic for the treatment of non-infectious intermediate uveitis (MYCUV-IIT02) [Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectious intermediate uveitis - a prospective, controlled randomized multicenter trial]. clinicaltrials.gov/ct2/show/study/NCT01092533 (first received 25 March 2010). ">Deuter 2018</a>; <a href="./references#CD014831-bbs2-0004" title="ISRCTN46576063. Tacrolimus monotherapy for uveitis [Dual steroid and tacrolimus therapy versus steroid withdrawal and tacrolimus therapy in the treatment of posterior segment intraocular inflammation (uveitis)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN46576063 (first received 16 April 2008). [DOI: https://doi.org/10.1186/ISRCTN46576063]LeeR , GreenwoodR , TaylorH , AmerR , BiesterS , HeissigerovaJ , et al. A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. Ophthalmology2012;119(6):1223‐30. [DOI: 10.1016/j.ophtha.2011.12.030]LeeRW , GreenwoodR , AmerR , BiesterS , PlskovaJ , ForresterJV , et al. Tacrolimus monotherapy versus tacrolimus and prednisone for the maintenance of disease remission in non-infectious posterior segment intraocular inflammation. Investigative Ophthalmology and Visual Science2009;50(13):2024. ">Lee 2012</a>; <a href="./references#CD014831-bbs2-0005" title="MurphyC , GreinerK , PlskovaJ , DuncanL , FrostN , ForresterJ , et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Archives of Ophthalmology2005;123(5):634‐41. [CENTRAL: CN-00511918] [DOI: 10.1001/archopht.123.5.634]">Murphy 2005</a>; <a href="./references#CD014831-bbs2-0006" title="NussenblattRB , PalestineA , ChanCC , FujikawaLS , StevensG , GreenSB . A randomised, double-masked trial of sandimmune vs. prednisolone for endogenous uveitis. American Academy of Ophthalmology1990;112:105. [CENTRAL: CN-00485269] NussenblattRB , PalestineAG , ChanCC , StevensG , MellowSD , GreenSB . Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. American Journal of Ophthalmology1991;112(2):138‐46. [CENTRAL: CN-00077346] [DOI: 10.1016/s0002-9394(14)76692-9]">Nussenblatt 1991</a>; <a href="./references#CD014831-bbs2-0007" title="NussenblattRB , De SmetMD , RubinB , FreidlinV , WhitcupSM , DavisJ , et al. A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin. American Journal of Ophthalmology1993;115(5):583‐91. [CENTRAL: CN-00093004] [DOI: 10.1016/s0002-9394(14)71454-0]">Nussenblatt 1993</a>), tumbling E chart (<a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a>), or a combination of these (<a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a>). <a href="./references#CD014831-bbs2-0008" title="JPRN-UMIN000014387. A prospective multicenter comparative clinical trial between corticosteroid pulse therapy vs. combination therapy of oral corticosteroid and cyclosporine on Vogt-Koyanagi-Harada disease. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000014387 (first received 27 June 2014). [CENTRAL: CN-01827271] OnoT , GotoH , SakaiT , NittaF , MizukiN , TakaseH , et al. Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt–Koyanagi–Harada disease. Japanese Journal of Ophthalmology 2021 Oct 24 [Epub ahead of print]. [DOI: 10.1007/s10384-021-00878-w]OnoT , MochizukiM , GotoH , SakaiT , NittaF , MizukiN , et al. A prospective multi-center randomized clinical study comparing steroid-pulse therapy and a combined therapy with oral prednisolone and cyclosporine for new-onset acute Vogt-Koyanagi-Harada disease. Investigative Ophthalmology and Visual Science2020;61(7):3169. [CENTRAL: CN-02179109] [EMBASE: 632697033]">Ono 2021</a> did not report which eye chart was used for visual acuity assessment. </p> <p>Most studies included a change in visual acuity as a part of their definition of treatment success or failure. <a href="./references#CD014831-bbs2-0003" title="De VriesJ , BaarsmaG , ZaalM , Boen-TanT , RothovaA , BuitenhuisH , et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. British Journal of Ophthalmology1990;74(6):344‐9. [CENTRAL: CN-00069296] [DOI: 10.1136/bjo.74.6.344]">De Vries 1990</a> considered a decrease in visual acuity of two rank numbers or more (presumably in either eye, although this is not explicitly mentioned) compared with the best visual acuity measured at six months, as part of their definition of treatment failure. <a href="./references#CD014831-bbs2-0006" title="NussenblattRB , PalestineA , ChanCC , FujikawaLS , StevensG , GreenSB . A randomised, double-masked trial of sandimmune vs. prednisolone for endogenous uveitis. American Academy of Ophthalmology1990;112:105. [CENTRAL: CN-00485269] NussenblattRB , PalestineAG , ChanCC , StevensG , MellowSD , GreenSB . Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. American Journal of Ophthalmology1991;112(2):138‐46. [CENTRAL: CN-00077346] [DOI: 10.1016/s0002-9394(14)76692-9]">Nussenblatt 1991</a> also included visual acuity outcomes as primary endpoints: improvement of three lines of BCVA at three months in at least one eye was a part of their definition of treatment success, whereas worsening by two lines or more after maximal therapy of one week was a criterion for treatment failure. Therapy with cyclosporine A or G was considered successful in <a href="./references#CD014831-bbs2-0007" title="NussenblattRB , De SmetMD , RubinB , FreidlinV , WhitcupSM , DavisJ , et al. A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin. American Journal of Ophthalmology1993;115(5):583‐91. [CENTRAL: CN-00093004] [DOI: 10.1016/s0002-9394(14)71454-0]">Nussenblatt 1993</a> if there was a 2‐line improvement in baseline visual acuity by 16 weeks; similarly, <a href="./references#CD014831-bbs2-0005" title="MurphyC , GreinerK , PlskovaJ , DuncanL , FrostN , ForresterJ , et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Archives of Ophthalmology2005;123(5):634‐41. [CENTRAL: CN-00511918] [DOI: 10.1001/archopht.123.5.634]">Murphy 2005</a> considered cyclosporine or tacrolimus treatment a success if there was a 2‐line improvement by 12 weeks in at least one eye. The primary outcome in <a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a> was change in best‐corrected visual acuity at 54 weeks of follow‐up. <a href="./references#CD014831-bbs2-0004" title="ISRCTN46576063. Tacrolimus monotherapy for uveitis [Dual steroid and tacrolimus therapy versus steroid withdrawal and tacrolimus therapy in the treatment of posterior segment intraocular inflammation (uveitis)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN46576063 (first received 16 April 2008). [DOI: https://doi.org/10.1186/ISRCTN46576063]LeeR , GreenwoodR , TaylorH , AmerR , BiesterS , HeissigerovaJ , et al. A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. Ophthalmology2012;119(6):1223‐30. [DOI: 10.1016/j.ophtha.2011.12.030]LeeRW , GreenwoodR , AmerR , BiesterS , PlskovaJ , ForresterJV , et al. Tacrolimus monotherapy versus tacrolimus and prednisone for the maintenance of disease remission in non-infectious posterior segment intraocular inflammation. Investigative Ophthalmology and Visual Science2009;50(13):2024. ">Lee 2012</a>, studying participants with inactive disease for time to treatment failure, defined relapse in part as a 2‐line decrease in visual acuity at any point after the start of the trial, or by a subjective decrease in vision accompanied by a change in the BIO score, in either eye. <a href="./references#CD014831-bbs2-0002" title="DeuterC , EngelmannK , HeiligenhausA , LanzlI , MackensenF , NessT , et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. British Journal of Ophthalmology2018;102(5):647‐53. [CENTRAL: CN-00781196] [DOI: 10.1136/bjophthalmol-2017-310156]EUCTR2009-009998-10-DE. Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009998-10 (first received 2 December 2009). NCT01092533. Myfortic for the treatment of non-infectious intermediate uveitis (MYCUV-IIT02) [Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectious intermediate uveitis - a prospective, controlled randomized multicenter trial]. clinicaltrials.gov/ct2/show/study/NCT01092533 (first received 25 March 2010). ">Deuter 2018</a> also used a decrease in visual acuity as a criterion for relapse, requiring a three‐line or greater decrease in BCVA from baseline. </p> <p><a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a> and <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a> both reported a mean change in BCVA at six months, but this was a secondary outcome, and change in visual acuity was not included in their definition of control of inflammation. Change in mean BCVA at each study visit was also a reported secondary outcome in <a href="./references#CD014831-bbs2-0008" title="JPRN-UMIN000014387. A prospective multicenter comparative clinical trial between corticosteroid pulse therapy vs. combination therapy of oral corticosteroid and cyclosporine on Vogt-Koyanagi-Harada disease. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000014387 (first received 27 June 2014). [CENTRAL: CN-01827271] OnoT , GotoH , SakaiT , NittaF , MizukiN , TakaseH , et al. Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt–Koyanagi–Harada disease. Japanese Journal of Ophthalmology 2021 Oct 24 [Epub ahead of print]. [DOI: 10.1007/s10384-021-00878-w]OnoT , MochizukiM , GotoH , SakaiT , NittaF , MizukiN , et al. A prospective multi-center randomized clinical study comparing steroid-pulse therapy and a combined therapy with oral prednisolone and cyclosporine for new-onset acute Vogt-Koyanagi-Harada disease. Investigative Ophthalmology and Visual Science2020;61(7):3169. [CENTRAL: CN-02179109] [EMBASE: 632697033]">Ono 2021</a> over 12 months of follow‐up. The change in BCVA was reported at three and 12 months by <a href="./references#CD014831-bbs2-0011" title="WiederholtM , KämpeC , HansenLL , HövenerG . Treatment of posterior uveitis with cyclosporin or prednisolone--one-year report of a randomized prospective study [Behandlung der uveitis posterior mit cyclosporin oder prednisolon--jahresbericht über eine randomisierte prospektive studie]. Fortschritte der Ophthalmologie1986;83(3):348‐52. [CENTRAL: CN-00044224] [EMBASE: 1986247564] [PMID: 3527903]">Wiederholt 1986</a>, but it is not clear whether one or both eyes were reported in cases of bilateral disease. </p> </section> <section id="CD014831-sec-0053"> <h6 class="title"><i>Macular edema</i> </h6> <p>Two studies discussed the incidence or resolution of macular edema without providing specifics about how this outcome was measured or how presence/worsening was defined (<a href="./references#CD014831-bbs2-0003" title="De VriesJ , BaarsmaG , ZaalM , Boen-TanT , RothovaA , BuitenhuisH , et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. British Journal of Ophthalmology1990;74(6):344‐9. [CENTRAL: CN-00069296] [DOI: 10.1136/bjo.74.6.344]">De Vries 1990</a>; <a href="./references#CD014831-bbs2-0006" title="NussenblattRB , PalestineA , ChanCC , FujikawaLS , StevensG , GreenSB . A randomised, double-masked trial of sandimmune vs. prednisolone for endogenous uveitis. American Academy of Ophthalmology1990;112:105. [CENTRAL: CN-00485269] NussenblattRB , PalestineAG , ChanCC , StevensG , MellowSD , GreenSB . Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. American Journal of Ophthalmology1991;112(2):138‐46. [CENTRAL: CN-00077346] [DOI: 10.1016/s0002-9394(14)76692-9]">Nussenblatt 1991</a>). <a href="./references#CD014831-bbs2-0007" title="NussenblattRB , De SmetMD , RubinB , FreidlinV , WhitcupSM , DavisJ , et al. A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin. American Journal of Ophthalmology1993;115(5):583‐91. [CENTRAL: CN-00093004] [DOI: 10.1016/s0002-9394(14)71454-0]">Nussenblatt 1993</a> determined CME by biomicroscopic examination and reported the proportion with resolution at 16 weeks. <a href="./references#CD014831-bbs2-0004" title="ISRCTN46576063. Tacrolimus monotherapy for uveitis [Dual steroid and tacrolimus therapy versus steroid withdrawal and tacrolimus therapy in the treatment of posterior segment intraocular inflammation (uveitis)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN46576063 (first received 16 April 2008). [DOI: https://doi.org/10.1186/ISRCTN46576063]LeeR , GreenwoodR , TaylorH , AmerR , BiesterS , HeissigerovaJ , et al. A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. Ophthalmology2012;119(6):1223‐30. [DOI: 10.1016/j.ophtha.2011.12.030]LeeRW , GreenwoodR , AmerR , BiesterS , PlskovaJ , ForresterJV , et al. Tacrolimus monotherapy versus tacrolimus and prednisone for the maintenance of disease remission in non-infectious posterior segment intraocular inflammation. Investigative Ophthalmology and Visual Science2009;50(13):2024. ">Lee 2012</a> allowed an increase in central macular thickness to qualify a subjective change in visual acuity as a treatment failure, and required there to be no evidence of CME (by clinical examination, fundus FA, or OCT) at the start of the trial. <a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a> reported the proportion of participants with resolution of macular edema (measured by OCT) at six months, while <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a> reported the mean change in central macular thickness on OCT at six months compared to baseline. <a href="./references#CD014831-bbs2-0002" title="DeuterC , EngelmannK , HeiligenhausA , LanzlI , MackensenF , NessT , et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. British Journal of Ophthalmology2018;102(5):647‐53. [CENTRAL: CN-00781196] [DOI: 10.1136/bjophthalmol-2017-310156]EUCTR2009-009998-10-DE. Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009998-10 (first received 2 December 2009). NCT01092533. Myfortic for the treatment of non-infectious intermediate uveitis (MYCUV-IIT02) [Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectious intermediate uveitis - a prospective, controlled randomized multicenter trial]. clinicaltrials.gov/ct2/show/study/NCT01092533 (first received 25 March 2010). ">Deuter 2018</a> included new‐onset or worsening macular edema, measured by OCT, as a criterion for relapse. </p> </section> <section id="CD014831-sec-0054"> <h6 class="title"><i>Proportion achieving steroid‐sparing control</i> </h6> <p>Several studies did not allow oral steroids to be used in combination with the experimental treatment (<a href="./references#CD014831-bbs2-0004" title="ISRCTN46576063. Tacrolimus monotherapy for uveitis [Dual steroid and tacrolimus therapy versus steroid withdrawal and tacrolimus therapy in the treatment of posterior segment intraocular inflammation (uveitis)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN46576063 (first received 16 April 2008). [DOI: https://doi.org/10.1186/ISRCTN46576063]LeeR , GreenwoodR , TaylorH , AmerR , BiesterS , HeissigerovaJ , et al. A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. Ophthalmology2012;119(6):1223‐30. [DOI: 10.1016/j.ophtha.2011.12.030]LeeRW , GreenwoodR , AmerR , BiesterS , PlskovaJ , ForresterJV , et al. Tacrolimus monotherapy versus tacrolimus and prednisone for the maintenance of disease remission in non-infectious posterior segment intraocular inflammation. Investigative Ophthalmology and Visual Science2009;50(13):2024. ">Lee 2012</a>; <a href="./references#CD014831-bbs2-0006" title="NussenblattRB , PalestineA , ChanCC , FujikawaLS , StevensG , GreenSB . A randomised, double-masked trial of sandimmune vs. prednisolone for endogenous uveitis. American Academy of Ophthalmology1990;112:105. [CENTRAL: CN-00485269] NussenblattRB , PalestineAG , ChanCC , StevensG , MellowSD , GreenSB . Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. American Journal of Ophthalmology1991;112(2):138‐46. [CENTRAL: CN-00077346] [DOI: 10.1016/s0002-9394(14)76692-9]">Nussenblatt 1991</a>; <a href="./references#CD014831-bbs2-0007" title="NussenblattRB , De SmetMD , RubinB , FreidlinV , WhitcupSM , DavisJ , et al. A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin. American Journal of Ophthalmology1993;115(5):583‐91. [CENTRAL: CN-00093004] [DOI: 10.1016/s0002-9394(14)71454-0]">Nussenblatt 1993</a>; <a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a>; <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a>; <a href="./references#CD014831-bbs2-0011" title="WiederholtM , KämpeC , HansenLL , HövenerG . Treatment of posterior uveitis with cyclosporin or prednisolone--one-year report of a randomized prospective study [Behandlung der uveitis posterior mit cyclosporin oder prednisolon--jahresbericht über eine randomisierte prospektive studie]. Fortschritte der Ophthalmologie1986;83(3):348‐52. [CENTRAL: CN-00044224] [EMBASE: 1986247564] [PMID: 3527903]">Wiederholt 1986</a>). Thus, all treatment successes in this group had, by definition, achieved steroid‐sparing control. Similarly, participants whose disease remained active at the start of the <a href="./references#CD014831-bbs2-0004" title="ISRCTN46576063. Tacrolimus monotherapy for uveitis [Dual steroid and tacrolimus therapy versus steroid withdrawal and tacrolimus therapy in the treatment of posterior segment intraocular inflammation (uveitis)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN46576063 (first received 16 April 2008). [DOI: https://doi.org/10.1186/ISRCTN46576063]LeeR , GreenwoodR , TaylorH , AmerR , BiesterS , HeissigerovaJ , et al. A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. Ophthalmology2012;119(6):1223‐30. [DOI: 10.1016/j.ophtha.2011.12.030]LeeRW , GreenwoodR , AmerR , BiesterS , PlskovaJ , ForresterJV , et al. Tacrolimus monotherapy versus tacrolimus and prednisone for the maintenance of disease remission in non-infectious posterior segment intraocular inflammation. Investigative Ophthalmology and Visual Science2009;50(13):2024. ">Lee 2012</a> study on 10 mg or less per day of steroid (plus tacrolimus) were excluded. </p> <p>All participants in the <a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a> study initially received oral steroid monotherapy with a long steroid taper to 5 mg to 10 mg/day over 12 months, and the proportion who developed chronic inflammation despite this therapy was reported. The proportion with chronic inflammation randomized to azathioprine or tacrolimus who could then taper oral steroids to 10 mg or less per day without clinical relapse was also reported, along with the average steroid dose at remission, mean time to reach remission with a steroid dose of 10 mg or less per day, and cumulative steroid dose. </p> <p>The FAST trial and preceding pilot study both utilized steroid‐sparing control as a key feature for treatment success (<a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a>; <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a>), requiring participants to be taking 10 mg or less per day of oral steroid in the 2014 study and 7.5 mg or less per day in the 2019 study (and two drops or less per day of topical 1% prednisolone drops or equivalent in both). Both studies reported the mean time to reach steroid‐sparing control. </p> <p>Other studies discussed steroid‐sparing control but did not explicitly report a proportion or likelihood of steroid‐sparing control. For example, <a href="./references#CD014831-bbs2-0003" title="De VriesJ , BaarsmaG , ZaalM , Boen-TanT , RothovaA , BuitenhuisH , et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. British Journal of Ophthalmology1990;74(6):344‐9. [CENTRAL: CN-00069296] [DOI: 10.1136/bjo.74.6.344]">De Vries 1990</a> only reported the number of participants still tapering from oral steroids at the time of their treatment failure between the cyclosporine‐tapered group and the control group. <a href="./references#CD014831-bbs2-0007" title="NussenblattRB , De SmetMD , RubinB , FreidlinV , WhitcupSM , DavisJ , et al. A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin. American Journal of Ophthalmology1993;115(5):583‐91. [CENTRAL: CN-00093004] [DOI: 10.1016/s0002-9394(14)71454-0]">Nussenblatt 1993</a> reported the number of participants who received more than 20 mg/kg/day of steroids but did not go into detail about the likelihood of steroid‐sparing control. <a href="./references#CD014831-bbs2-0005" title="MurphyC , GreinerK , PlskovaJ , DuncanL , FrostN , ForresterJ , et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Archives of Ophthalmology2005;123(5):634‐41. [CENTRAL: CN-00511918] [DOI: 10.1001/archopht.123.5.634]">Murphy 2005</a> reported the median steroid dose at baseline and months one, three, and six. <a href="./references#CD014831-bbs2-0002" title="DeuterC , EngelmannK , HeiligenhausA , LanzlI , MackensenF , NessT , et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. British Journal of Ophthalmology2018;102(5):647‐53. [CENTRAL: CN-00781196] [DOI: 10.1136/bjophthalmol-2017-310156]EUCTR2009-009998-10-DE. Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009998-10 (first received 2 December 2009). NCT01092533. Myfortic for the treatment of non-infectious intermediate uveitis (MYCUV-IIT02) [Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectious intermediate uveitis - a prospective, controlled randomized multicenter trial]. clinicaltrials.gov/ct2/show/study/NCT01092533 (first received 25 March 2010). ">Deuter 2018</a> required both treatment and control groups to attempt to taper to a maintenance oral steroid dose of 5 mg/day over the course of three months. The proportion of participants achieving steroid‐sparing control was not reported explicitly but can be inferred from the number of participants with disease‐free survival after the three‐month taper. The average steroid dose at the time of first relapse was also reported. In the <a href="./references#CD014831-bbs2-0008" title="JPRN-UMIN000014387. A prospective multicenter comparative clinical trial between corticosteroid pulse therapy vs. combination therapy of oral corticosteroid and cyclosporine on Vogt-Koyanagi-Harada disease. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000014387 (first received 27 June 2014). [CENTRAL: CN-01827271] OnoT , GotoH , SakaiT , NittaF , MizukiN , TakaseH , et al. Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt–Koyanagi–Harada disease. Japanese Journal of Ophthalmology 2021 Oct 24 [Epub ahead of print]. [DOI: 10.1007/s10384-021-00878-w]OnoT , MochizukiM , GotoH , SakaiT , NittaF , MizukiN , et al. A prospective multi-center randomized clinical study comparing steroid-pulse therapy and a combined therapy with oral prednisolone and cyclosporine for new-onset acute Vogt-Koyanagi-Harada disease. Investigative Ophthalmology and Visual Science2020;61(7):3169. [CENTRAL: CN-02179109] [EMBASE: 632697033]">Ono 2021</a> study, a complete taper from oral steroid was attempted in both groups, with only a 20% or one‐week adjustment in steroid dose/duration allowed. Systemic therapy terminated at approximately 26 weeks in this study, and follow‐up was conducted for 12 months. Therefore, any participant experiencing treatment success after the conclusion of the systemic therapy would, by definition, also have steroid‐sparing success. </p> </section> <section id="CD014831-sec-0055"> <h6 class="title"><i>Change in other activity domains (anterior chamber cells, 'snowballs', etc.)</i>  </h6> <p><a href="./references#CD014831-bbs2-0011" title="WiederholtM , KämpeC , HansenLL , HövenerG . Treatment of posterior uveitis with cyclosporin or prednisolone--one-year report of a randomized prospective study [Behandlung der uveitis posterior mit cyclosporin oder prednisolon--jahresbericht über eine randomisierte prospektive studie]. Fortschritte der Ophthalmologie1986;83(3):348‐52. [CENTRAL: CN-00044224] [EMBASE: 1986247564] [PMID: 3527903]">Wiederholt 1986</a> reported the change in vitreous opacities over the course of 12 months (in three‐month increments) using a 0 to 4 scale. As mentioned above, <a href="./references#CD014831-bbs2-0003" title="De VriesJ , BaarsmaG , ZaalM , Boen-TanT , RothovaA , BuitenhuisH , et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. British Journal of Ophthalmology1990;74(6):344‐9. [CENTRAL: CN-00069296] [DOI: 10.1136/bjo.74.6.344]">De Vries 1990</a> collected a variety of activity domains in the anterior and posterior segment as a part of a composite "inflammatory activity score," and reported these findings as a part of their definition of treatment failure (an increase in inflammatory activity score of 4 points or more at any point over the one‐year study). </p> <p>Many studies' definitions of control of inflammation used grading of anterior chamber cells (<a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a>; <a href="./references#CD014831-bbs2-0002" title="DeuterC , EngelmannK , HeiligenhausA , LanzlI , MackensenF , NessT , et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. British Journal of Ophthalmology2018;102(5):647‐53. [CENTRAL: CN-00781196] [DOI: 10.1136/bjophthalmol-2017-310156]EUCTR2009-009998-10-DE. Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009998-10 (first received 2 December 2009). NCT01092533. Myfortic for the treatment of non-infectious intermediate uveitis (MYCUV-IIT02) [Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectious intermediate uveitis - a prospective, controlled randomized multicenter trial]. clinicaltrials.gov/ct2/show/study/NCT01092533 (first received 25 March 2010). ">Deuter 2018</a>; <a href="./references#CD014831-bbs2-0003" title="De VriesJ , BaarsmaG , ZaalM , Boen-TanT , RothovaA , BuitenhuisH , et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. British Journal of Ophthalmology1990;74(6):344‐9. [CENTRAL: CN-00069296] [DOI: 10.1136/bjo.74.6.344]">De Vries 1990</a>; <a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a>; <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a>; <a href="./references#CD014831-bbs2-0011" title="WiederholtM , KämpeC , HansenLL , HövenerG . Treatment of posterior uveitis with cyclosporin or prednisolone--one-year report of a randomized prospective study [Behandlung der uveitis posterior mit cyclosporin oder prednisolon--jahresbericht über eine randomisierte prospektive studie]. Fortschritte der Ophthalmologie1986;83(3):348‐52. [CENTRAL: CN-00044224] [EMBASE: 1986247564] [PMID: 3527903]">Wiederholt 1986</a>). For example, a maximum amount of anterior chamber cells (grade ≤ 0.5) was a part of the definition of control of inflammation in <a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a> and <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a> at the six‐month time point, while many other studies used a two‐step change in anterior chamber cell to define a treatment success or failure. <a href="./references#CD014831-bbs2-0006" title="NussenblattRB , PalestineA , ChanCC , FujikawaLS , StevensG , GreenSB . A randomised, double-masked trial of sandimmune vs. prednisolone for endogenous uveitis. American Academy of Ophthalmology1990;112:105. [CENTRAL: CN-00485269] NussenblattRB , PalestineAG , ChanCC , StevensG , MellowSD , GreenSB . Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. American Journal of Ophthalmology1991;112(2):138‐46. [CENTRAL: CN-00077346] [DOI: 10.1016/s0002-9394(14)76692-9]">Nussenblatt 1991</a> reported anterior chamber cell and flare in addition to vitreous cell and haze in monthly increments for months 0 to three but did not include this in their definition of treatment success/failure. </p> <p><a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a>, a study with only VKH patients, also discussed the rate of serous retinal detachment. <a href="./references#CD014831-bbs2-0008" title="JPRN-UMIN000014387. A prospective multicenter comparative clinical trial between corticosteroid pulse therapy vs. combination therapy of oral corticosteroid and cyclosporine on Vogt-Koyanagi-Harada disease. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000014387 (first received 27 June 2014). [CENTRAL: CN-01827271] OnoT , GotoH , SakaiT , NittaF , MizukiN , TakaseH , et al. Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt–Koyanagi–Harada disease. Japanese Journal of Ophthalmology 2021 Oct 24 [Epub ahead of print]. [DOI: 10.1007/s10384-021-00878-w]OnoT , MochizukiM , GotoH , SakaiT , NittaF , MizukiN , et al. A prospective multi-center randomized clinical study comparing steroid-pulse therapy and a combined therapy with oral prednisolone and cyclosporine for new-onset acute Vogt-Koyanagi-Harada disease. Investigative Ophthalmology and Visual Science2020;61(7):3169. [CENTRAL: CN-02179109] [EMBASE: 632697033]">Ono 2021</a> also examined a VKH‐only population, and incorporated recurrence of a serous retinal detachment into their definition of relapse. They also reported other VKH‐specific activity domains, such as mean sub‐foveal choroidal thickness by enhanced‐depth imaging OCT (EDI‐OCT), incidence of hypofluorescent dark dots evaluated by indocyanine green angiography (ICGA), and 'sunset glow' fundus, in addition to more general uveitic activity domains, such as anterior chamber cell and flare, at all study time points through 12 months of follow‐up. </p> <p>Most studies did not report other activity domains, such as 'snowballs'.</p> </section> <section id="CD014831-sec-0056"> <h6 class="title"><i>Quality of life </i> </h6> <p><a href="./references#CD014831-bbs2-0005" title="MurphyC , GreinerK , PlskovaJ , DuncanL , FrostN , ForresterJ , et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Archives of Ophthalmology2005;123(5):634‐41. [CENTRAL: CN-00511918] [DOI: 10.1001/archopht.123.5.634]">Murphy 2005</a> reported both vision‐related and health‐related quality of life data through self‐administered questionnaires at one, three, six, and 12 months of follow‐up using the Vision Core Module‐1 (VCM‐1) and UK standard version of the 36‐item Short‐Form Heath Survey (SF‐36), respectively. <a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a> and <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a> reported vision‐related quality of life with the National Eye Institute Visual Function Questionnaire (NEI‐VFQ) or the Indian Visual Function Questionnaire (IND‐VFQ), a Tamil version validated for use in southern India. Health‐related quality of life data were collected with version 2 of the SF‐36 (SF‐36v2). These studies collected quality of life metrics at baseline and six months, and for the 2019 study, at 12 months. The rest of the included studies did not report quality of life measures. </p> </section> <section id="CD014831-sec-0057"> <h6 class="title"><i>Cost </i> </h6> <p>No studies reported cost‐effectiveness outcomes.</p> </section> <section id="CD014831-sec-0058"> <h6 class="title"><i>Adverse events/safety reporting</i> </h6> <p>Collection and reporting of adverse events also varied widely from study to study, with some reporting incidences (i.e. number) of events, some reporting the proportion or percentage of participants experiencing events (<a href="./references#CD014831-bbs2-0003" title="De VriesJ , BaarsmaG , ZaalM , Boen-TanT , RothovaA , BuitenhuisH , et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. British Journal of Ophthalmology1990;74(6):344‐9. [CENTRAL: CN-00069296] [DOI: 10.1136/bjo.74.6.344]">De Vries 1990</a>; <a href="./references#CD014831-bbs2-0006" title="NussenblattRB , PalestineA , ChanCC , FujikawaLS , StevensG , GreenSB . A randomised, double-masked trial of sandimmune vs. prednisolone for endogenous uveitis. American Academy of Ophthalmology1990;112:105. [CENTRAL: CN-00485269] NussenblattRB , PalestineAG , ChanCC , StevensG , MellowSD , GreenSB . Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. American Journal of Ophthalmology1991;112(2):138‐46. [CENTRAL: CN-00077346] [DOI: 10.1016/s0002-9394(14)76692-9]">Nussenblatt 1991</a>), or some combination of both. Many of the smaller studies simply listed systemic and ocular adverse events which had occurred without commenting on the proportion of participants experiencing them or specific laboratory values (<a href="./references#CD014831-bbs2-0011" title="WiederholtM , KämpeC , HansenLL , HövenerG . Treatment of posterior uveitis with cyclosporin or prednisolone--one-year report of a randomized prospective study [Behandlung der uveitis posterior mit cyclosporin oder prednisolon--jahresbericht über eine randomisierte prospektive studie]. Fortschritte der Ophthalmologie1986;83(3):348‐52. [CENTRAL: CN-00044224] [EMBASE: 1986247564] [PMID: 3527903]">Wiederholt 1986</a>). Included studies frequently did not report when adverse events had occurred in the course of the study. Given the wide range of study durations, this made temporal comparisons about adverse events challenging. </p> <p><a href="./references#CD014831-bbs2-0007" title="NussenblattRB , De SmetMD , RubinB , FreidlinV , WhitcupSM , DavisJ , et al. A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin. American Journal of Ophthalmology1993;115(5):583‐91. [CENTRAL: CN-00093004] [DOI: 10.1016/s0002-9394(14)71454-0]">Nussenblatt 1993</a> reported detailed parameters for renal toxicity, including glomerular filtration rate and effective renal plasma flow, liver toxicity, hypertension, and blood counts. <a href="./references#CD014831-bbs2-0005" title="MurphyC , GreinerK , PlskovaJ , DuncanL , FrostN , ForresterJ , et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Archives of Ophthalmology2005;123(5):634‐41. [CENTRAL: CN-00511918] [DOI: 10.1001/archopht.123.5.634]">Murphy 2005</a> reported median serum creatinine levels at baseline, month 1, and month 3, along with median total serum cholesterol levels and median mean arterial pressures at the same time points. <a href="./references#CD014831-bbs2-0004" title="ISRCTN46576063. Tacrolimus monotherapy for uveitis [Dual steroid and tacrolimus therapy versus steroid withdrawal and tacrolimus therapy in the treatment of posterior segment intraocular inflammation (uveitis)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN46576063 (first received 16 April 2008). [DOI: https://doi.org/10.1186/ISRCTN46576063]LeeR , GreenwoodR , TaylorH , AmerR , BiesterS , HeissigerovaJ , et al. A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. Ophthalmology2012;119(6):1223‐30. [DOI: 10.1016/j.ophtha.2011.12.030]LeeRW , GreenwoodR , AmerR , BiesterS , PlskovaJ , ForresterJV , et al. Tacrolimus monotherapy versus tacrolimus and prednisone for the maintenance of disease remission in non-infectious posterior segment intraocular inflammation. Investigative Ophthalmology and Visual Science2009;50(13):2024. ">Lee 2012</a> did not report values for serum creatinine levels but did use a rise in serum creatinine as part of their definition of medication intolerance. </p> <p><a href="./references#CD014831-bbs2-0005" title="MurphyC , GreinerK , PlskovaJ , DuncanL , FrostN , ForresterJ , et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Archives of Ophthalmology2005;123(5):634‐41. [CENTRAL: CN-00511918] [DOI: 10.1001/archopht.123.5.634]">Murphy 2005</a> utilized a self‐reported adverse‐events questionnaire with a 0 to 5 scale in which participants ranked how much adverse reactions affected quality of life. However, only proportions of participants experiencing each of these were reported in their publication rather than the self‐reported severity. <a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a> utilized predefined hematologic parameters (leukocyte count, platelet count, and hemoglobin) as indications for withdrawal of azathioprine or tacrolimus immunosuppression, and also reported the proportion of participants experiencing a variety of ocular and systemic complications. <a href="./references#CD014831-bbs2-0004" title="ISRCTN46576063. Tacrolimus monotherapy for uveitis [Dual steroid and tacrolimus therapy versus steroid withdrawal and tacrolimus therapy in the treatment of posterior segment intraocular inflammation (uveitis)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN46576063 (first received 16 April 2008). [DOI: https://doi.org/10.1186/ISRCTN46576063]LeeR , GreenwoodR , TaylorH , AmerR , BiesterS , HeissigerovaJ , et al. A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. Ophthalmology2012;119(6):1223‐30. [DOI: 10.1016/j.ophtha.2011.12.030]LeeRW , GreenwoodR , AmerR , BiesterS , PlskovaJ , ForresterJV , et al. Tacrolimus monotherapy versus tacrolimus and prednisone for the maintenance of disease remission in non-infectious posterior segment intraocular inflammation. Investigative Ophthalmology and Visual Science2009;50(13):2024. ">Lee 2012</a> reported rates of blood test abnormalities as incidence rates per patient‐year of treatment, but other adverse events, such as headache and tremor, as a proportion of participants experiencing the event at any time post‐randomization. <a href="./references#CD014831-bbs2-0002" title="DeuterC , EngelmannK , HeiligenhausA , LanzlI , MackensenF , NessT , et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. British Journal of Ophthalmology2018;102(5):647‐53. [CENTRAL: CN-00781196] [DOI: 10.1136/bjophthalmol-2017-310156]EUCTR2009-009998-10-DE. Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009998-10 (first received 2 December 2009). NCT01092533. Myfortic for the treatment of non-infectious intermediate uveitis (MYCUV-IIT02) [Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectious intermediate uveitis - a prospective, controlled randomized multicenter trial]. clinicaltrials.gov/ct2/show/study/NCT01092533 (first received 25 March 2010). ">Deuter 2018</a> also reported adverse events in patient‐years, and grouped them by serious adverse events, all adverse events, laboratory abnormalities, events requiring discontinuation of the medication, and listed a few specific adverse events, such as infections, headache, and gastrointestinal problems. </p> <p><a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a> and <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a> formally incorporated "no safety or intolerability concerns" in their definition of treatment success. These studies collected adverse events in three categories: ocular, systemic, and laboratory (changes in alanine transaminase [ALT], aspartate transaminase [AST], hemoglobin, leukocyte count, creatinine), and reported them as proportions of participants experiencing each over the six months of follow‐up. </p> <p><a href="./references#CD014831-bbs2-0008" title="JPRN-UMIN000014387. A prospective multicenter comparative clinical trial between corticosteroid pulse therapy vs. combination therapy of oral corticosteroid and cyclosporine on Vogt-Koyanagi-Harada disease. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000014387 (first received 27 June 2014). [CENTRAL: CN-01827271] OnoT , GotoH , SakaiT , NittaF , MizukiN , TakaseH , et al. Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt–Koyanagi–Harada disease. Japanese Journal of Ophthalmology 2021 Oct 24 [Epub ahead of print]. [DOI: 10.1007/s10384-021-00878-w]OnoT , MochizukiM , GotoH , SakaiT , NittaF , MizukiN , et al. A prospective multi-center randomized clinical study comparing steroid-pulse therapy and a combined therapy with oral prednisolone and cyclosporine for new-onset acute Vogt-Koyanagi-Harada disease. Investigative Ophthalmology and Visual Science2020;61(7):3169. [CENTRAL: CN-02179109] [EMBASE: 632697033]">Ono 2021</a> reported a survival curve of cataract formation over the course of 12 or more months of follow‐up. "Serious" adverse events (hyponatremia, severe headache) were reported as a proportion. "Non‐serious adverse events", including systemic events (fatigue, tremor) and laboratory abnormalities (hyperglycemia, elevation in liver enzymes), were also grouped together into an overall proportion of participants experiencing any of these over the course of the study. </p> <p>All studies did report if serious adverse events or intolerability required cessation of medication. Dose reductions were allowed in some studies (<a href="./references#CD014831-bbs2-0002" title="DeuterC , EngelmannK , HeiligenhausA , LanzlI , MackensenF , NessT , et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. British Journal of Ophthalmology2018;102(5):647‐53. [CENTRAL: CN-00781196] [DOI: 10.1136/bjophthalmol-2017-310156]EUCTR2009-009998-10-DE. Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009998-10 (first received 2 December 2009). NCT01092533. Myfortic for the treatment of non-infectious intermediate uveitis (MYCUV-IIT02) [Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectious intermediate uveitis - a prospective, controlled randomized multicenter trial]. clinicaltrials.gov/ct2/show/study/NCT01092533 (first received 25 March 2010). ">Deuter 2018</a>; <a href="./references#CD014831-bbs2-0003" title="De VriesJ , BaarsmaG , ZaalM , Boen-TanT , RothovaA , BuitenhuisH , et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. British Journal of Ophthalmology1990;74(6):344‐9. [CENTRAL: CN-00069296] [DOI: 10.1136/bjo.74.6.344]">De Vries 1990</a>; <a href="./references#CD014831-bbs2-0005" title="MurphyC , GreinerK , PlskovaJ , DuncanL , FrostN , ForresterJ , et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Archives of Ophthalmology2005;123(5):634‐41. [CENTRAL: CN-00511918] [DOI: 10.1001/archopht.123.5.634]">Murphy 2005</a>; <a href="./references#CD014831-bbs2-0006" title="NussenblattRB , PalestineA , ChanCC , FujikawaLS , StevensG , GreenSB . A randomised, double-masked trial of sandimmune vs. prednisolone for endogenous uveitis. American Academy of Ophthalmology1990;112:105. [CENTRAL: CN-00485269] NussenblattRB , PalestineAG , ChanCC , StevensG , MellowSD , GreenSB . Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. American Journal of Ophthalmology1991;112(2):138‐46. [CENTRAL: CN-00077346] [DOI: 10.1016/s0002-9394(14)76692-9]">Nussenblatt 1991</a>; <a href="./references#CD014831-bbs2-0007" title="NussenblattRB , De SmetMD , RubinB , FreidlinV , WhitcupSM , DavisJ , et al. A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin. American Journal of Ophthalmology1993;115(5):583‐91. [CENTRAL: CN-00093004] [DOI: 10.1016/s0002-9394(14)71454-0]">Nussenblatt 1993</a>; <a href="./references#CD014831-bbs2-0008" title="JPRN-UMIN000014387. A prospective multicenter comparative clinical trial between corticosteroid pulse therapy vs. combination therapy of oral corticosteroid and cyclosporine on Vogt-Koyanagi-Harada disease. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000014387 (first received 27 June 2014). [CENTRAL: CN-01827271] OnoT , GotoH , SakaiT , NittaF , MizukiN , TakaseH , et al. Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt–Koyanagi–Harada disease. Japanese Journal of Ophthalmology 2021 Oct 24 [Epub ahead of print]. [DOI: 10.1007/s10384-021-00878-w]OnoT , MochizukiM , GotoH , SakaiT , NittaF , MizukiN , et al. A prospective multi-center randomized clinical study comparing steroid-pulse therapy and a combined therapy with oral prednisolone and cyclosporine for new-onset acute Vogt-Koyanagi-Harada disease. Investigative Ophthalmology and Visual Science2020;61(7):3169. [CENTRAL: CN-02179109] [EMBASE: 632697033]">Ono 2021</a>; <a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a>; <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a>). </p> </section> <section id="CD014831-sec-0059"> <h6 class="title"><i>Subgroup analyses</i> </h6> <p>Most studies were too small to analyze subgroups with any statistical power. <a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a> and <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a> analyzed treatment success by anatomic subgroup, breaking participants into anterior and intermediate/intermediate only versus posterior/panuveitis groups. Both trials also carried out separate subgroup analyses for participants with VKH. </p> </section> </section> </section> <section id="CD014831-sec-0060"> <h4 class="title">Excluded studies</h4> <p>We excluded six studies (11 records) at the full‐text screening stage. The primary reasons for exclusion were: ineligible study design (one study); ineligible comparator (two studies); ineligible intervention or co‐intervention (two studies); ineligible population (one study). Please see the <a href="./references#CD014831-sec-0163" title="">Characteristics of excluded studies</a> for further details. </p> </section> </section> <section id="CD014831-sec-0061"> <h3 class="title">Risk of bias in included studies</h3> <p>We evaluated the risk of bias using the Risk of Bias 2 (RoB2) tool for two outcomes, "proportion of participants achieving control of inflammation" (<a href="#CD014831-fig-0002">Figure 2</a>) and "proportion of participants experiencing complications or requiring cessation of medication" (<a href="#CD014831-fig-0003">Figure 3</a>). One study did not report the efficacy outcome (<a href="./references#CD014831-bbs2-0007" title="NussenblattRB , De SmetMD , RubinB , FreidlinV , WhitcupSM , DavisJ , et al. A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin. American Journal of Ophthalmology1993;115(5):583‐91. [CENTRAL: CN-00093004] [DOI: 10.1016/s0002-9394(14)71454-0]">Nussenblatt 1993</a>), and two studies did not report the safety outcome to allow for the risk of bias assessment (<a href="./references#CD014831-bbs2-0006" title="NussenblattRB , PalestineA , ChanCC , FujikawaLS , StevensG , GreenSB . A randomised, double-masked trial of sandimmune vs. prednisolone for endogenous uveitis. American Academy of Ophthalmology1990;112:105. [CENTRAL: CN-00485269] NussenblattRB , PalestineAG , ChanCC , StevensG , MellowSD , GreenSB . Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. American Journal of Ophthalmology1991;112(2):138‐46. [CENTRAL: CN-00077346] [DOI: 10.1016/s0002-9394(14)76692-9]">Nussenblatt 1991</a>; <a href="./references#CD014831-bbs2-0011" title="WiederholtM , KämpeC , HansenLL , HövenerG . Treatment of posterior uveitis with cyclosporin or prednisolone--one-year report of a randomized prospective study [Behandlung der uveitis posterior mit cyclosporin oder prednisolon--jahresbericht über eine randomisierte prospektive studie]. Fortschritte der Ophthalmologie1986;83(3):348‐52. [CENTRAL: CN-00044224] [EMBASE: 1986247564] [PMID: 3527903]">Wiederholt 1986</a>). Therefore, we included 10 and nine studies, respectively, in the risk of bias assessments of these outcomes. </p> <div class="figure" id="CD014831-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: proportion of participants achieving control of inflammation  " data-id="CD014831-fig-0002" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-FIG-02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: proportion of participants achieving control of inflammation   </p> </div> </div> </div> <div class="figure" id="CD014831-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: proportion of participants experiencing complications or requiring cessation of medication " data-id="CD014831-fig-0003" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-FIG-03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: proportion of participants experiencing complications or requiring cessation of medication  </p> </div> </div> </div> <p>Regarding the efficacy outcome, we judged only <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a> to be at low risk of bias overall. We judged five of the 10 studies (50%) to have a high risk of bias (<a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a>; <a href="./references#CD014831-bbs2-0002" title="DeuterC , EngelmannK , HeiligenhausA , LanzlI , MackensenF , NessT , et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. British Journal of Ophthalmology2018;102(5):647‐53. [CENTRAL: CN-00781196] [DOI: 10.1136/bjophthalmol-2017-310156]EUCTR2009-009998-10-DE. Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009998-10 (first received 2 December 2009). NCT01092533. Myfortic for the treatment of non-infectious intermediate uveitis (MYCUV-IIT02) [Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectious intermediate uveitis - a prospective, controlled randomized multicenter trial]. clinicaltrials.gov/ct2/show/study/NCT01092533 (first received 25 March 2010). ">Deuter 2018</a>; <a href="./references#CD014831-bbs2-0004" title="ISRCTN46576063. Tacrolimus monotherapy for uveitis [Dual steroid and tacrolimus therapy versus steroid withdrawal and tacrolimus therapy in the treatment of posterior segment intraocular inflammation (uveitis)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN46576063 (first received 16 April 2008). [DOI: https://doi.org/10.1186/ISRCTN46576063]LeeR , GreenwoodR , TaylorH , AmerR , BiesterS , HeissigerovaJ , et al. A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. Ophthalmology2012;119(6):1223‐30. [DOI: 10.1016/j.ophtha.2011.12.030]LeeRW , GreenwoodR , AmerR , BiesterS , PlskovaJ , ForresterJV , et al. Tacrolimus monotherapy versus tacrolimus and prednisone for the maintenance of disease remission in non-infectious posterior segment intraocular inflammation. Investigative Ophthalmology and Visual Science2009;50(13):2024. ">Lee 2012</a>; <a href="./references#CD014831-bbs2-0005" title="MurphyC , GreinerK , PlskovaJ , DuncanL , FrostN , ForresterJ , et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Archives of Ophthalmology2005;123(5):634‐41. [CENTRAL: CN-00511918] [DOI: 10.1001/archopht.123.5.634]">Murphy 2005</a>; <a href="./references#CD014831-bbs2-0011" title="WiederholtM , KämpeC , HansenLL , HövenerG . Treatment of posterior uveitis with cyclosporin or prednisolone--one-year report of a randomized prospective study [Behandlung der uveitis posterior mit cyclosporin oder prednisolon--jahresbericht über eine randomisierte prospektive studie]. Fortschritte der Ophthalmologie1986;83(3):348‐52. [CENTRAL: CN-00044224] [EMBASE: 1986247564] [PMID: 3527903]">Wiederholt 1986</a>). We judged the remaining RCTs to have "some concerns" in the overall risk of bias (<a href="./references#CD014831-bbs2-0006" title="NussenblattRB , PalestineA , ChanCC , FujikawaLS , StevensG , GreenSB . A randomised, double-masked trial of sandimmune vs. prednisolone for endogenous uveitis. American Academy of Ophthalmology1990;112:105. [CENTRAL: CN-00485269] NussenblattRB , PalestineAG , ChanCC , StevensG , MellowSD , GreenSB . Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. American Journal of Ophthalmology1991;112(2):138‐46. [CENTRAL: CN-00077346] [DOI: 10.1016/s0002-9394(14)76692-9]">Nussenblatt 1991</a>; <a href="./references#CD014831-bbs2-0008" title="JPRN-UMIN000014387. A prospective multicenter comparative clinical trial between corticosteroid pulse therapy vs. combination therapy of oral corticosteroid and cyclosporine on Vogt-Koyanagi-Harada disease. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000014387 (first received 27 June 2014). [CENTRAL: CN-01827271] OnoT , GotoH , SakaiT , NittaF , MizukiN , TakaseH , et al. Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt–Koyanagi–Harada disease. Japanese Journal of Ophthalmology 2021 Oct 24 [Epub ahead of print]. [DOI: 10.1007/s10384-021-00878-w]OnoT , MochizukiM , GotoH , SakaiT , NittaF , MizukiN , et al. A prospective multi-center randomized clinical study comparing steroid-pulse therapy and a combined therapy with oral prednisolone and cyclosporine for new-onset acute Vogt-Koyanagi-Harada disease. Investigative Ophthalmology and Visual Science2020;61(7):3169. [CENTRAL: CN-02179109] [EMBASE: 632697033]">Ono 2021</a>; <a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a>). We considered no study to be at low risk of bias for the safety outcome. We judged five studies to have "some concerns" overall (<a href="./references#CD014831-bbs2-0003" title="De VriesJ , BaarsmaG , ZaalM , Boen-TanT , RothovaA , BuitenhuisH , et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. British Journal of Ophthalmology1990;74(6):344‐9. [CENTRAL: CN-00069296] [DOI: 10.1136/bjo.74.6.344]">De Vries 1990</a>; <a href="./references#CD014831-bbs2-0007" title="NussenblattRB , De SmetMD , RubinB , FreidlinV , WhitcupSM , DavisJ , et al. A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin. American Journal of Ophthalmology1993;115(5):583‐91. [CENTRAL: CN-00093004] [DOI: 10.1016/s0002-9394(14)71454-0]">Nussenblatt 1993</a>; <a href="./references#CD014831-bbs2-0008" title="JPRN-UMIN000014387. A prospective multicenter comparative clinical trial between corticosteroid pulse therapy vs. combination therapy of oral corticosteroid and cyclosporine on Vogt-Koyanagi-Harada disease. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000014387 (first received 27 June 2014). [CENTRAL: CN-01827271] OnoT , GotoH , SakaiT , NittaF , MizukiN , TakaseH , et al. Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt–Koyanagi–Harada disease. Japanese Journal of Ophthalmology 2021 Oct 24 [Epub ahead of print]. [DOI: 10.1007/s10384-021-00878-w]OnoT , MochizukiM , GotoH , SakaiT , NittaF , MizukiN , et al. A prospective multi-center randomized clinical study comparing steroid-pulse therapy and a combined therapy with oral prednisolone and cyclosporine for new-onset acute Vogt-Koyanagi-Harada disease. Investigative Ophthalmology and Visual Science2020;61(7):3169. [CENTRAL: CN-02179109] [EMBASE: 632697033]">Ono 2021</a>; <a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a>; <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a>). We determined the overall risk of bias in the safety outcome to be high in four (44%) of the nine studies (<a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a>; <a href="./references#CD014831-bbs2-0002" title="DeuterC , EngelmannK , HeiligenhausA , LanzlI , MackensenF , NessT , et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. British Journal of Ophthalmology2018;102(5):647‐53. [CENTRAL: CN-00781196] [DOI: 10.1136/bjophthalmol-2017-310156]EUCTR2009-009998-10-DE. Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009998-10 (first received 2 December 2009). NCT01092533. Myfortic for the treatment of non-infectious intermediate uveitis (MYCUV-IIT02) [Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectious intermediate uveitis - a prospective, controlled randomized multicenter trial]. clinicaltrials.gov/ct2/show/study/NCT01092533 (first received 25 March 2010). ">Deuter 2018</a>; <a href="./references#CD014831-bbs2-0004" title="ISRCTN46576063. Tacrolimus monotherapy for uveitis [Dual steroid and tacrolimus therapy versus steroid withdrawal and tacrolimus therapy in the treatment of posterior segment intraocular inflammation (uveitis)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN46576063 (first received 16 April 2008). [DOI: https://doi.org/10.1186/ISRCTN46576063]LeeR , GreenwoodR , TaylorH , AmerR , BiesterS , HeissigerovaJ , et al. A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. Ophthalmology2012;119(6):1223‐30. [DOI: 10.1016/j.ophtha.2011.12.030]LeeRW , GreenwoodR , AmerR , BiesterS , PlskovaJ , ForresterJV , et al. Tacrolimus monotherapy versus tacrolimus and prednisone for the maintenance of disease remission in non-infectious posterior segment intraocular inflammation. Investigative Ophthalmology and Visual Science2009;50(13):2024. ">Lee 2012</a>; <a href="./references#CD014831-bbs2-0005" title="MurphyC , GreinerK , PlskovaJ , DuncanL , FrostN , ForresterJ , et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Archives of Ophthalmology2005;123(5):634‐41. [CENTRAL: CN-00511918] [DOI: 10.1001/archopht.123.5.634]">Murphy 2005</a>). </p> <section id="CD014831-sec-0062"> <h4 class="title"><i>Bias arising from the randomization process</i> </h4> <p>Three studies did not describe the randomization process whatsoever (<a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a>; <a href="./references#CD014831-bbs2-0006" title="NussenblattRB , PalestineA , ChanCC , FujikawaLS , StevensG , GreenSB . A randomised, double-masked trial of sandimmune vs. prednisolone for endogenous uveitis. American Academy of Ophthalmology1990;112:105. [CENTRAL: CN-00485269] NussenblattRB , PalestineAG , ChanCC , StevensG , MellowSD , GreenSB . Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. American Journal of Ophthalmology1991;112(2):138‐46. [CENTRAL: CN-00077346] [DOI: 10.1016/s0002-9394(14)76692-9]">Nussenblatt 1991</a>; <a href="./references#CD014831-bbs2-0007" title="NussenblattRB , De SmetMD , RubinB , FreidlinV , WhitcupSM , DavisJ , et al. A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin. American Journal of Ophthalmology1993;115(5):583‐91. [CENTRAL: CN-00093004] [DOI: 10.1016/s0002-9394(14)71454-0]">Nussenblatt 1993</a>). Allocation sequence concealment was also frequently not mentioned in the included studies, and was missing from three studies (<a href="./references#CD014831-bbs2-0002" title="DeuterC , EngelmannK , HeiligenhausA , LanzlI , MackensenF , NessT , et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. British Journal of Ophthalmology2018;102(5):647‐53. [CENTRAL: CN-00781196] [DOI: 10.1136/bjophthalmol-2017-310156]EUCTR2009-009998-10-DE. Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009998-10 (first received 2 December 2009). NCT01092533. Myfortic for the treatment of non-infectious intermediate uveitis (MYCUV-IIT02) [Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectious intermediate uveitis - a prospective, controlled randomized multicenter trial]. clinicaltrials.gov/ct2/show/study/NCT01092533 (first received 25 March 2010). ">Deuter 2018</a>; <a href="./references#CD014831-bbs2-0003" title="De VriesJ , BaarsmaG , ZaalM , Boen-TanT , RothovaA , BuitenhuisH , et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. British Journal of Ophthalmology1990;74(6):344‐9. [CENTRAL: CN-00069296] [DOI: 10.1136/bjo.74.6.344]">De Vries 1990</a>; <a href="./references#CD014831-bbs2-0005" title="MurphyC , GreinerK , PlskovaJ , DuncanL , FrostN , ForresterJ , et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Archives of Ophthalmology2005;123(5):634‐41. [CENTRAL: CN-00511918] [DOI: 10.1001/archopht.123.5.634]">Murphy 2005</a>). We judged these studies to have some concerns for bias arising from the randomization process (five out of 10 studies for efficacy; five out of nine studies for safety). Baseline characteristics were generally felt to be similar between groups for the evaluated studies. In the case of the smaller studies, we judged large differences in baseline characteristics to be likely due to chance alone. We judged five studies have a low risk of bias arising from the randomization process (<a href="./references#CD014831-bbs2-0004" title="ISRCTN46576063. Tacrolimus monotherapy for uveitis [Dual steroid and tacrolimus therapy versus steroid withdrawal and tacrolimus therapy in the treatment of posterior segment intraocular inflammation (uveitis)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN46576063 (first received 16 April 2008). [DOI: https://doi.org/10.1186/ISRCTN46576063]LeeR , GreenwoodR , TaylorH , AmerR , BiesterS , HeissigerovaJ , et al. A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. Ophthalmology2012;119(6):1223‐30. [DOI: 10.1016/j.ophtha.2011.12.030]LeeRW , GreenwoodR , AmerR , BiesterS , PlskovaJ , ForresterJV , et al. Tacrolimus monotherapy versus tacrolimus and prednisone for the maintenance of disease remission in non-infectious posterior segment intraocular inflammation. Investigative Ophthalmology and Visual Science2009;50(13):2024. ">Lee 2012</a>; <a href="./references#CD014831-bbs2-0008" title="JPRN-UMIN000014387. A prospective multicenter comparative clinical trial between corticosteroid pulse therapy vs. combination therapy of oral corticosteroid and cyclosporine on Vogt-Koyanagi-Harada disease. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000014387 (first received 27 June 2014). [CENTRAL: CN-01827271] OnoT , GotoH , SakaiT , NittaF , MizukiN , TakaseH , et al. Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt–Koyanagi–Harada disease. Japanese Journal of Ophthalmology 2021 Oct 24 [Epub ahead of print]. [DOI: 10.1007/s10384-021-00878-w]OnoT , MochizukiM , GotoH , SakaiT , NittaF , MizukiN , et al. A prospective multi-center randomized clinical study comparing steroid-pulse therapy and a combined therapy with oral prednisolone and cyclosporine for new-onset acute Vogt-Koyanagi-Harada disease. Investigative Ophthalmology and Visual Science2020;61(7):3169. [CENTRAL: CN-02179109] [EMBASE: 632697033]">Ono 2021</a>; <a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a>; <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a>; <a href="./references#CD014831-bbs2-0011" title="WiederholtM , KämpeC , HansenLL , HövenerG . Treatment of posterior uveitis with cyclosporin or prednisolone--one-year report of a randomized prospective study [Behandlung der uveitis posterior mit cyclosporin oder prednisolon--jahresbericht über eine randomisierte prospektive studie]. Fortschritte der Ophthalmologie1986;83(3):348‐52. [CENTRAL: CN-00044224] [EMBASE: 1986247564] [PMID: 3527903]">Wiederholt 1986</a>). </p> </section> <section id="CD014831-sec-0063"> <h4 class="title"><i>Bias due to deviations from the intended intervention</i> </h4> <p>We judged most studies (six out of 10 for efficacy; six out of nine for safety) to be at low risk of bias for deviations from the intended intervention (<a href="./references#CD014831-bbs2-0003" title="De VriesJ , BaarsmaG , ZaalM , Boen-TanT , RothovaA , BuitenhuisH , et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. British Journal of Ophthalmology1990;74(6):344‐9. [CENTRAL: CN-00069296] [DOI: 10.1136/bjo.74.6.344]">De Vries 1990</a>; <a href="./references#CD014831-bbs2-0005" title="MurphyC , GreinerK , PlskovaJ , DuncanL , FrostN , ForresterJ , et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Archives of Ophthalmology2005;123(5):634‐41. [CENTRAL: CN-00511918] [DOI: 10.1001/archopht.123.5.634]">Murphy 2005</a>; <a href="./references#CD014831-bbs2-0006" title="NussenblattRB , PalestineA , ChanCC , FujikawaLS , StevensG , GreenSB . A randomised, double-masked trial of sandimmune vs. prednisolone for endogenous uveitis. American Academy of Ophthalmology1990;112:105. [CENTRAL: CN-00485269] NussenblattRB , PalestineAG , ChanCC , StevensG , MellowSD , GreenSB . Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. American Journal of Ophthalmology1991;112(2):138‐46. [CENTRAL: CN-00077346] [DOI: 10.1016/s0002-9394(14)76692-9]">Nussenblatt 1991</a>; <a href="./references#CD014831-bbs2-0007" title="NussenblattRB , De SmetMD , RubinB , FreidlinV , WhitcupSM , DavisJ , et al. A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin. American Journal of Ophthalmology1993;115(5):583‐91. [CENTRAL: CN-00093004] [DOI: 10.1016/s0002-9394(14)71454-0]">Nussenblatt 1993</a>; <a href="./references#CD014831-bbs2-0008" title="JPRN-UMIN000014387. A prospective multicenter comparative clinical trial between corticosteroid pulse therapy vs. combination therapy of oral corticosteroid and cyclosporine on Vogt-Koyanagi-Harada disease. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000014387 (first received 27 June 2014). [CENTRAL: CN-01827271] OnoT , GotoH , SakaiT , NittaF , MizukiN , TakaseH , et al. Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt–Koyanagi–Harada disease. Japanese Journal of Ophthalmology 2021 Oct 24 [Epub ahead of print]. [DOI: 10.1007/s10384-021-00878-w]OnoT , MochizukiM , GotoH , SakaiT , NittaF , MizukiN , et al. A prospective multi-center randomized clinical study comparing steroid-pulse therapy and a combined therapy with oral prednisolone and cyclosporine for new-onset acute Vogt-Koyanagi-Harada disease. Investigative Ophthalmology and Visual Science2020;61(7):3169. [CENTRAL: CN-02179109] [EMBASE: 632697033]">Ono 2021</a>; <a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a>; <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a>). We had some concerns about risk of bias in this domain for <a href="./references#CD014831-bbs2-0002" title="DeuterC , EngelmannK , HeiligenhausA , LanzlI , MackensenF , NessT , et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. British Journal of Ophthalmology2018;102(5):647‐53. [CENTRAL: CN-00781196] [DOI: 10.1136/bjophthalmol-2017-310156]EUCTR2009-009998-10-DE. Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009998-10 (first received 2 December 2009). NCT01092533. Myfortic for the treatment of non-infectious intermediate uveitis (MYCUV-IIT02) [Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectious intermediate uveitis - a prospective, controlled randomized multicenter trial]. clinicaltrials.gov/ct2/show/study/NCT01092533 (first received 25 March 2010). ">Deuter 2018</a>, <a href="./references#CD014831-bbs2-0004" title="ISRCTN46576063. Tacrolimus monotherapy for uveitis [Dual steroid and tacrolimus therapy versus steroid withdrawal and tacrolimus therapy in the treatment of posterior segment intraocular inflammation (uveitis)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN46576063 (first received 16 April 2008). [DOI: https://doi.org/10.1186/ISRCTN46576063]LeeR , GreenwoodR , TaylorH , AmerR , BiesterS , HeissigerovaJ , et al. A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. Ophthalmology2012;119(6):1223‐30. [DOI: 10.1016/j.ophtha.2011.12.030]LeeRW , GreenwoodR , AmerR , BiesterS , PlskovaJ , ForresterJV , et al. Tacrolimus monotherapy versus tacrolimus and prednisone for the maintenance of disease remission in non-infectious posterior segment intraocular inflammation. Investigative Ophthalmology and Visual Science2009;50(13):2024. ">Lee 2012</a>, and <a href="./references#CD014831-bbs2-0011" title="WiederholtM , KämpeC , HansenLL , HövenerG . Treatment of posterior uveitis with cyclosporin or prednisolone--one-year report of a randomized prospective study [Behandlung der uveitis posterior mit cyclosporin oder prednisolon--jahresbericht über eine randomisierte prospektive studie]. Fortschritte der Ophthalmologie1986;83(3):348‐52. [CENTRAL: CN-00044224] [EMBASE: 1986247564] [PMID: 3527903]">Wiederholt 1986</a>. The participants and investigators were aware of assignment in <a href="./references#CD014831-bbs2-0004" title="ISRCTN46576063. Tacrolimus monotherapy for uveitis [Dual steroid and tacrolimus therapy versus steroid withdrawal and tacrolimus therapy in the treatment of posterior segment intraocular inflammation (uveitis)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN46576063 (first received 16 April 2008). [DOI: https://doi.org/10.1186/ISRCTN46576063]LeeR , GreenwoodR , TaylorH , AmerR , BiesterS , HeissigerovaJ , et al. A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. Ophthalmology2012;119(6):1223‐30. [DOI: 10.1016/j.ophtha.2011.12.030]LeeRW , GreenwoodR , AmerR , BiesterS , PlskovaJ , ForresterJV , et al. Tacrolimus monotherapy versus tacrolimus and prednisone for the maintenance of disease remission in non-infectious posterior segment intraocular inflammation. Investigative Ophthalmology and Visual Science2009;50(13):2024. ">Lee 2012</a> and treatment tolerance was a factor prior to randomization, which could lead to deviations from intended interventions, even though they used an intention‐to‐treat analysis. Although <a href="./references#CD014831-bbs2-0002" title="DeuterC , EngelmannK , HeiligenhausA , LanzlI , MackensenF , NessT , et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. British Journal of Ophthalmology2018;102(5):647‐53. [CENTRAL: CN-00781196] [DOI: 10.1136/bjophthalmol-2017-310156]EUCTR2009-009998-10-DE. Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009998-10 (first received 2 December 2009). NCT01092533. Myfortic for the treatment of non-infectious intermediate uveitis (MYCUV-IIT02) [Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectious intermediate uveitis - a prospective, controlled randomized multicenter trial]. clinicaltrials.gov/ct2/show/study/NCT01092533 (first received 25 March 2010). ">Deuter 2018</a> reported utilizing an intention‐to‐treat analysis, the authors required participants to have received one dose of medication and undergone one follow‐up visit to be analyzed in the group to which they were randomized. <a href="./references#CD014831-bbs2-0011" title="WiederholtM , KämpeC , HansenLL , HövenerG . Treatment of posterior uveitis with cyclosporin or prednisolone--one-year report of a randomized prospective study [Behandlung der uveitis posterior mit cyclosporin oder prednisolon--jahresbericht über eine randomisierte prospektive studie]. Fortschritte der Ophthalmologie1986;83(3):348‐52. [CENTRAL: CN-00044224] [EMBASE: 1986247564] [PMID: 3527903]">Wiederholt 1986</a> did not provide a detailed protocol and thus did not state whether non‐experimental interventions (such as vitrectomy) should be considered deviations from the intended intervention. We judged <a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a> to be at high risk of bias for this domain because of unbalanced additions of other immunomodulating therapies to the azathioprine group (five participants total: three received additional cyclosporine, the comparator medication, and two were switched to other immunomodulating therapies). </p> </section> <section id="CD014831-sec-0064"> <h4 class="title"><i>Bias due to missing outcome data</i> </h4> <p>Given the small size of most of the studies included in this review, it is not surprising that we had few concerns with bias arising from missing outcome data. We judged all studies to be at low risk of bias for this domain for both safety and efficacy, except for <a href="./references#CD014831-bbs2-0002" title="DeuterC , EngelmannK , HeiligenhausA , LanzlI , MackensenF , NessT , et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. British Journal of Ophthalmology2018;102(5):647‐53. [CENTRAL: CN-00781196] [DOI: 10.1136/bjophthalmol-2017-310156]EUCTR2009-009998-10-DE. Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009998-10 (first received 2 December 2009). NCT01092533. Myfortic for the treatment of non-infectious intermediate uveitis (MYCUV-IIT02) [Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectious intermediate uveitis - a prospective, controlled randomized multicenter trial]. clinicaltrials.gov/ct2/show/study/NCT01092533 (first received 25 March 2010). ">Deuter 2018</a>, which we judged to be at some concern for the safety outcome in this domain. This was due to missing data for three (6.8%) out of 44 participants. Participants experiencing severe side effects may have stopped following up, and the missingness in the outcome could have influenced the true rate of serious side effects, although we felt this was unlikely. </p> </section> <section id="CD014831-sec-0065"> <h4 class="title"><i>Bias in measurement of the outcome</i> </h4> <p>We judged <a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a>, <a href="./references#CD014831-bbs2-0003" title="De VriesJ , BaarsmaG , ZaalM , Boen-TanT , RothovaA , BuitenhuisH , et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. British Journal of Ophthalmology1990;74(6):344‐9. [CENTRAL: CN-00069296] [DOI: 10.1136/bjo.74.6.344]">De Vries 1990</a>, <a href="./references#CD014831-bbs2-0006" title="NussenblattRB , PalestineA , ChanCC , FujikawaLS , StevensG , GreenSB . A randomised, double-masked trial of sandimmune vs. prednisolone for endogenous uveitis. American Academy of Ophthalmology1990;112:105. [CENTRAL: CN-00485269] NussenblattRB , PalestineAG , ChanCC , StevensG , MellowSD , GreenSB . Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. American Journal of Ophthalmology1991;112(2):138‐46. [CENTRAL: CN-00077346] [DOI: 10.1016/s0002-9394(14)76692-9]">Nussenblatt 1991</a>, <a href="./references#CD014831-bbs2-0008" title="JPRN-UMIN000014387. A prospective multicenter comparative clinical trial between corticosteroid pulse therapy vs. combination therapy of oral corticosteroid and cyclosporine on Vogt-Koyanagi-Harada disease. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000014387 (first received 27 June 2014). [CENTRAL: CN-01827271] OnoT , GotoH , SakaiT , NittaF , MizukiN , TakaseH , et al. Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt–Koyanagi–Harada disease. Japanese Journal of Ophthalmology 2021 Oct 24 [Epub ahead of print]. [DOI: 10.1007/s10384-021-00878-w]OnoT , MochizukiM , GotoH , SakaiT , NittaF , MizukiN , et al. A prospective multi-center randomized clinical study comparing steroid-pulse therapy and a combined therapy with oral prednisolone and cyclosporine for new-onset acute Vogt-Koyanagi-Harada disease. Investigative Ophthalmology and Visual Science2020;61(7):3169. [CENTRAL: CN-02179109] [EMBASE: 632697033]">Ono 2021</a>, <a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a>, and <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a> to be at low risk of bias in measurement of the efficacy outcome (six out of 10 studies). We determined <a href="./references#CD014831-bbs2-0002" title="DeuterC , EngelmannK , HeiligenhausA , LanzlI , MackensenF , NessT , et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. British Journal of Ophthalmology2018;102(5):647‐53. [CENTRAL: CN-00781196] [DOI: 10.1136/bjophthalmol-2017-310156]EUCTR2009-009998-10-DE. Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009998-10 (first received 2 December 2009). NCT01092533. Myfortic for the treatment of non-infectious intermediate uveitis (MYCUV-IIT02) [Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectious intermediate uveitis - a prospective, controlled randomized multicenter trial]. clinicaltrials.gov/ct2/show/study/NCT01092533 (first received 25 March 2010). ">Deuter 2018</a>, <a href="./references#CD014831-bbs2-0004" title="ISRCTN46576063. Tacrolimus monotherapy for uveitis [Dual steroid and tacrolimus therapy versus steroid withdrawal and tacrolimus therapy in the treatment of posterior segment intraocular inflammation (uveitis)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN46576063 (first received 16 April 2008). [DOI: https://doi.org/10.1186/ISRCTN46576063]LeeR , GreenwoodR , TaylorH , AmerR , BiesterS , HeissigerovaJ , et al. A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. Ophthalmology2012;119(6):1223‐30. [DOI: 10.1016/j.ophtha.2011.12.030]LeeRW , GreenwoodR , AmerR , BiesterS , PlskovaJ , ForresterJV , et al. Tacrolimus monotherapy versus tacrolimus and prednisone for the maintenance of disease remission in non-infectious posterior segment intraocular inflammation. Investigative Ophthalmology and Visual Science2009;50(13):2024. ">Lee 2012</a>, and <a href="./references#CD014831-bbs2-0005" title="MurphyC , GreinerK , PlskovaJ , DuncanL , FrostN , ForresterJ , et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Archives of Ophthalmology2005;123(5):634‐41. [CENTRAL: CN-00511918] [DOI: 10.1001/archopht.123.5.634]">Murphy 2005</a> to be at high risk of bias in the measurement of control of inflammation. Outcome assessors were not blinded in these studies, and they used somewhat subjective measures (e.g. vitreous haze grading and BIO score) as the main determinant of control of inflammation, which could have been influenced by knowledge of the participants' treatment assignment. We judged <a href="./references#CD014831-bbs2-0011" title="WiederholtM , KämpeC , HansenLL , HövenerG . Treatment of posterior uveitis with cyclosporin or prednisolone--one-year report of a randomized prospective study [Behandlung der uveitis posterior mit cyclosporin oder prednisolon--jahresbericht über eine randomisierte prospektive studie]. Fortschritte der Ophthalmologie1986;83(3):348‐52. [CENTRAL: CN-00044224] [EMBASE: 1986247564] [PMID: 3527903]">Wiederholt 1986</a> to be at some concern for risk of bias due to a lack of blinding of outcome assessors: although the scales were standardized, lack of blinding could lead to some bias in outcome measurement. </p> <p>We determined there was a low risk of bias in measurement of the safety outcome in <a href="./references#CD014831-bbs2-0007" title="NussenblattRB , De SmetMD , RubinB , FreidlinV , WhitcupSM , DavisJ , et al. A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin. American Journal of Ophthalmology1993;115(5):583‐91. [CENTRAL: CN-00093004] [DOI: 10.1016/s0002-9394(14)71454-0]">Nussenblatt 1993</a>, which provided clear laboratory thresholds necessitating cessation of medication, collected detailed adverse effects data, and was ostensibly a safety and tolerability study for cyclosporine A versus G. We had some concerns for bias in most other studies (five of nine studies) for the safety outcome (<a href="./references#CD014831-bbs2-0002" title="DeuterC , EngelmannK , HeiligenhausA , LanzlI , MackensenF , NessT , et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. British Journal of Ophthalmology2018;102(5):647‐53. [CENTRAL: CN-00781196] [DOI: 10.1136/bjophthalmol-2017-310156]EUCTR2009-009998-10-DE. Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009998-10 (first received 2 December 2009). NCT01092533. Myfortic for the treatment of non-infectious intermediate uveitis (MYCUV-IIT02) [Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectious intermediate uveitis - a prospective, controlled randomized multicenter trial]. clinicaltrials.gov/ct2/show/study/NCT01092533 (first received 25 March 2010). ">Deuter 2018</a>; <a href="./references#CD014831-bbs2-0003" title="De VriesJ , BaarsmaG , ZaalM , Boen-TanT , RothovaA , BuitenhuisH , et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. British Journal of Ophthalmology1990;74(6):344‐9. [CENTRAL: CN-00069296] [DOI: 10.1136/bjo.74.6.344]">De Vries 1990</a>; <a href="./references#CD014831-bbs2-0008" title="JPRN-UMIN000014387. A prospective multicenter comparative clinical trial between corticosteroid pulse therapy vs. combination therapy of oral corticosteroid and cyclosporine on Vogt-Koyanagi-Harada disease. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000014387 (first received 27 June 2014). [CENTRAL: CN-01827271] OnoT , GotoH , SakaiT , NittaF , MizukiN , TakaseH , et al. Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt–Koyanagi–Harada disease. Japanese Journal of Ophthalmology 2021 Oct 24 [Epub ahead of print]. [DOI: 10.1007/s10384-021-00878-w]OnoT , MochizukiM , GotoH , SakaiT , NittaF , MizukiN , et al. A prospective multi-center randomized clinical study comparing steroid-pulse therapy and a combined therapy with oral prednisolone and cyclosporine for new-onset acute Vogt-Koyanagi-Harada disease. Investigative Ophthalmology and Visual Science2020;61(7):3169. [CENTRAL: CN-02179109] [EMBASE: 632697033]">Ono 2021</a>; <a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a>; <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a>), often because of lack of masking to treatment assignment for participants/outcome assessors, or the use of subjective outcomes (fatigue, dizziness, etc.) without clear descriptions for how these self‐reported outcomes might trigger cessation. We judged <a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a>, <a href="./references#CD014831-bbs2-0004" title="ISRCTN46576063. Tacrolimus monotherapy for uveitis [Dual steroid and tacrolimus therapy versus steroid withdrawal and tacrolimus therapy in the treatment of posterior segment intraocular inflammation (uveitis)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN46576063 (first received 16 April 2008). [DOI: https://doi.org/10.1186/ISRCTN46576063]LeeR , GreenwoodR , TaylorH , AmerR , BiesterS , HeissigerovaJ , et al. A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. Ophthalmology2012;119(6):1223‐30. [DOI: 10.1016/j.ophtha.2011.12.030]LeeRW , GreenwoodR , AmerR , BiesterS , PlskovaJ , ForresterJV , et al. Tacrolimus monotherapy versus tacrolimus and prednisone for the maintenance of disease remission in non-infectious posterior segment intraocular inflammation. Investigative Ophthalmology and Visual Science2009;50(13):2024. ">Lee 2012</a>, and <a href="./references#CD014831-bbs2-0005" title="MurphyC , GreinerK , PlskovaJ , DuncanL , FrostN , ForresterJ , et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Archives of Ophthalmology2005;123(5):634‐41. [CENTRAL: CN-00511918] [DOI: 10.1001/archopht.123.5.634]">Murphy 2005</a> to be at high risk of bias for this domain because participants and investigators were not masked, some adverse events were self‐reported, and criteria for requiring cessation of medication were not described. Therefore, the measurement of this outcome could have been influenced by the observers' or participants' biases, or both. </p> </section> <section id="CD014831-sec-0066"> <h4 class="title"><i>Bias in selection of the reported result</i> </h4> <p>No studies provided a predetermined statistical analysis plan (SAP), except for <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a>, which we judged to be at an overall low risk of bias for selection of the reported result for both the efficacy and safety measures. </p> <p>Regarding efficacy data, most studies did not appear to utilize multiple eligible analyses of the data, although it is not possible to determine if final analyses matched prespecified outcome measures without a statistical analysis plan. We judged these studies (seven out of 10) to have some concerns of bias in this domain (<a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a>; <a href="./references#CD014831-bbs2-0002" title="DeuterC , EngelmannK , HeiligenhausA , LanzlI , MackensenF , NessT , et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. British Journal of Ophthalmology2018;102(5):647‐53. [CENTRAL: CN-00781196] [DOI: 10.1136/bjophthalmol-2017-310156]EUCTR2009-009998-10-DE. Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009998-10 (first received 2 December 2009). NCT01092533. Myfortic for the treatment of non-infectious intermediate uveitis (MYCUV-IIT02) [Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectious intermediate uveitis - a prospective, controlled randomized multicenter trial]. clinicaltrials.gov/ct2/show/study/NCT01092533 (first received 25 March 2010). ">Deuter 2018</a>; <a href="./references#CD014831-bbs2-0003" title="De VriesJ , BaarsmaG , ZaalM , Boen-TanT , RothovaA , BuitenhuisH , et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. British Journal of Ophthalmology1990;74(6):344‐9. [CENTRAL: CN-00069296] [DOI: 10.1136/bjo.74.6.344]">De Vries 1990</a>; <a href="./references#CD014831-bbs2-0005" title="MurphyC , GreinerK , PlskovaJ , DuncanL , FrostN , ForresterJ , et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Archives of Ophthalmology2005;123(5):634‐41. [CENTRAL: CN-00511918] [DOI: 10.1001/archopht.123.5.634]">Murphy 2005</a>; <a href="./references#CD014831-bbs2-0006" title="NussenblattRB , PalestineA , ChanCC , FujikawaLS , StevensG , GreenSB . A randomised, double-masked trial of sandimmune vs. prednisolone for endogenous uveitis. American Academy of Ophthalmology1990;112:105. [CENTRAL: CN-00485269] NussenblattRB , PalestineAG , ChanCC , StevensG , MellowSD , GreenSB . Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. American Journal of Ophthalmology1991;112(2):138‐46. [CENTRAL: CN-00077346] [DOI: 10.1016/s0002-9394(14)76692-9]">Nussenblatt 1991</a>; <a href="./references#CD014831-bbs2-0008" title="JPRN-UMIN000014387. A prospective multicenter comparative clinical trial between corticosteroid pulse therapy vs. combination therapy of oral corticosteroid and cyclosporine on Vogt-Koyanagi-Harada disease. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000014387 (first received 27 June 2014). [CENTRAL: CN-01827271] OnoT , GotoH , SakaiT , NittaF , MizukiN , TakaseH , et al. Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt–Koyanagi–Harada disease. Japanese Journal of Ophthalmology 2021 Oct 24 [Epub ahead of print]. [DOI: 10.1007/s10384-021-00878-w]OnoT , MochizukiM , GotoH , SakaiT , NittaF , MizukiN , et al. A prospective multi-center randomized clinical study comparing steroid-pulse therapy and a combined therapy with oral prednisolone and cyclosporine for new-onset acute Vogt-Koyanagi-Harada disease. Investigative Ophthalmology and Visual Science2020;61(7):3169. [CENTRAL: CN-02179109] [EMBASE: 632697033]">Ono 2021</a>; <a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a>). Because there was no detailed analysis plan and minimal information on the possibility of multiple measurements and analyses, we judged <a href="./references#CD014831-bbs2-0004" title="ISRCTN46576063. Tacrolimus monotherapy for uveitis [Dual steroid and tacrolimus therapy versus steroid withdrawal and tacrolimus therapy in the treatment of posterior segment intraocular inflammation (uveitis)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN46576063 (first received 16 April 2008). [DOI: https://doi.org/10.1186/ISRCTN46576063]LeeR , GreenwoodR , TaylorH , AmerR , BiesterS , HeissigerovaJ , et al. A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. Ophthalmology2012;119(6):1223‐30. [DOI: 10.1016/j.ophtha.2011.12.030]LeeRW , GreenwoodR , AmerR , BiesterS , PlskovaJ , ForresterJV , et al. Tacrolimus monotherapy versus tacrolimus and prednisone for the maintenance of disease remission in non-infectious posterior segment intraocular inflammation. Investigative Ophthalmology and Visual Science2009;50(13):2024. ">Lee 2012</a> to be at some concern for risk of bias for this outcome domain. We judged <a href="./references#CD014831-bbs2-0011" title="WiederholtM , KämpeC , HansenLL , HövenerG . Treatment of posterior uveitis with cyclosporin or prednisolone--one-year report of a randomized prospective study [Behandlung der uveitis posterior mit cyclosporin oder prednisolon--jahresbericht über eine randomisierte prospektive studie]. Fortschritte der Ophthalmologie1986;83(3):348‐52. [CENTRAL: CN-00044224] [EMBASE: 1986247564] [PMID: 3527903]">Wiederholt 1986</a> to be at high risk of bias in selection of the reported result for control of inflammation because definitions of relapse and treatment success were not laid out, and multiple time points at which a participant could be declared to have relapsed seem possible. As mentioned previously, we judged <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a> to be at low risk of bias for this domain and outcome. </p> <p>We determined <a href="./references#CD014831-bbs2-0002" title="DeuterC , EngelmannK , HeiligenhausA , LanzlI , MackensenF , NessT , et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. British Journal of Ophthalmology2018;102(5):647‐53. [CENTRAL: CN-00781196] [DOI: 10.1136/bjophthalmol-2017-310156]EUCTR2009-009998-10-DE. Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009998-10 (first received 2 December 2009). NCT01092533. Myfortic for the treatment of non-infectious intermediate uveitis (MYCUV-IIT02) [Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectious intermediate uveitis - a prospective, controlled randomized multicenter trial]. clinicaltrials.gov/ct2/show/study/NCT01092533 (first received 25 March 2010). ">Deuter 2018</a>, <a href="./references#CD014831-bbs2-0004" title="ISRCTN46576063. Tacrolimus monotherapy for uveitis [Dual steroid and tacrolimus therapy versus steroid withdrawal and tacrolimus therapy in the treatment of posterior segment intraocular inflammation (uveitis)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN46576063 (first received 16 April 2008). [DOI: https://doi.org/10.1186/ISRCTN46576063]LeeR , GreenwoodR , TaylorH , AmerR , BiesterS , HeissigerovaJ , et al. A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. Ophthalmology2012;119(6):1223‐30. [DOI: 10.1016/j.ophtha.2011.12.030]LeeRW , GreenwoodR , AmerR , BiesterS , PlskovaJ , ForresterJV , et al. Tacrolimus monotherapy versus tacrolimus and prednisone for the maintenance of disease remission in non-infectious posterior segment intraocular inflammation. Investigative Ophthalmology and Visual Science2009;50(13):2024. ">Lee 2012</a>, and <a href="./references#CD014831-bbs2-0005" title="MurphyC , GreinerK , PlskovaJ , DuncanL , FrostN , ForresterJ , et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Archives of Ophthalmology2005;123(5):634‐41. [CENTRAL: CN-00511918] [DOI: 10.1001/archopht.123.5.634]">Murphy 2005</a> to be at high risk of bias for the safety outcome in this domain. These studies reported multiple adverse effects without a description of prespecified adverse effects which would result in cessation of medication; therefore, need for discontinuation of the drug may have depended on multiple eligible outcome measurements (i.e. different definitions of severe renal toxicity). In addition to <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a>, we judged <a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a> to be at low risk of bias for the safety outcome in terms of selection of the reported result. We had some concerns in this domain for <a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a>, <a href="./references#CD014831-bbs2-0003" title="De VriesJ , BaarsmaG , ZaalM , Boen-TanT , RothovaA , BuitenhuisH , et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. British Journal of Ophthalmology1990;74(6):344‐9. [CENTRAL: CN-00069296] [DOI: 10.1136/bjo.74.6.344]">De Vries 1990</a>, <a href="./references#CD014831-bbs2-0007" title="NussenblattRB , De SmetMD , RubinB , FreidlinV , WhitcupSM , DavisJ , et al. A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin. American Journal of Ophthalmology1993;115(5):583‐91. [CENTRAL: CN-00093004] [DOI: 10.1016/s0002-9394(14)71454-0]">Nussenblatt 1993</a>, and <a href="./references#CD014831-bbs2-0008" title="JPRN-UMIN000014387. A prospective multicenter comparative clinical trial between corticosteroid pulse therapy vs. combination therapy of oral corticosteroid and cyclosporine on Vogt-Koyanagi-Harada disease. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000014387 (first received 27 June 2014). [CENTRAL: CN-01827271] OnoT , GotoH , SakaiT , NittaF , MizukiN , TakaseH , et al. Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt–Koyanagi–Harada disease. Japanese Journal of Ophthalmology 2021 Oct 24 [Epub ahead of print]. [DOI: 10.1007/s10384-021-00878-w]OnoT , MochizukiM , GotoH , SakaiT , NittaF , MizukiN , et al. A prospective multi-center randomized clinical study comparing steroid-pulse therapy and a combined therapy with oral prednisolone and cyclosporine for new-onset acute Vogt-Koyanagi-Harada disease. Investigative Ophthalmology and Visual Science2020;61(7):3169. [CENTRAL: CN-02179109] [EMBASE: 632697033]">Ono 2021</a>, generally because of a lack of information provided about whether the adverse effects triggering cessation of medication were prespecified. Overall, we judged four of nine studies to have some concerns for bias for the safety outcome in this domain. </p> </section> </section> <section id="CD014831-sec-0067"> <h3 class="title" id="CD014831-sec-0067">Effects of interventions</h3> <p>See: <a href="./full#CD014831-tbl-0001"><b>Summary of findings 1</b> Non‐biologic disease‐modifying antirheumatic drugs (DMARDs) versus steroid for NIIPPU</a>; <a href="./full#CD014831-tbl-0002"><b>Summary of findings 2</b> Methotrexate versus mycophenolate for NIIPPU</a>; <a href="./full#CD014831-tbl-0003"><b>Summary of findings 3</b> Steroids with or without azathioprine versus cyclosporine A for NIIPPU</a> </p> <section id="CD014831-sec-0068"> <h4 class="title">Comparison 1: DMARDs plus steroid versus steroid monotherapy</h4> <p>Two studies with a total of 68 participants compared oral steroids with or without an experimental DMARD (<a href="./references#CD014831-bbs2-0002" title="DeuterC , EngelmannK , HeiligenhausA , LanzlI , MackensenF , NessT , et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. British Journal of Ophthalmology2018;102(5):647‐53. [CENTRAL: CN-00781196] [DOI: 10.1136/bjophthalmol-2017-310156]EUCTR2009-009998-10-DE. Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009998-10 (first received 2 December 2009). NCT01092533. Myfortic for the treatment of non-infectious intermediate uveitis (MYCUV-IIT02) [Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectious intermediate uveitis - a prospective, controlled randomized multicenter trial]. clinicaltrials.gov/ct2/show/study/NCT01092533 (first received 25 March 2010). ">Deuter 2018</a>; <a href="./references#CD014831-bbs2-0003" title="De VriesJ , BaarsmaG , ZaalM , Boen-TanT , RothovaA , BuitenhuisH , et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. British Journal of Ophthalmology1990;74(6):344‐9. [CENTRAL: CN-00069296] [DOI: 10.1136/bjo.74.6.344]">De Vries 1990</a>). The <a href="./references#CD014831-bbs2-0003" title="De VriesJ , BaarsmaG , ZaalM , Boen-TanT , RothovaA , BuitenhuisH , et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. British Journal of Ophthalmology1990;74(6):344‐9. [CENTRAL: CN-00069296] [DOI: 10.1136/bjo.74.6.344]">De Vries 1990</a> study compared cyclosporine with placebo, both in combination with oral steroid (0.3 mg/kg/day), while <a href="./references#CD014831-bbs2-0002" title="DeuterC , EngelmannK , HeiligenhausA , LanzlI , MackensenF , NessT , et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. British Journal of Ophthalmology2018;102(5):647‐53. [CENTRAL: CN-00781196] [DOI: 10.1136/bjophthalmol-2017-310156]EUCTR2009-009998-10-DE. Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009998-10 (first received 2 December 2009). NCT01092533. Myfortic for the treatment of non-infectious intermediate uveitis (MYCUV-IIT02) [Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectious intermediate uveitis - a prospective, controlled randomized multicenter trial]. clinicaltrials.gov/ct2/show/study/NCT01092533 (first received 25 March 2010). ">Deuter 2018</a> compared enteric‐coated mycophenolate sodium (EC‐MPS) plus low‐dose oral steroid (5 mg/day) versus steroid monotherapy. We did not combine these studies in a meta‐analysis because the dose of cyclosporine A used in <a href="./references#CD014831-bbs2-0003" title="De VriesJ , BaarsmaG , ZaalM , Boen-TanT , RothovaA , BuitenhuisH , et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. British Journal of Ophthalmology1990;74(6):344‐9. [CENTRAL: CN-00069296] [DOI: 10.1136/bjo.74.6.344]">De Vries 1990</a> (10 mg/kg/day) is higher than that used in current clinical practice. See <a href="./full#CD014831-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD014831-sec-0069"> <h5 class="title">Critical outcomes</h5> <section id="CD014831-sec-0070"> <h6 class="title">Control of inflammation</h6> <p><a href="./references#CD014831-bbs2-0002" title="DeuterC , EngelmannK , HeiligenhausA , LanzlI , MackensenF , NessT , et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. British Journal of Ophthalmology2018;102(5):647‐53. [CENTRAL: CN-00781196] [DOI: 10.1136/bjophthalmol-2017-310156]EUCTR2009-009998-10-DE. Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009998-10 (first received 2 December 2009). NCT01092533. Myfortic for the treatment of non-infectious intermediate uveitis (MYCUV-IIT02) [Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectious intermediate uveitis - a prospective, controlled randomized multicenter trial]. clinicaltrials.gov/ct2/show/study/NCT01092533 (first received 25 March 2010). ">Deuter 2018</a> was designed as a time‐to‐relapse study measuring time to first relapse; therefore, in this context, control of inflammation meant a lack of relapse. Relapses were defined as a decrease in BCVA of three or more lines compared to baseline, a two‐step increase in vitreous haze or anterior chamber cells compared with the lowest grade from baseline (or an increase from 3+ to 4+), a new onset or worsening of pre‐existing CME, or a new onset or worsening of retinal vasculitis proven by fluorescein angiography. The evidence may suggest that participants treated with EC‐MPS and low‐dose oral steroid have a higher chance of gaining control of inflammation at six months compared to low‐dose steroid alone (risk ratio [RR] of 2.81, where &gt; 1 favors EC‐MPS plus steroid, 95% CI 1.10 to 7.17; <a href="#CD014831-fig-0004">Figure 4</a>), but is uncertain. </p> <div class="figure" id="CD014831-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison 1: DMARDs versus control, outcome: 1.1 Control of inflammation " data-id="CD014831-fig-0004" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison 1: DMARDs versus control, outcome: 1.1 Control of inflammation </p> </div> </div> </div> <p>We judged the overall certainty of the evidence from this single study with 41 events to be of very low certainty, downgrading two levels because of the overall high risk of bias and one level for imprecision. </p> <p><a href="./references#CD014831-bbs2-0003" title="De VriesJ , BaarsmaG , ZaalM , Boen-TanT , RothovaA , BuitenhuisH , et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. British Journal of Ophthalmology1990;74(6):344‐9. [CENTRAL: CN-00069296] [DOI: 10.1136/bjo.74.6.344]">De Vries 1990</a> measured control of inflammatory activity, defined using a modified Hogan‐Thygeson‐Kimura scale which scored congestion, keratic precipitates, anterior chamber cells and flare, vitreous opacity, macular edema, optic disc edema, vasculitis, infiltrates, 'snowballs' and 'snowbanks', exudates, and hemorrhages. The evidence is very uncertain about the effect of cyclosporine plus oral steroid versus placebo plus oral steroid on the control of inflammation (RR 0.93, where &gt; 1 favors cyclosporine plus steroid, 95% CI 0.06 to 13.37; <a href="./references#CD014831-fig-0010" title="">Analysis 1.2</a>). The high dose of cyclosporine used in this study (10 mg/kg/day) is not consistent with current clinical practice and therefore the results of this study provide only indirect evidence on the effectiveness of cyclosporine A plus low dose steroid versus steroid monotherapy. This single study represented 27 total events for this outcome. </p> <p>Because <a href="./references#CD014831-bbs2-0003" title="De VriesJ , BaarsmaG , ZaalM , Boen-TanT , RothovaA , BuitenhuisH , et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. British Journal of Ophthalmology1990;74(6):344‐9. [CENTRAL: CN-00069296] [DOI: 10.1136/bjo.74.6.344]">De Vries 1990</a> did not use modern cyclosporine dosing, we did not apply the GRADE assessment. </p> </section> <section id="CD014831-sec-0071"> <h6 class="title">Change in BCVA</h6> <p>Change in BCVA was reported by <a href="./references#CD014831-bbs2-0002" title="DeuterC , EngelmannK , HeiligenhausA , LanzlI , MackensenF , NessT , et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. British Journal of Ophthalmology2018;102(5):647‐53. [CENTRAL: CN-00781196] [DOI: 10.1136/bjophthalmol-2017-310156]EUCTR2009-009998-10-DE. Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009998-10 (first received 2 December 2009). NCT01092533. Myfortic for the treatment of non-infectious intermediate uveitis (MYCUV-IIT02) [Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectious intermediate uveitis - a prospective, controlled randomized multicenter trial]. clinicaltrials.gov/ct2/show/study/NCT01092533 (first received 25 March 2010). ">Deuter 2018</a> separately for the right and left eyes. EC‐MPS with oral low‐dose steroid may result in little to no change in BCVA over control, but the evidence is very uncertain (MD ‐0.03 for right eyes, MD ‐0.10 for left eyes, where &lt; 0 favors combination therapy; <a href="./references#CD014831-fig-0011" title="">Analysis 1.3</a>). Both analyses have CIs which cross the null threshold (95% CI ‐0.96 to 0.90 for right eyes, ‐0.27 to 0.07 for left eyes). There were 22 eyes, right and left, in the EC‐MPS plus steroid group, and 19, right and left, in the control group. </p> <p>We judged the results from this single small study to be of very low certainty, downgrading two levels because of risk of bias and one level for imprecision. </p> </section> <section id="CD014831-sec-0072"> <h6 class="title">Proportion of participants achieving a 2‐line improvement in visual acuity</h6> <p>No included studies reported this outcome.</p> </section> <section id="CD014831-sec-0073"> <h6 class="title">Proportion of participants with macular edema</h6> <p>No included studies reported this outcome.</p> </section> </section> <section id="CD014831-sec-0074"> <h5 class="title">Important outcomes</h5> <section id="CD014831-sec-0075"> <h6 class="title">Mean time to relapse</h6> <p>The median time to relapse was reported by <a href="./references#CD014831-bbs2-0002" title="DeuterC , EngelmannK , HeiligenhausA , LanzlI , MackensenF , NessT , et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. British Journal of Ophthalmology2018;102(5):647‐53. [CENTRAL: CN-00781196] [DOI: 10.1136/bjophthalmol-2017-310156]EUCTR2009-009998-10-DE. Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009998-10 (first received 2 December 2009). NCT01092533. Myfortic for the treatment of non-infectious intermediate uveitis (MYCUV-IIT02) [Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectious intermediate uveitis - a prospective, controlled randomized multicenter trial]. clinicaltrials.gov/ct2/show/study/NCT01092533 (first received 25 March 2010). ">Deuter 2018</a> as a primary outcome; however, the mean times were not reported, and we could not extract data on means in a useable format. The authors also reported the probability of relapse‐free survival at 15 months and the percentage of participants that experienced a first relapse. For all of these measures, EC‐MPS plus oral steroid may increase the median time to first relapse than control (MD &gt; 15 months versus [vs] 2.8 months; P = 0.07), have a higher probability of relapse‐free survival at 15 months (52.9% vs 19.7%; P = 0.01), and reduce the proportion of participants experiencing a first relapse (40.9% vs 78.9%; P = 0.03). However, the evidence is very uncertain: the authors do not report confidence intervals or the effect measure. These results represent only 41 participants total. </p> <p>We judged the data for this outcome to be of very low certainty, downgrading two levels given concerns for risk of bias and one level for imprecision. </p> </section> <section id="CD014831-sec-0076"> <h6 class="title">Reduction in cumulative hazard of disease relapse</h6> <p>No included studies reported this outcome.</p> </section> <section id="CD014831-sec-0077"> <h6 class="title">Proportion of participants with change in anterior chamber flare and cells</h6> <p>No included studies reported this outcome.</p> </section> <section id="CD014831-sec-0078"> <h6 class="title">Mean change in CMT</h6> <p>Change in CMT was reported by <a href="./references#CD014831-bbs2-0002" title="DeuterC , EngelmannK , HeiligenhausA , LanzlI , MackensenF , NessT , et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. British Journal of Ophthalmology2018;102(5):647‐53. [CENTRAL: CN-00781196] [DOI: 10.1136/bjophthalmol-2017-310156]EUCTR2009-009998-10-DE. Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009998-10 (first received 2 December 2009). NCT01092533. Myfortic for the treatment of non-infectious intermediate uveitis (MYCUV-IIT02) [Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectious intermediate uveitis - a prospective, controlled randomized multicenter trial]. clinicaltrials.gov/ct2/show/study/NCT01092533 (first received 25 March 2010). ">Deuter 2018</a> separately for the right and left eyes. The low‐dose oral steroid may result in a larger mean decrease in CMT than combination therapy with EC‐MPS (MD 17.00 for right eyes, MD 1.00 for left eyes, where &lt; 0 favors combination therapy; <a href="./references#CD014831-fig-0012" title="">Analysis 1.4</a>). However, the data are very uncertain. Both analyses have CIs which cross the null threshold (95% CI ‐2.18 to 36.18 for right eyes, ‐1.41 to 3.41 for left eyes). </p> <p>The data for this outcome were derived from a single study with 41 events. We judged the evidence to be of very low certainty, downgrading one level because of imprecision and two levels because of risk of bias. </p> </section> <section id="CD014831-sec-0079"> <h6 class="title">Change in other activity domains</h6> <p>Other activity domains (including anterior chamber cell, vitreous cell/opacities, vascular leakage, etc.) were included in the definition of control of inflammation or inflammatory activity in both <a href="./references#CD014831-bbs2-0002" title="DeuterC , EngelmannK , HeiligenhausA , LanzlI , MackensenF , NessT , et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. British Journal of Ophthalmology2018;102(5):647‐53. [CENTRAL: CN-00781196] [DOI: 10.1136/bjophthalmol-2017-310156]EUCTR2009-009998-10-DE. Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009998-10 (first received 2 December 2009). NCT01092533. Myfortic for the treatment of non-infectious intermediate uveitis (MYCUV-IIT02) [Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectious intermediate uveitis - a prospective, controlled randomized multicenter trial]. clinicaltrials.gov/ct2/show/study/NCT01092533 (first received 25 March 2010). ">Deuter 2018</a> and <a href="./references#CD014831-bbs2-0003" title="De VriesJ , BaarsmaG , ZaalM , Boen-TanT , RothovaA , BuitenhuisH , et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. British Journal of Ophthalmology1990;74(6):344‐9. [CENTRAL: CN-00069296] [DOI: 10.1136/bjo.74.6.344]">De Vries 1990</a> (see above). No included studies reported this outcome directly. </p> </section> <section id="CD014831-sec-0080"> <h6 class="title">Proportion of participants to achieve steroid‐sparing control or to achieve reduction in oral steroid dose </h6> <p>No included studies reported this outcome directly. <a href="./references#CD014831-bbs2-0002" title="DeuterC , EngelmannK , HeiligenhausA , LanzlI , MackensenF , NessT , et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. British Journal of Ophthalmology2018;102(5):647‐53. [CENTRAL: CN-00781196] [DOI: 10.1136/bjophthalmol-2017-310156]EUCTR2009-009998-10-DE. Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009998-10 (first received 2 December 2009). NCT01092533. Myfortic for the treatment of non-infectious intermediate uveitis (MYCUV-IIT02) [Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectious intermediate uveitis - a prospective, controlled randomized multicenter trial]. clinicaltrials.gov/ct2/show/study/NCT01092533 (first received 25 March 2010). ">Deuter 2018</a> required participants to be taking a low‐dose of oral steroid (5 mg/day) without relapse and therefore all participants without a relapse can be considered to have achieved steroid‐sparing control. <a href="./references#CD014831-bbs2-0003" title="De VriesJ , BaarsmaG , ZaalM , Boen-TanT , RothovaA , BuitenhuisH , et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. British Journal of Ophthalmology1990;74(6):344‐9. [CENTRAL: CN-00069296] [DOI: 10.1136/bjo.74.6.344]">De Vries 1990</a> used a higher dose of oral steroid (0.3 mg/kg/day) which does not meet our definition of steroid‐sparing control (dose ≤ 10 mg/day). </p> </section> <section id="CD014831-sec-0081"> <h6 class="title">Cost‐effectiveness</h6> <p>No included studies measured this outcome.</p> </section> <section id="CD014831-sec-0082"> <h6 class="title">Mean change in vision‐related quality of life</h6> <p>No included studies reported this outcome.</p> </section> <section id="CD014831-sec-0083"> <h6 class="title">Mean change in general health‐related quality of life</h6> <p>No included studies reported this outcome.</p> </section> <section id="CD014831-sec-0084"> <h6 class="title">Adverse effects</h6> <section id="CD014831-sec-0085"> <p><b>Proportion of participants experiencing any adverse effects</b></p> <p>No included studies reported this outcome.</p> </section> <section id="CD014831-sec-0086"> <p><b>Proportion of participants experiencing complications or requiring cessation of medication</b></p> <p>Both studies reported the proportion of participants requiring cessation of medication. However, the risk ratio was not estimable for <a href="./references#CD014831-bbs2-0003" title="De VriesJ , BaarsmaG , ZaalM , Boen-TanT , RothovaA , BuitenhuisH , et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. British Journal of Ophthalmology1990;74(6):344‐9. [CENTRAL: CN-00069296] [DOI: 10.1136/bjo.74.6.344]">De Vries 1990</a>, with no events reported for cyclosporine A (0 of 14 participants) or placebo (0 of 13 participants). As reported by the <a href="./references#CD014831-bbs2-0002" title="DeuterC , EngelmannK , HeiligenhausA , LanzlI , MackensenF , NessT , et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. British Journal of Ophthalmology2018;102(5):647‐53. [CENTRAL: CN-00781196] [DOI: 10.1136/bjophthalmol-2017-310156]EUCTR2009-009998-10-DE. Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009998-10 (first received 2 December 2009). NCT01092533. Myfortic for the treatment of non-infectious intermediate uveitis (MYCUV-IIT02) [Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectious intermediate uveitis - a prospective, controlled randomized multicenter trial]. clinicaltrials.gov/ct2/show/study/NCT01092533 (first received 25 March 2010). ">Deuter 2018</a> study, the evidence is uncertain whether combination therapy with EC‐MPS plus oral steroid reduces the risk of patient cessation compared to oral steroid monotherapy (RR 2.61, where &lt; 1 favors combination therapy, 95% CI 0.11 to 60.51; <a href="./references#CD014831-fig-0013" title="">Analysis 1.5</a>). </p> <p>We judged the data to be of very low overall certainty, downgrading two levels because of concerns for risk of bias and one level for imprecision. </p> </section> <section id="CD014831-sec-0087"> <p><b>Proportion of participants experiencing ocular complications</b></p> <p>No included studies reported this outcome.</p> </section> </section> </section> </section> <section id="CD014831-sec-0088"> <h4 class="title">Comparison 2: methotrexate versus mycophenolate</h4> <p>Two studies with a total of 261 participants compared methotrexate versus mycophenolate mofetil and were analyzed together in a meta‐analysis (<a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a>; <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a>). See <a href="./full#CD014831-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD014831-sec-0089"> <h5 class="title">Critical outcomes</h5> <section id="CD014831-sec-0090"> <h6 class="title">Control of inflammation</h6> <p>At six months of follow‐up, the two studies reported that 88 of 131 participants taking methotrexate and 71 of 130 participants taking mycophenolate mofetil had achieved treatment success (261 participants total). Both studies defined control of ocular inflammation as less than or equal to 0.5 + anterior chamber cells, less than or equal to 0.5 + vitreous haze, and no active retinal/choroidal lesions in both eyes, and required that participants be on a low dose of oral steroid (≤ 10 mg/day in the 2014 study, ≤ 7.5 mg/day in the 2019 study) and two drops or fewer per day of topical 1% prednisolone acetate. There is evidence that methotrexate slightly increases the likelihood of control of inflammation compared to mycophenolate (RR 1.23, where &gt; 1 favors methotrexate, 95% CI 1.01 to 1.50; <a href="#CD014831-fig-0005">Figure 5</a>). Heterogeneity was low (I² = 0%, Chi² = 0.84, degrees of freedom [df] = 1, P = 0.36). </p> <div class="figure" id="CD014831-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison 2: Methotrexate versus mycophenolate, outcome 2.1: Control of inflammation" data-id="CD014831-fig-0005" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison 2: Methotrexate versus mycophenolate, outcome 2.1: Control of inflammation </p> </div> </div> </div> <p>We graded the overall certainty of the evidence as moderate, downgrading by one level for imprecision because of the small number of events. </p> <p>We also analyzed these outcomes for the VKH subgroup using data from <a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a>. Outcomes for the VKH subgroup were not reported in <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a> in a way in which we could combine the data. For control of inflammation, mycophenolate probably results in little to no difference in outcome compared to methotrexate, but the evidence is very uncertain (RR 1.39, where &gt; 1 favors methotrexate, 95% CI 0.81 to 2.36; <a href="./references#CD014831-fig-0015" title="">Analysis 2.2</a>). A similar, statistically uncertain finding for this outcome was reported in <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a> for all participants (RR 1.17, 95% CI 0.93 to 1.50; <a href="#CD014831-fig-0005">Figure 5</a>). </p> <p>We graded the overall certainty of the evidence as very low, downgrading two levels for imprecision and one level for indirectness of the evidence, as the data were derived from a small VKH subgroup from a single study. </p> </section> <section id="CD014831-sec-0091"> <h6 class="title">Change in BCVA</h6> <p>Methotrexate likely results in little to no difference in BCVA over six months compared to mycophenolate for the 490 eyes included. For this outcome, a negative MD means better vision. <a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a> found a ‐0.26 change (standard deviation [SD] 0.33) in BCVA for participants treated with methotrexate versus a ‐0.19 change (SD 0.36) in participants treated with mycophenolate. <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a> reported MDs of ‐0.10 (SD 0.24) and ‐0.12 (SD 0.23) for participants treated with methotrexate and mycophenolate, respectively. Overall, the change in BCVA in 490 uveitic eyes was 0.01 (95% CI ‐0.04 to 0.05; P = 0.18, I<sup>2</sup> = 44%; <a href="./references#CD014831-fig-0016" title="">Analysis 2.3</a>), with a negative MD favoring methotrexate. </p> <p>We graded the overall certainty of the evidence as moderate, downgrading one level due to the imprecision of the results. </p> </section> <section id="CD014831-sec-0092"> <h6 class="title">Proportion of participants achieving a 2‐line improvement in visual acuity</h6> <p>No included studies reported this outcome.</p> </section> <section id="CD014831-sec-0093"> <h6 class="title">Proportion of participants with macular edema</h6> <p><a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a> reported the proportion of participants with unresolved macular edema in a subgroup of participants with macular edema at the start of the study (35 eyes). Macular edema was measured by masked OCT operators with thresholds derived from normative data for central subfield thickness for each OCT device (&gt; 252 micrometers for Stratus and &gt; 308 micrometers for Cirrus). Five of 22 participants treated with methotrexate and six of 13 participants treated with mycophenolate still had residual macular edema at six months of follow‐up. The evidence is very uncertain regarding residual macular edema in participants treated with methotrexate compared with those treated with mycophenolate (RR 0.49, where &lt; 1 favors methotrexate, 95% CI 0.19 to 1.30; <a href="./references#CD014831-fig-0017" title="">Analysis 2.4</a>). </p> <p>We judged the evidence to be of very low certainty, downgrading two levels for imprecision and one level for indirectness of the evidence, as the data for this outcome were derived from a small VKH subgroup from a single study. </p> </section> </section> <section id="CD014831-sec-0094"> <h5 class="title">Important outcomes</h5> <section id="CD014831-sec-0095"> <h6 class="title">Mean time to relapse</h6> <p>No included studies reported this outcome.</p> </section> <section id="CD014831-sec-0096"> <h6 class="title">Reduction in cumulative hazard of disease relapse</h6> <p>No included studies reported this outcome.</p> </section> <section id="CD014831-sec-0097"> <h6 class="title">Proportion of participants with change in anterior chamber flare and cells</h6> <p>No included studies reported this outcome.</p> </section> <section id="CD014831-sec-0098"> <h6 class="title">Mean change in CMT</h6> <p><a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a> reported a mean change in central macular thickness recorded on OCT over six months of follow‐up in 97 eyes, excluding participants who had a serous retinal detachment in the setting of VKH. Mean change in CMT was ‐26 (SD 69.6) for participants receiving methotrexate (55 eyes) and ‐14 (SD 61.7) for those receiving mycophenolate (42 eyes). The evidence suggests that mycophenolate may result in little to no difference in mean change in central macular thickness compared to methotrexate (MD ‐12.00, where &lt; 0 favors methotrexate, 95% CI ‐38.20 to 14.20; <a href="./references#CD014831-fig-0018" title="">Analysis 2.5</a>). </p> <p>We judged the data to be of overall low certainty, downgrading one level due to imprecision.</p> </section> <section id="CD014831-sec-0099"> <h6 class="title">Change in other activity domains</h6> <p>No included studies reported this outcome.</p> </section> <section id="CD014831-sec-0100"> <h6 class="title">Proportion of participants to achieve steroid‐sparing control or to achieve reduction in oral steroid dose </h6> <p>As part of their definition of control of inflammation, both <a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a> and <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a> included a requirement for steroid‐sparing control, albeit with different steroid cutoffs. Therefore, the RR of control of inflammation for this outcome is the same as for <a href="./references#CD014831-fig-0014" title="">Analysis 2.1</a>, suggesting that participants treated with methotrexate have a slightly higher chance of achieving steroid‐sparing control compared to those treated with mycophenolate (RR 1.23, where &gt; 1 favors methotrexate, 95% CI 1.01 to 1.50; I<sup>2</sup> = 0%; <a href="./references#CD014831-fig-0019" title="">Analysis 2.6</a>). </p> <p>We graded the overall certainty of the evidence as moderate, downgrading by one level due to imprecision of the results. </p> </section> <section id="CD014831-sec-0101"> <h6 class="title">Cost‐effectiveness</h6> <p>No included studies measured this outcome.</p> </section> <section id="CD014831-sec-0102"> <h6 class="title">Mean change in vision‐related quality of life</h6> <p>Both <a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a> and <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a> reported outcomes for the Indian Visual Function Questionnaire (IND VFQ‐25), and <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a> also reported the National Eye Institute Visual Function Questionnaire (NEI‐VFQ), with measurements compared between baseline and primary study endpoint (either at six months of follow‐up if treatment was successful, or at treatment failure if occurring before six months). Scores were compared between treatment groups (methotrexate versus mycophenolate) using multivariate models that controlled for baseline score, age, sex, and site (included as a random effect), and were reported as β coefficients. Together, 186 participants were included, and combined, the evidence suggests mycophenolate does not increase improvement in vision‐related quality of life over methotrexate (MD 2.27, where MD &lt; 0 favors mycophenolate, 95% CI ‐2.25 to 6.79; P = 0.26, I<sup>2</sup> = 20%; <a href="./references#CD014831-fig-0020" title="">Analysis 2.7</a>). The NEI‐VFQ data from <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a> also suggest that mycophenolate does not improve vision‐related quality of life scores over methotrexate (MD 2.20, where MD &lt; 0 favors mycophenolate, 95% CI ‐1.39 to 5.79; <a href="./references#CD014831-fig-0020" title="">Analysis 2.7</a>). </p> <p>We considered the data to be of moderate overall certainty, downgrading one level due to imprecision. </p> </section> <section id="CD014831-sec-0103"> <h6 class="title">Mean change in general health‐related quality of life</h6> <p>Health‐related quality of life scores were reported by both <a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a> and <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a> utilizing the Medical Outcomes Study 36‐Item Short‐Form Survey (SF‐36v2), with the same comparison as used in the VFQ measurements (baseline compared to follow‐up at six months if treatment successful, or at treatment failure if occurring prior to six months). Scores were compared between treatment groups (methotrexate versus mycophenolate) using multivariate models that controlled for baseline score, age, sex, and site (included as a random effect). Both studies reported physical and mental health components of the SF‐36 for 260 participants total. Mycophenolate likely does not result in an improvement in self‐reported physical (MD 1.18, where MD &gt; 0 favors methotrexate, 95% CI ‐0.48 to 2.85; P = 0.25, I<sup>2</sup> = 23%; <a href="./references#CD014831-fig-0021" title="">Analysis 2.8</a>) or mental (MD 0.04, 95% CI ‐2.24 to 2.31; I<sup>2</sup> = 0%; <a href="./references#CD014831-fig-0021" title="">Analysis 2.8</a>) quality of life scores over methotrexate. Both components of the SF‐36v2 had wide CIs crossing the null threshold. </p> <p>We considered the data to be of moderate overall certainty, downgrading one level due to imprecision. </p> </section> <section id="CD014831-sec-0104"> <h6 class="title">Adverse effects</h6> <section id="CD014831-sec-0105"> <p><b>Proportion of participants experiencing any adverse effects</b></p> <p>In the two studies, 140 participants out of 148 on methotrexate, and 139 participants out of 148 on mycophenolate experienced any adverse effect over the course of six months of follow‐up, including non‐serious and serious ocular, systemic, and laboratory events. The evidence suggests that treatment with mycophenolate results in little to no difference in the proportion of participants experiencing any adverse effects compared to methotrexate (RR 1.02, 95% CI 0.99 to 1.05; I<sup>2</sup> = 0; <a href="./references#CD014831-fig-0022" title="">Analysis 2.9</a>). </p> <p>We rated the overall certainty of evidence as low, downgrading one level because of imprecision in the data and one level due to indirectness of the evidence due to differing adverse event definitions and thresholds for reporting. </p> </section> <section id="CD014831-sec-0106"> <p><b>Proportion of participants experiencing complications or requiring cessation of medication</b></p> <p><a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a> and <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a> reported the number of participants experiencing complications requiring cessation of medication. Cessation of medication because of safety or intolerability occurred in 10 of 137 participants on methotrexate and 10 of 137 participants on mycophenolate, or about 7% of participants in both groups. Therefore, treatment with mycophenolate likely results in little to no difference in the proportion of participants requiring cessation of medication over methotrexate (RR 0.99, where RR &lt; 1 favors methotrexate, 95% CI 0.43 to 2.27; P = 0.31, I<sup>2</sup> = 2%; <a href="#CD014831-fig-0006">Figure 6</a>). We had some concerns for risk of bias for this safety outcome due to bias in the measurement of the outcome. We downgraded this evidence by one level, to moderate certainty, due to imprecision. </p> <div class="figure" id="CD014831-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison 2: Methotrexate versus mycophenolate, outcome: 2.10 Proportion of participants experiencing complications or requiring cessation of medication" data-id="CD014831-fig-0006" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison 2: Methotrexate versus mycophenolate, outcome: 2.10 Proportion of participants experiencing complications or requiring cessation of medication </p> </div> </div> </div> <p>Mycophenolate likely does not influence the rate of cessation in the VKH subgroup from <a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a> compared to methotrexate, although the data are uncertain (RR 1.19, 95% CI 0.12 to 12.05; <a href="./references#CD014831-fig-0024" title="">Analysis 2.11</a>). We downgraded the evidence to very low certainty, downgrading one level for indirectness and two levels for imprecision as it was from a subgroup from a single study with a small size.  </p> <p>Both <a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a> and <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a> reported participants experiencing elevated liver enzymes (AST or ALT) or abnormal hemoglobin. Elevations in AST or ALT, or both, greater than two times the upper limit of normal were observed in 18 of 148 participants on methotrexate, versus 10 of 148 participants on mycophenolate, or 12% versus 7% of participants. Mycophenolate likely results in little to no difference in liver test abnormalities compared to methotrexate (RR 1.81, where &lt; 1 favors methotrexate, 95% CI 0.86 to 3.78; <a href="./references#CD014831-fig-0025" title="">Analysis 2.12</a>). <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a> further separated liver enzyme elevations into serious and non‐serious categories, with non‐serious defined as elevations greater than two to five times the upper limit of normal lasting less than 28 days, and serious defined as greater than two to five times the upper limit of normal for at least 28 days or greater than five times the upper limit of normal. Three participants had serious elevations in AST or ALT, or both, on methotrexate and two participants on mycophenolate. The study reported by <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a> did not demonstrate a difference between treatments (RR 1.53, 95% CI 0.26 to 8.96; 216 participants; <a href="./references#CD014831-fig-0025" title="">Analysis 2.12</a>). We judged the evidence to be of moderate overall certainty, downgrading one level due to imprecision of results. </p> <p>Two of 148 participants on methotrexate developed a non‐serious abnormal hemoglobin level (defined as &gt; 6.5 to &lt; 9 g/dL lasting less than 28 days in the <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a> study, and simply listed as "abnormal" in the <a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a> study), compared to five of 148 participants on mycophenolate. No participants in <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a> developed a serious change in hemoglobin level (&lt; 9 g/dL for at least 28 days or &lt; 6.5 g/dL). Mycophenolate likely results in little to no difference in the risk of abnormal hemoglobin levels compared to methotrexate (RR 0.45 for this outcome, where &lt; 1 favors fewer events with methotrexate, 95% CI 0.10 to 1.97; <a href="./references#CD014831-fig-0025" title="">Analysis 2.12</a>). Heterogeneity was low (I<sup>2</sup> = 0). We judged the evidence to be of moderate overall certainty, downgrading one level because of imprecision in the results. </p> <p><a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a> also reported the number of participants that developed low leukocyte counts (non‐serious defined as &gt; 1000 and &lt; 2500/μL lasting less than 28 days, serious defined as &lt; 2500/μL for at least 28 days or &lt; 1000/μL) and elevated creatinine (non‐serious defined as ≥ 1.5 to &lt; 2 mg/dL lasting less than 28 days, serious defined as ≥ 1.5 to &lt; 2 mg/dL for at least 28 days or ≥ 2 mg/dL). No participants in the study had low leukocyte or elevated creatinine levels qualifying as serious events. Three of 107 participants on methotrexate versus one of 109 participants on mycophenolate developed a non‐serious low leukocyte level. Mycophenolate likely results in little to no difference in the risk of leukopenia compared to methotrexate (RR 3.06, where &lt; 1 favors methotrexate, 95% CI 0.32 to 28.92; <a href="./references#CD014831-fig-0025" title="">Analysis 2.12</a>). One participant on methotrexate out of 107 developed a non‐serious elevated creatinine versus 0 of 107 on mycophenolate. Mycophenolate probably results in no difference in the risk of elevated creatinine compared to methotrexate (RR 3.06, 95% CI 0.13 to 74.18; <a href="./references#CD014831-fig-0025" title="">Analysis 2.12</a>). We judged the evidence to be of moderate overall certainty, downgrading one level because of imprecision. </p> </section> <section id="CD014831-sec-0107"> <p><b>Proportion of participants experiencing ocular complications</b></p> <p>Both <a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a> and <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a> reported the number of participants experiencing ocular adverse events. We analyzed data for glaucoma/increased intraocular pressure (IOP), hypotony, and cataract formation. </p> <p>Eighteen (12%) of 148 participants in the methotrexate group developed ocular hypertension (IOP &gt; 24 mmHg) or suspected or confirmed glaucoma, compared to 20 (13.5%) of 148 participants in the mycophenolate group. Mycophenolate likely results in little to no difference in the risk of ocular hypertension/glaucoma compared to methotrexate (RR 0.90, where &lt; 1 favors methotrexate, 95% CI 0.50 to 1.64; <a href="./references#CD014831-fig-0026" title="">Analysis 2.13</a>). Heterogeneity was low (I<sup>2</sup> = 0%). We judged the data to be of moderate overall certainty, downgrading one level for imprecision. </p> <p>No significant differences were observed in cataract formation between the groups. Five (3%) of 148 participants on methotrexate developed a visually significant cataract or cataract in which surgery was indicated versus 10 (7%) of 148 participants on mycophenolate. Mycophenolate probably does not increase rate of cataract formation compared to mycophenolate (RR 0.51, where &lt; 1 favors methotrexate, 95% CI 0.18 to 1.44; <a href="./references#CD014831-fig-0026" title="">Analysis 2.13</a>). Heterogeneity was low (I<sup>2</sup> = 0%). We judged the data to be of moderate overall certainty, downgrading one level given imprecision in the data. </p> <p>Similarly, the incidence of hypotony (IOP &lt; 5mmHg) was not found to differ significantly between the treatment groups: three participants in the methotrexate group out of 148 developed hypotony, versus 0 in the mycophenolate group. Mycophenolate likely does not increase the risk of hypotony compared to methotrexate (RR 4.08, where &lt; 1 favors methotrexate, 95% CI 0.47 to 35.72; I<sup>2</sup> = 0%; <a href="./references#CD014831-fig-0026" title="">Analysis 2.13</a>). We judged the data to be of moderate overall certainty, downgrading one level for imprecision. </p> <p>We also analyzed the VKH subgroup from <a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a>. Mycophenolate probably results in little to no difference in the risk for glaucoma/increased IOP (RR 6.68, where &lt; 1 favors methotrexate, 95% CI 0.39 to 113.36; <a href="./references#CD014831-fig-0027" title="">Analysis 2.14</a>), cataract formation (RR 5.46, 95% CI 0.31 to 95.31; <a href="./references#CD014831-fig-0027" title="">Analysis 2.14</a>), or hypotony (RR 3.50, 95% CI 0.17 to 70.14; <a href="./references#CD014831-fig-0027" title="">Analysis 2.14</a>) compared to methotrexate, although the evidence is very uncertain. We judged the data to be of very low certainty, downgrading two levels for imprecision and one level for indirectness of the evidence, as they arose from a small VKH subgroup from a single study. </p> </section> </section> </section> </section> <section id="CD014831-sec-0108"> <h4 class="title">Comparison 3: steroids with or without azathioprine versus cyclosporine A</h4> <p>Four studies with a total of 145 participants compared steroids with or without azathioprine to cyclosporine A (<a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a>; <a href="./references#CD014831-bbs2-0006" title="NussenblattRB , PalestineA , ChanCC , FujikawaLS , StevensG , GreenSB . A randomised, double-masked trial of sandimmune vs. prednisolone for endogenous uveitis. American Academy of Ophthalmology1990;112:105. [CENTRAL: CN-00485269] NussenblattRB , PalestineAG , ChanCC , StevensG , MellowSD , GreenSB . Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. American Journal of Ophthalmology1991;112(2):138‐46. [CENTRAL: CN-00077346] [DOI: 10.1016/s0002-9394(14)76692-9]">Nussenblatt 1991</a>; <a href="./references#CD014831-bbs2-0008" title="JPRN-UMIN000014387. A prospective multicenter comparative clinical trial between corticosteroid pulse therapy vs. combination therapy of oral corticosteroid and cyclosporine on Vogt-Koyanagi-Harada disease. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000014387 (first received 27 June 2014). [CENTRAL: CN-01827271] OnoT , GotoH , SakaiT , NittaF , MizukiN , TakaseH , et al. Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt–Koyanagi–Harada disease. Japanese Journal of Ophthalmology 2021 Oct 24 [Epub ahead of print]. [DOI: 10.1007/s10384-021-00878-w]OnoT , MochizukiM , GotoH , SakaiT , NittaF , MizukiN , et al. A prospective multi-center randomized clinical study comparing steroid-pulse therapy and a combined therapy with oral prednisolone and cyclosporine for new-onset acute Vogt-Koyanagi-Harada disease. Investigative Ophthalmology and Visual Science2020;61(7):3169. [CENTRAL: CN-02179109] [EMBASE: 632697033]">Ono 2021</a>; <a href="./references#CD014831-bbs2-0011" title="WiederholtM , KämpeC , HansenLL , HövenerG . Treatment of posterior uveitis with cyclosporin or prednisolone--one-year report of a randomized prospective study [Behandlung der uveitis posterior mit cyclosporin oder prednisolon--jahresbericht über eine randomisierte prospektive studie]. Fortschritte der Ophthalmologie1986;83(3):348‐52. [CENTRAL: CN-00044224] [EMBASE: 1986247564] [PMID: 3527903]">Wiederholt 1986</a>). <a href="./references#CD014831-bbs2-0011" title="WiederholtM , KämpeC , HansenLL , HövenerG . Treatment of posterior uveitis with cyclosporin or prednisolone--one-year report of a randomized prospective study [Behandlung der uveitis posterior mit cyclosporin oder prednisolon--jahresbericht über eine randomisierte prospektive studie]. Fortschritte der Ophthalmologie1986;83(3):348‐52. [CENTRAL: CN-00044224] [EMBASE: 1986247564] [PMID: 3527903]">Wiederholt 1986</a> and <a href="./references#CD014831-bbs2-0006" title="NussenblattRB , PalestineA , ChanCC , FujikawaLS , StevensG , GreenSB . A randomised, double-masked trial of sandimmune vs. prednisolone for endogenous uveitis. American Academy of Ophthalmology1990;112:105. [CENTRAL: CN-00485269] NussenblattRB , PalestineAG , ChanCC , StevensG , MellowSD , GreenSB . Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. American Journal of Ophthalmology1991;112(2):138‐46. [CENTRAL: CN-00077346] [DOI: 10.1016/s0002-9394(14)76692-9]">Nussenblatt 1991</a> compared cyclosporine A with oral steroid monotherapy. The other studies examined cyclosporine in combination with oral steroid: <a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a> compared cyclosporine A plus oral steroid with azathioprine plus oral steroid; <a href="./references#CD014831-bbs2-0008" title="JPRN-UMIN000014387. A prospective multicenter comparative clinical trial between corticosteroid pulse therapy vs. combination therapy of oral corticosteroid and cyclosporine on Vogt-Koyanagi-Harada disease. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000014387 (first received 27 June 2014). [CENTRAL: CN-01827271] OnoT , GotoH , SakaiT , NittaF , MizukiN , TakaseH , et al. Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt–Koyanagi–Harada disease. Japanese Journal of Ophthalmology 2021 Oct 24 [Epub ahead of print]. [DOI: 10.1007/s10384-021-00878-w]OnoT , MochizukiM , GotoH , SakaiT , NittaF , MizukiN , et al. A prospective multi-center randomized clinical study comparing steroid-pulse therapy and a combined therapy with oral prednisolone and cyclosporine for new-onset acute Vogt-Koyanagi-Harada disease. Investigative Ophthalmology and Visual Science2020;61(7):3169. [CENTRAL: CN-02179109] [EMBASE: 632697033]">Ono 2021</a> studied an oral steroid taper in combination with cyclosporine with three days of pulse‐dose IV steroids plus a steroid taper. </p> <p>Two of the studies included in this analysis were based on all‐VKH populations (<a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a>; <a href="./references#CD014831-bbs2-0008" title="JPRN-UMIN000014387. A prospective multicenter comparative clinical trial between corticosteroid pulse therapy vs. combination therapy of oral corticosteroid and cyclosporine on Vogt-Koyanagi-Harada disease. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000014387 (first received 27 June 2014). [CENTRAL: CN-01827271] OnoT , GotoH , SakaiT , NittaF , MizukiN , TakaseH , et al. Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt–Koyanagi–Harada disease. Japanese Journal of Ophthalmology 2021 Oct 24 [Epub ahead of print]. [DOI: 10.1007/s10384-021-00878-w]OnoT , MochizukiM , GotoH , SakaiT , NittaF , MizukiN , et al. A prospective multi-center randomized clinical study comparing steroid-pulse therapy and a combined therapy with oral prednisolone and cyclosporine for new-onset acute Vogt-Koyanagi-Harada disease. Investigative Ophthalmology and Visual Science2020;61(7):3169. [CENTRAL: CN-02179109] [EMBASE: 632697033]">Ono 2021</a>), and the VKH subgroup analyses are included where relevant. For further information, see <a href="./full#CD014831-tbl-0003">summary of findings Table 3</a>. </p> <section id="CD014831-sec-0109"> <h5 class="title">Critical outcomes</h5> <section id="CD014831-sec-0110"> <h6 class="title">Control of inflammation</h6> <p>We included two studies in the analysis of control of inflammation at 12 months (<a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a>; <a href="./references#CD014831-bbs2-0008" title="JPRN-UMIN000014387. A prospective multicenter comparative clinical trial between corticosteroid pulse therapy vs. combination therapy of oral corticosteroid and cyclosporine on Vogt-Koyanagi-Harada disease. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000014387 (first received 27 June 2014). [CENTRAL: CN-01827271] OnoT , GotoH , SakaiT , NittaF , MizukiN , TakaseH , et al. Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt–Koyanagi–Harada disease. Japanese Journal of Ophthalmology 2021 Oct 24 [Epub ahead of print]. [DOI: 10.1007/s10384-021-00878-w]OnoT , MochizukiM , GotoH , SakaiT , NittaF , MizukiN , et al. A prospective multi-center randomized clinical study comparing steroid-pulse therapy and a combined therapy with oral prednisolone and cyclosporine for new-onset acute Vogt-Koyanagi-Harada disease. Investigative Ophthalmology and Visual Science2020;61(7):3169. [CENTRAL: CN-02179109] [EMBASE: 632697033]">Ono 2021</a>). Together, these two trials comprised 112 participants, all of whom had VKH. Control of inflammation was defined heterogeneously between the studies. <a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a> used a weighted visual morbidity scale based on anterior chamber cells and flare and vitreous haze, while <a href="./references#CD014831-bbs2-0008" title="JPRN-UMIN000014387. A prospective multicenter comparative clinical trial between corticosteroid pulse therapy vs. combination therapy of oral corticosteroid and cyclosporine on Vogt-Koyanagi-Harada disease. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000014387 (first received 27 June 2014). [CENTRAL: CN-01827271] OnoT , GotoH , SakaiT , NittaF , MizukiN , TakaseH , et al. Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt–Koyanagi–Harada disease. Japanese Journal of Ophthalmology 2021 Oct 24 [Epub ahead of print]. [DOI: 10.1007/s10384-021-00878-w]OnoT , MochizukiM , GotoH , SakaiT , NittaF , MizukiN , et al. A prospective multi-center randomized clinical study comparing steroid-pulse therapy and a combined therapy with oral prednisolone and cyclosporine for new-onset acute Vogt-Koyanagi-Harada disease. Investigative Ophthalmology and Visual Science2020;61(7):3169. [CENTRAL: CN-02179109] [EMBASE: 632697033]">Ono 2021</a> used a definition for worsening based on anterior chamber cells or vitreous haze, or recurrence based on the reappearance of serous retinal detachment or other systemic signs of VKH disease. The evidence may suggest the steroids with or without azathioprine result in little to no difference in control of inflammation over cyclosporine, but is very uncertain (RR 0.84, where &lt; 1 favors cyclosporine A, 95% CI 0.70 to 1.02; I<sup>2</sup> = 0%; <a href="#CD014831-fig-0007">Figure 7</a>). </p> <div class="figure" id="CD014831-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison 3: steroids ± azathioprine versus cyclosporin A, outcome: 3.1 Control of inflammation" data-id="CD014831-fig-0007" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-FIG-07.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison 3: steroids ± azathioprine versus cyclosporin A, outcome: 3.1 Control of inflammation </p> </div> </div> </div> <p>We judged both studies included in this outcome to be at some concern or high risk of bias, including bias due to deviations from intended interventions and in selection of reported result. Overall, we judged these data to be of very low overall certainty, downgrading two levels because of concerns for bias and one level for imprecision in the data. </p> <p>We excluded from the evidence synthesis two studies using high‐dose cyclosporine A which reported control of inflammation (<a href="./references#CD014831-bbs2-0006" title="NussenblattRB , PalestineA , ChanCC , FujikawaLS , StevensG , GreenSB . A randomised, double-masked trial of sandimmune vs. prednisolone for endogenous uveitis. American Academy of Ophthalmology1990;112:105. [CENTRAL: CN-00485269] NussenblattRB , PalestineAG , ChanCC , StevensG , MellowSD , GreenSB . Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. American Journal of Ophthalmology1991;112(2):138‐46. [CENTRAL: CN-00077346] [DOI: 10.1016/s0002-9394(14)76692-9]">Nussenblatt 1991</a>; <a href="./references#CD014831-bbs2-0011" title="WiederholtM , KämpeC , HansenLL , HövenerG . Treatment of posterior uveitis with cyclosporin or prednisolone--one-year report of a randomized prospective study [Behandlung der uveitis posterior mit cyclosporin oder prednisolon--jahresbericht über eine randomisierte prospektive studie]. Fortschritte der Ophthalmologie1986;83(3):348‐52. [CENTRAL: CN-00044224] [EMBASE: 1986247564] [PMID: 3527903]">Wiederholt 1986</a>). Both were conducted in non‐VKH patients, with a total of 64 participants. <a href="./references#CD014831-bbs2-0011" title="WiederholtM , KämpeC , HansenLL , HövenerG . Treatment of posterior uveitis with cyclosporin or prednisolone--one-year report of a randomized prospective study [Behandlung der uveitis posterior mit cyclosporin oder prednisolon--jahresbericht über eine randomisierte prospektive studie]. Fortschritte der Ophthalmologie1986;83(3):348‐52. [CENTRAL: CN-00044224] [EMBASE: 1986247564] [PMID: 3527903]">Wiederholt 1986</a> used a grading scheme involving anterior chamber cells and vitreous opacities; <a href="./references#CD014831-bbs2-0006" title="NussenblattRB , PalestineA , ChanCC , FujikawaLS , StevensG , GreenSB . A randomised, double-masked trial of sandimmune vs. prednisolone for endogenous uveitis. American Academy of Ophthalmology1990;112:105. [CENTRAL: CN-00485269] NussenblattRB , PalestineAG , ChanCC , StevensG , MellowSD , GreenSB . Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. American Journal of Ophthalmology1991;112(2):138‐46. [CENTRAL: CN-00077346] [DOI: 10.1016/s0002-9394(14)76692-9]">Nussenblatt 1991</a> used a vitreal haze grading scheme to define the control of inflammation. Regarding the superiority of steroid monotherapy over high‐dose cyclosporine A, the RR was 1.21 (95% CI 0.72 to 2.01; P = 0.14, I<sup>2</sup> = 53%; <a href="./references#CD014831-fig-0029" title="">Analysis 3.2</a>). </p> </section> <section id="CD014831-sec-0111"> <h6 class="title">Change in BCVA</h6> <p>Two trials, comprising 91 eyes, reported data on the change in BCVA (<a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a>; <a href="./references#CD014831-bbs2-0008" title="JPRN-UMIN000014387. A prospective multicenter comparative clinical trial between corticosteroid pulse therapy vs. combination therapy of oral corticosteroid and cyclosporine on Vogt-Koyanagi-Harada disease. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000014387 (first received 27 June 2014). [CENTRAL: CN-01827271] OnoT , GotoH , SakaiT , NittaF , MizukiN , TakaseH , et al. Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt–Koyanagi–Harada disease. Japanese Journal of Ophthalmology 2021 Oct 24 [Epub ahead of print]. [DOI: 10.1007/s10384-021-00878-w]OnoT , MochizukiM , GotoH , SakaiT , NittaF , MizukiN , et al. A prospective multi-center randomized clinical study comparing steroid-pulse therapy and a combined therapy with oral prednisolone and cyclosporine for new-onset acute Vogt-Koyanagi-Harada disease. Investigative Ophthalmology and Visual Science2020;61(7):3169. [CENTRAL: CN-02179109] [EMBASE: 632697033]">Ono 2021</a>). For this outcome, a more negative mean change indicates improved vision. The mean change and SD in BCVA at 12 months, extracted from a graphical reading in <a href="./references#CD014831-bbs2-0008" title="JPRN-UMIN000014387. A prospective multicenter comparative clinical trial between corticosteroid pulse therapy vs. combination therapy of oral corticosteroid and cyclosporine on Vogt-Koyanagi-Harada disease. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000014387 (first received 27 June 2014). [CENTRAL: CN-01827271] OnoT , GotoH , SakaiT , NittaF , MizukiN , TakaseH , et al. Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt–Koyanagi–Harada disease. Japanese Journal of Ophthalmology 2021 Oct 24 [Epub ahead of print]. [DOI: 10.1007/s10384-021-00878-w]OnoT , MochizukiM , GotoH , SakaiT , NittaF , MizukiN , et al. A prospective multi-center randomized clinical study comparing steroid-pulse therapy and a combined therapy with oral prednisolone and cyclosporine for new-onset acute Vogt-Koyanagi-Harada disease. Investigative Ophthalmology and Visual Science2020;61(7):3169. [CENTRAL: CN-02179109] [EMBASE: 632697033]">Ono 2021</a>, were nearly identical for the IV steroid plus oral steroid taper group versus the cyclosporine plus oral steroid taper group (‐0.34 ± 0.25 versus ‐0.32 ± 0.24). Similarly, <a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a> reported a mean change of ‐0.32 ± 0.24 for the azathioprine plus oral steroid group compared to ‐0.21 ± 0.31 for the cyclosporine plus oral steroid group. The evidence is very uncertain whether the steroids with or without azathioprine improve vision over cyclosporine (RR ‐0.04, where &lt; 0 favors comparators, 95% CI ‐0.14 to 0.07; I² = 0%; <a href="./references#CD014831-fig-0030" title="">Analysis 3.3</a>). </p> <p>We judged the evidence to be of very low overall certainty, downgrading two levels because of concerns for bias and one level for imprecision. </p> </section> <section id="CD014831-sec-0112"> <h6 class="title">Proportion of participants achieving a 2‐line improvement in visual acuity</h6> <p>This outcome was not reported by any study which used modern cyclosporine dosing. Two studies using high doses of cyclosporine A reported the proportion of participants achieving improvement in visual acuity at three months (<a href="./references#CD014831-bbs2-0006" title="NussenblattRB , PalestineA , ChanCC , FujikawaLS , StevensG , GreenSB . A randomised, double-masked trial of sandimmune vs. prednisolone for endogenous uveitis. American Academy of Ophthalmology1990;112:105. [CENTRAL: CN-00485269] NussenblattRB , PalestineAG , ChanCC , StevensG , MellowSD , GreenSB . Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. American Journal of Ophthalmology1991;112(2):138‐46. [CENTRAL: CN-00077346] [DOI: 10.1016/s0002-9394(14)76692-9]">Nussenblatt 1991</a>; <a href="./references#CD014831-bbs2-0011" title="WiederholtM , KämpeC , HansenLL , HövenerG . Treatment of posterior uveitis with cyclosporin or prednisolone--one-year report of a randomized prospective study [Behandlung der uveitis posterior mit cyclosporin oder prednisolon--jahresbericht über eine randomisierte prospektive studie]. Fortschritte der Ophthalmologie1986;83(3):348‐52. [CENTRAL: CN-00044224] [EMBASE: 1986247564] [PMID: 3527903]">Wiederholt 1986</a>), with a higher score indicating a larger proportion with vision improvement. Improvement was defined as 2‐3 Snellen optotypes by <a href="./references#CD014831-bbs2-0011" title="WiederholtM , KämpeC , HansenLL , HövenerG . Treatment of posterior uveitis with cyclosporin or prednisolone--one-year report of a randomized prospective study [Behandlung der uveitis posterior mit cyclosporin oder prednisolon--jahresbericht über eine randomisierte prospektive studie]. Fortschritte der Ophthalmologie1986;83(3):348‐52. [CENTRAL: CN-00044224] [EMBASE: 1986247564] [PMID: 3527903]">Wiederholt 1986</a> or as 15 or more ETDRS letters by <a href="./references#CD014831-bbs2-0006" title="NussenblattRB , PalestineA , ChanCC , FujikawaLS , StevensG , GreenSB . A randomised, double-masked trial of sandimmune vs. prednisolone for endogenous uveitis. American Academy of Ophthalmology1990;112:105. [CENTRAL: CN-00485269] NussenblattRB , PalestineAG , ChanCC , StevensG , MellowSD , GreenSB . Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. American Journal of Ophthalmology1991;112(2):138‐46. [CENTRAL: CN-00077346] [DOI: 10.1016/s0002-9394(14)76692-9]">Nussenblatt 1991</a>. Overall, 13 out of 32 participants treated with cyclosporine and 12 out of 32 participants treated with steroid monotherapy had improvement in visual acuity. The evidence is very uncertain whether steroid monotherapy produces a higher proportion of participants achieving improvement in visual acuity compared to cyclosporine (RR 0.92, where &gt; 1 favors steroid monotherapy, 95% CI 0.50 to 1.69; I² = 0%; <a href="./references#CD014831-fig-0031" title="">Analysis 3.4</a>). </p> <p>Because these studies do not use modern cyclosporine dosing, we did not apply the GRADE assessment. </p> </section> <section id="CD014831-sec-0113"> <h6 class="title">Proportion of participants with macular edema</h6> <p>No study using modern cyclosporine dosing reported this outcome. <a href="./references#CD014831-bbs2-0006" title="NussenblattRB , PalestineA , ChanCC , FujikawaLS , StevensG , GreenSB . A randomised, double-masked trial of sandimmune vs. prednisolone for endogenous uveitis. American Academy of Ophthalmology1990;112:105. [CENTRAL: CN-00485269] NussenblattRB , PalestineAG , ChanCC , StevensG , MellowSD , GreenSB . Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. American Journal of Ophthalmology1991;112(2):138‐46. [CENTRAL: CN-00077346] [DOI: 10.1016/s0002-9394(14)76692-9]">Nussenblatt 1991</a> reported the proportion of participants with macular edema, finding that macular edema persisted in eight of 15 participants treated with cyclosporine A and in six of 16 participants treated with oral steroid monotherapy at three months of follow‐up. The evidence is very uncertain whether oral steroid treatment leads to a lower proportion of participants with macular edema compared to cyclosporine A (RR 0.70, 95% CI 0.32 to 1.55; <a href="./references#CD014831-fig-0032" title="">Analysis 3.5</a>). </p> <p>Because these studies do not use modern cyclosporine dosing, we did not apply the GRADE assessment. </p> </section> </section> <section id="CD014831-sec-0114"> <h5 class="title">Important outcomes</h5> <section id="CD014831-sec-0115"> <h6 class="title">Mean time to relapse</h6> <p>No included studies reported this outcome.</p> </section> <section id="CD014831-sec-0116"> <h6 class="title">Reduction in cumulative hazard of disease relapse</h6> <p>No included studies reported this outcome.</p> </section> <section id="CD014831-sec-0117"> <h6 class="title">Proportion of participants with change in anterior chamber flare and cells</h6> <p>No included studies reported this outcome.</p> </section> <section id="CD014831-sec-0118"> <h6 class="title">Mean change in CMT</h6> <p>No included studies reported this outcome.</p> </section> <section id="CD014831-sec-0119"> <h6 class="title">Change in other activity domains</h6> <p>No included studies reported this outcome.</p> </section> <section id="CD014831-sec-0120"> <h6 class="title">Proportion of participants to achieve steroid‐sparing control or to achieve reduction in oral steroid dose </h6> <p><a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a> reported the proportion of participants who achieved steroid‐sparing control (&lt; 10 mg/day) at 12 months of follow‐up. The authors found that more VKH patients on cyclosporine (seven of nine) achieved this low maintenance steroid dose than those on azathioprine (six of 12). The evidence is very uncertain if there is a difference in the proportion of participants achieving steroid‐sparing control with azathioprine or cyclosporine A (RR 0.64, where &lt; 1 favors cyclosporine, 95% CI 0.33 to 1.25; <a href="./references#CD014831-fig-0033" title="">Analysis 3.6</a>). </p> <p>We considered the data to be of very low overall certainty, downgrading one level given the imprecision of the data and two levels due to risk of bias. </p> </section> <section id="CD014831-sec-0121"> <h6 class="title">Cost‐effectiveness</h6> <p>No included studies measured this outcome.</p> </section> <section id="CD014831-sec-0122"> <h6 class="title">Mean change in vision‐related quality of life</h6> <p>No included studies reported this outcome.</p> </section> <section id="CD014831-sec-0123"> <h6 class="title">Mean change in general health‐related quality of life</h6> <p>No included studies reported this outcome.</p> </section> <section id="CD014831-sec-0124"> <h6 class="title">Adverse effects</h6> <section id="CD014831-sec-0125"> <p><b>Proportion of participants experiencing any adverse effects</b></p> <p><a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a> reported the number of participants experiencing any adverse event over the course of 12 months of follow‐up. Two‐thirds of participants on cyclosporine (six of nine) and azathioprine (eight of 12) experienced any adverse event. The risk ratio of 1.00 is situated at the null value (95% CI 0.54 to 1.84) and therefore there may be no difference between the treatments; however, the evidence is very uncertain (<a href="./references#CD014831-fig-0034" title="">Analysis 3.7</a>). </p> <p>We judged the evidence to be of very low overall certainty, downgrading one level for imprecision of the data and two levels for risk of bias.  </p> </section> <section id="CD014831-sec-0126"> <p><b>Proportion of participants experiencing complications or requiring cessation of medication</b></p> <p>Using data from <a href="./references#CD014831-bbs2-0008" title="JPRN-UMIN000014387. A prospective multicenter comparative clinical trial between corticosteroid pulse therapy vs. combination therapy of oral corticosteroid and cyclosporine on Vogt-Koyanagi-Harada disease. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000014387 (first received 27 June 2014). [CENTRAL: CN-01827271] OnoT , GotoH , SakaiT , NittaF , MizukiN , TakaseH , et al. Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt–Koyanagi–Harada disease. Japanese Journal of Ophthalmology 2021 Oct 24 [Epub ahead of print]. [DOI: 10.1007/s10384-021-00878-w]OnoT , MochizukiM , GotoH , SakaiT , NittaF , MizukiN , et al. A prospective multi-center randomized clinical study comparing steroid-pulse therapy and a combined therapy with oral prednisolone and cyclosporine for new-onset acute Vogt-Koyanagi-Harada disease. Investigative Ophthalmology and Visual Science2020;61(7):3169. [CENTRAL: CN-02179109] [EMBASE: 632697033]">Ono 2021</a> and <a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a>, three of 43 participants with VKH treated with cyclosporine required cessation of the medication, versus three of 48 participants treated with the comparators (IV steroid plus oral steroid taper or azathioprine). There may be no difference between the comparators and cyclosporine A regarding the risk of participants requiring cessation of medication, but the data are very uncertain (RR 0.87, where &gt; 1 favors cyclosporine; P = 0.08, I<sup>2</sup> = 68%; <a href="#CD014831-fig-0008">Figure 8</a>). </p> <div class="figure" id="CD014831-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Forest plot of comparison 3: steroids ± azathioprine versus cyclosporin A, outcome: 3.8 Proportion of participants experiencing complications or requiring cessation of medication" data-id="CD014831-fig-0008" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-FIG-08.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison 3: steroids ± azathioprine versus cyclosporin A, outcome: 3.8 Proportion of participants experiencing complications or requiring cessation of medication </p> </div> </div> </div> <p>We judged both studies included for this outcome to be at some concerns for or high risk of bias. Therefore, we graded the overall certainty of the data as very low, downgrading one level for imprecision and two levels for risk of bias. </p> <p>Alongside the above three serious adverse events, a variety of non‐serious systemic issues, such as fatigue, tremor, moon‐face, and hyperglycemia, were reported as a percentage in <a href="./references#CD014831-bbs2-0008" title="JPRN-UMIN000014387. A prospective multicenter comparative clinical trial between corticosteroid pulse therapy vs. combination therapy of oral corticosteroid and cyclosporine on Vogt-Koyanagi-Harada disease. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000014387 (first received 27 June 2014). [CENTRAL: CN-01827271] OnoT , GotoH , SakaiT , NittaF , MizukiN , TakaseH , et al. Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt–Koyanagi–Harada disease. Japanese Journal of Ophthalmology 2021 Oct 24 [Epub ahead of print]. [DOI: 10.1007/s10384-021-00878-w]OnoT , MochizukiM , GotoH , SakaiT , NittaF , MizukiN , et al. A prospective multi-center randomized clinical study comparing steroid-pulse therapy and a combined therapy with oral prednisolone and cyclosporine for new-onset acute Vogt-Koyanagi-Harada disease. Investigative Ophthalmology and Visual Science2020;61(7):3169. [CENTRAL: CN-02179109] [EMBASE: 632697033]">Ono 2021</a>, with nine (26.5%) of 34 participants treated with IV steroid versus five (13.9%) of 36 participants receiving cyclosporine. <a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a> reported the number of participants experiencing a variety of systemic adverse events, including respiratory infections, urinary infections, and hypertension. Two (16.67%) of 12 participants on azathioprine versus 0 of nine participants on cyclosporine had elevated liver enzymes, although the cutoffs used for this designation were not described. One of 12 participants on azathioprine versus 0 of nine on cyclosporine had leukopenia (with laboratory cutoff not explicitly described), and no participants in either group had "renal damage," again without a definition of this provided. The evidence is very uncertain whether the comparators reduce the risk of complications (RR 0.61, where &gt;1 favors cyclosporine, 95% CI 0.35 to 1.06; P = 0.07, I² = 70%; <a href="./references#CD014831-fig-0036" title="">Analysis 3.9</a>).  </p> <p>We judged the overall certainty of the data as very low, downgrading one level for imprecision and two levels for risk of bias. </p> </section> <section id="CD014831-sec-0127"> <p><b>Proportion of participants experiencing ocular complications</b></p> <p><a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a> and <a href="./references#CD014831-bbs2-0008" title="JPRN-UMIN000014387. A prospective multicenter comparative clinical trial between corticosteroid pulse therapy vs. combination therapy of oral corticosteroid and cyclosporine on Vogt-Koyanagi-Harada disease. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000014387 (first received 27 June 2014). [CENTRAL: CN-01827271] OnoT , GotoH , SakaiT , NittaF , MizukiN , TakaseH , et al. Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt–Koyanagi–Harada disease. Japanese Journal of Ophthalmology 2021 Oct 24 [Epub ahead of print]. [DOI: 10.1007/s10384-021-00878-w]OnoT , MochizukiM , GotoH , SakaiT , NittaF , MizukiN , et al. A prospective multi-center randomized clinical study comparing steroid-pulse therapy and a combined therapy with oral prednisolone and cyclosporine for new-onset acute Vogt-Koyanagi-Harada disease. Investigative Ophthalmology and Visual Science2020;61(7):3169. [CENTRAL: CN-02179109] [EMBASE: 632697033]">Ono 2021</a> reported specific ocular complications. In their year‐long study of people with VKH, <a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a> reported that 10 of 24 participants on azathioprine versus nine of 18 participants on cyclosporine developed increased IOP. There may be little to no difference between azathioprine and cyclosporine A in terms of risk of ocular complications, but the data are statistically very uncertain (RR 0.83, 95% CI 0.43 to 1.61; <a href="./references#CD014831-fig-0037" title="">Analysis 3.10</a>). </p> <p><a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a> and <a href="./references#CD014831-bbs2-0008" title="JPRN-UMIN000014387. A prospective multicenter comparative clinical trial between corticosteroid pulse therapy vs. combination therapy of oral corticosteroid and cyclosporine on Vogt-Koyanagi-Harada disease. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000014387 (first received 27 June 2014). [CENTRAL: CN-01827271] OnoT , GotoH , SakaiT , NittaF , MizukiN , TakaseH , et al. Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt–Koyanagi–Harada disease. Japanese Journal of Ophthalmology 2021 Oct 24 [Epub ahead of print]. [DOI: 10.1007/s10384-021-00878-w]OnoT , MochizukiM , GotoH , SakaiT , NittaF , MizukiN , et al. A prospective multi-center randomized clinical study comparing steroid-pulse therapy and a combined therapy with oral prednisolone and cyclosporine for new-onset acute Vogt-Koyanagi-Harada disease. Investigative Ophthalmology and Visual Science2020;61(7):3169. [CENTRAL: CN-02179109] [EMBASE: 632697033]">Ono 2021</a> also reported the rate of cataract formation. Fewer participants on cyclosporine developed cataract (16 out of 80) versus the steroids with or without azathioprine (24 out of 88). Statistical heterogeneity was moderate (P = 0.09, I<sup>2</sup> = 64%) and estimates from both trials were largely overlapping, therefore we decided to combine reported adverse event rates of the two trials. The evidence is very uncertain about the effect of the steroids with or without azathioprine versus cyclosporine A on the risk of cataract formation (RR 1.59, 95% CI 0.90 to 2.81; <a href="./references#CD014831-fig-0037" title="">Analysis 3.10</a>). We judged the data as being of very low overall certainty, downgrading one level for imprecision and two levels for risk of bias. </p> <p><a href="./references#CD014831-bbs2-0006" title="NussenblattRB , PalestineA , ChanCC , FujikawaLS , StevensG , GreenSB . A randomised, double-masked trial of sandimmune vs. prednisolone for endogenous uveitis. American Academy of Ophthalmology1990;112:105. [CENTRAL: CN-00485269] NussenblattRB , PalestineAG , ChanCC , StevensG , MellowSD , GreenSB . Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. American Journal of Ophthalmology1991;112(2):138‐46. [CENTRAL: CN-00077346] [DOI: 10.1016/s0002-9394(14)76692-9]">Nussenblatt 1991</a>, a high‐dose cyclosporine study, also reported the risk of cataract development. The evidence is very uncertain regarding the effect of the therapies on cataract development (RR 0.25, 95% CI 0.03 to 2.10; <a href="./references#CD014831-fig-0038" title="">Analysis 3.11</a>). We did not perform a GRADE assessment on this high‐dose trial. </p> </section> </section> </section> </section> <section id="CD014831-sec-0128"> <h4 class="title">Descriptions of studies with comparisons not included in meta‐analysis</h4> <p><a href="./references#CD014831-bbs2-0007" title="NussenblattRB , De SmetMD , RubinB , FreidlinV , WhitcupSM , DavisJ , et al. A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin. American Journal of Ophthalmology1993;115(5):583‐91. [CENTRAL: CN-00093004] [DOI: 10.1016/s0002-9394(14)71454-0]">Nussenblatt 1993</a> tested cyclosporine A and G at four escalating doses in 32 participants. They reported the number of participants with resolution of macular edema at 12 weeks for each of the four doses tested. The proportion of participants with remaining macular edema at this time point was similar between the groups (two out of 14 for cyclosporine G, three out of 14 for cyclosporine A). The evidence is very uncertain whether cyclosporine G causes a lower rate of residual macular edema than cyclosporine A (RR 0.67, where &lt; 1 favors cyclosporine G, 95% CI 0.13 to 3.40). <a href="./references#CD014831-bbs2-0007" title="NussenblattRB , De SmetMD , RubinB , FreidlinV , WhitcupSM , DavisJ , et al. A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin. American Journal of Ophthalmology1993;115(5):583‐91. [CENTRAL: CN-00093004] [DOI: 10.1016/s0002-9394(14)71454-0]">Nussenblatt 1993</a> also reported improvement in visual acuity, which was similar between the two groups at four months of follow‐up. Detailed analyses were carried out regarding changes in renal parameters, liver function, and blood pressure. Although statistically significant differences were not noted between cyclosporine A and G, increased renal toxicity and rate of hypertension development were noted in participants on higher doses of either formulation of cyclosporine, suggesting a dose‐response. Four participants, all taking cyclosporine G, had hepatic abnormalities (abnormal AST, ALT, or bilirubin). </p> <p><a href="./references#CD014831-bbs2-0005" title="MurphyC , GreinerK , PlskovaJ , DuncanL , FrostN , ForresterJ , et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Archives of Ophthalmology2005;123(5):634‐41. [CENTRAL: CN-00511918] [DOI: 10.1001/archopht.123.5.634]">Murphy 2005</a> analyzed cyclosporine A versus tacrolimus in 37 participants with NIIPPU, none of whom had VKH. They defined control of inflammation as improvement in logMAR visual acuity or binocular indirect ophthalmoscopy (BIO) score, and found that 13 of 19 participants taking tacrolimus versus 12 of 18 taking cyclosporine had control of inflammation at three months. Four participants taking cyclosporine versus six taking tacrolimus had a relapse during the 12‐month follow‐up period. The authors did not find a difference in the ability to taper oral steroids between the two groups. Two participants taking cyclosporine and one taking tacrolimus required cessation of medication because of intolerability or safety concerns. Quality of life measures were also similar between the two groups. </p> <p><a href="./references#CD014831-bbs2-0004" title="ISRCTN46576063. Tacrolimus monotherapy for uveitis [Dual steroid and tacrolimus therapy versus steroid withdrawal and tacrolimus therapy in the treatment of posterior segment intraocular inflammation (uveitis)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN46576063 (first received 16 April 2008). [DOI: https://doi.org/10.1186/ISRCTN46576063]LeeR , GreenwoodR , TaylorH , AmerR , BiesterS , HeissigerovaJ , et al. A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. Ophthalmology2012;119(6):1223‐30. [DOI: 10.1016/j.ophtha.2011.12.030]LeeRW , GreenwoodR , AmerR , BiesterS , PlskovaJ , ForresterJV , et al. Tacrolimus monotherapy versus tacrolimus and prednisone for the maintenance of disease remission in non-infectious posterior segment intraocular inflammation. Investigative Ophthalmology and Visual Science2009;50(13):2024. ">Lee 2012</a> compared tacrolimus monotherapy versus tacrolimus plus oral steroid in 35 participants (most of whom were white and none of whom had VKH), who were successfully tapered from an oral steroid dose of 10 mg daily. The main outcome of this study was an improvement in visual acuity; cessation of medication because of safety/intolerability was also a primary outcome. There were no significant differences between the groups in the change in visual acuity (change in logMAR vision) or in the number of participants able to maintain remission at nine months. There were more treatment failures in the combination group than in the tacrolimus monotherapy group. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD014831-sec-0129" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD014831-sec-0129"></div> <p>Rather than representing a single clinical entity, non‐infectious intermediate, posterior, and panuveitis (NIIPPU) is an anatomic classification of a variety of disparate diseases not associated with infectious organisms that produce inflammation primarily in the vitreous, retina, choroid, and, in the case of panuveitis, the entire eye. Although many clinical syndromes within NIIPPU are well‐defined based on clinical features, genetic markers, and other diagnostic modalities, the pathophysiologic underpinnings of these inflammatory conditions remain poorly understood. Treatment for these potentially blinding conditions typically begins with systemic or topical corticosteroids, or both, but given the chronicity of most NIIPPU, steroid‐sparing agents are frequently required. Non‐biologic, disease‐modifying antirheumatic drugs (DMARDs) are often used in clinical practice for this purpose. In this review, we attempted to survey and synthesize the available data regarding the effectiveness and safety of DMARDs in the management of NIIPPU, specifically assessing the data on cyclosporine, azathioprine, tacrolimus, mycophenolate, and methotrexate in this heterogeneous group of conditions. </p> <section id="CD014831-sec-0130"> <h3 class="title" id="CD014831-sec-0130">Summary of main results</h3> <p>We included 11 RCTs in this analysis.</p> <p>We evaluated two individual studies comparing an experimental DMARD to oral steroid but did not combine them in a meta‐analysis: <a href="./references#CD014831-bbs2-0002" title="DeuterC , EngelmannK , HeiligenhausA , LanzlI , MackensenF , NessT , et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. British Journal of Ophthalmology2018;102(5):647‐53. [CENTRAL: CN-00781196] [DOI: 10.1136/bjophthalmol-2017-310156]EUCTR2009-009998-10-DE. Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009998-10 (first received 2 December 2009). NCT01092533. Myfortic for the treatment of non-infectious intermediate uveitis (MYCUV-IIT02) [Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectious intermediate uveitis - a prospective, controlled randomized multicenter trial]. clinicaltrials.gov/ct2/show/study/NCT01092533 (first received 25 March 2010). ">Deuter 2018</a> found that mycophenolate plus low‐dose oral steroid was associated with significantly better control of inflammation (improved time to relapse) over oral steroid monotherapy (low‐certainty evidence), whereas <a href="./references#CD014831-bbs2-0003" title="De VriesJ , BaarsmaG , ZaalM , Boen-TanT , RothovaA , BuitenhuisH , et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. British Journal of Ophthalmology1990;74(6):344‐9. [CENTRAL: CN-00069296] [DOI: 10.1136/bjo.74.6.344]">De Vries 1990</a> found no evidence of a difference between high‐dose cyclosporine plus oral steroid and steroid monotherapy. </p> <p>Methotrexate was found to be slightly more likely to result in control of inflammation, including steroid‐sparing control, over mycophenolate (moderate‐certainty evidence), although there was no benefit for one medication over the other in the Vogt‐Koyanagi‐Harada (VKH) subgroup (<a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a>; <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a>). Mycophenolate or methotrexate are likely similar in other clinical outcomes, such as cystoid macular edema (CME) or best‐corrected visual acuity (BCVA), quality of life measures, and systemic or ocular adverse events. </p> <p>Randomized controlled trials testing cyclosporine fell into two categories: studies published between 1986 and 1993, which used a higher dose of cyclosporine (8 mg to 15 mg/kg/day) than is currently used in clinical practice; and studies published between 2010 and 2021, which used modern dosing (3 mg to 5 mg/kg/day). We did not include the high‐dose cyclosporine studies in any meta‐analysis as we felt these did not inform current clinical practice. </p> <p>Seven studies examined cyclosporine A versus another DMARD or oral steroid. We combined two of these in a meta‐analysis comparing individual DMARDs plus oral steroids to modern dosing cyclosporine A plus oral steroids. Cyclosporine A plus oral steroid was not found to be superior to azathioprine plus oral steroid (<a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a>) or IV pulse of steroid plus steroid taper (<a href="./references#CD014831-bbs2-0008" title="JPRN-UMIN000014387. A prospective multicenter comparative clinical trial between corticosteroid pulse therapy vs. combination therapy of oral corticosteroid and cyclosporine on Vogt-Koyanagi-Harada disease. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000014387 (first received 27 June 2014). [CENTRAL: CN-01827271] OnoT , GotoH , SakaiT , NittaF , MizukiN , TakaseH , et al. Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt–Koyanagi–Harada disease. Japanese Journal of Ophthalmology 2021 Oct 24 [Epub ahead of print]. [DOI: 10.1007/s10384-021-00878-w]OnoT , MochizukiM , GotoH , SakaiT , NittaF , MizukiN , et al. A prospective multi-center randomized clinical study comparing steroid-pulse therapy and a combined therapy with oral prednisolone and cyclosporine for new-onset acute Vogt-Koyanagi-Harada disease. Investigative Ophthalmology and Visual Science2020;61(7):3169. [CENTRAL: CN-02179109] [EMBASE: 632697033]">Ono 2021</a>) in any efficacy or safety outcome (low‐ or very low‐certainty evidence). High‐dose cyclosporine A plus oral steroid was not found to be superior to steroid monotherapy (<a href="./references#CD014831-bbs2-0003" title="De VriesJ , BaarsmaG , ZaalM , Boen-TanT , RothovaA , BuitenhuisH , et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. British Journal of Ophthalmology1990;74(6):344‐9. [CENTRAL: CN-00069296] [DOI: 10.1136/bjo.74.6.344]">De Vries 1990</a>; <a href="./references#CD014831-bbs2-0006" title="NussenblattRB , PalestineA , ChanCC , FujikawaLS , StevensG , GreenSB . A randomised, double-masked trial of sandimmune vs. prednisolone for endogenous uveitis. American Academy of Ophthalmology1990;112:105. [CENTRAL: CN-00485269] NussenblattRB , PalestineAG , ChanCC , StevensG , MellowSD , GreenSB . Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. American Journal of Ophthalmology1991;112(2):138‐46. [CENTRAL: CN-00077346] [DOI: 10.1016/s0002-9394(14)76692-9]">Nussenblatt 1991</a>; <a href="./references#CD014831-bbs2-0011" title="WiederholtM , KämpeC , HansenLL , HövenerG . Treatment of posterior uveitis with cyclosporin or prednisolone--one-year report of a randomized prospective study [Behandlung der uveitis posterior mit cyclosporin oder prednisolon--jahresbericht über eine randomisierte prospektive studie]. Fortschritte der Ophthalmologie1986;83(3):348‐52. [CENTRAL: CN-00044224] [EMBASE: 1986247564] [PMID: 3527903]">Wiederholt 1986</a>). We excluded one study from the meta‐analysis because it compared tacrolimus to cyclosporine A, two medications of the same class (<a href="./references#CD014831-bbs2-0005" title="MurphyC , GreinerK , PlskovaJ , DuncanL , FrostN , ForresterJ , et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Archives of Ophthalmology2005;123(5):634‐41. [CENTRAL: CN-00511918] [DOI: 10.1001/archopht.123.5.634]">Murphy 2005</a>), and another because it compared cyclosporine A to cyclosporine G, which is not clinically available (<a href="./references#CD014831-bbs2-0007" title="NussenblattRB , De SmetMD , RubinB , FreidlinV , WhitcupSM , DavisJ , et al. A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin. American Journal of Ophthalmology1993;115(5):583‐91. [CENTRAL: CN-00093004] [DOI: 10.1016/s0002-9394(14)71454-0]">Nussenblatt 1993</a>). </p> <p>Finally, we were not able to add <a href="./references#CD014831-bbs2-0004" title="ISRCTN46576063. Tacrolimus monotherapy for uveitis [Dual steroid and tacrolimus therapy versus steroid withdrawal and tacrolimus therapy in the treatment of posterior segment intraocular inflammation (uveitis)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN46576063 (first received 16 April 2008). [DOI: https://doi.org/10.1186/ISRCTN46576063]LeeR , GreenwoodR , TaylorH , AmerR , BiesterS , HeissigerovaJ , et al. A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. Ophthalmology2012;119(6):1223‐30. [DOI: 10.1016/j.ophtha.2011.12.030]LeeRW , GreenwoodR , AmerR , BiesterS , PlskovaJ , ForresterJV , et al. Tacrolimus monotherapy versus tacrolimus and prednisone for the maintenance of disease remission in non-infectious posterior segment intraocular inflammation. Investigative Ophthalmology and Visual Science2009;50(13):2024. ">Lee 2012</a> to any of the comparison groups. This study tested tacrolimus monotherapy versus tacrolimus plus oral steroid. There were no significant differences in the change in visual acuity or in the number of participants able to maintain remission at nine months between the groups, but more treatment failures occurred throughout the whole course of study in the combination group than in the tacrolimus monotherapy group. </p> </section> <section id="CD014831-sec-0131"> <h3 class="title" id="CD014831-sec-0131">Overall completeness and applicability of evidence</h3> <p>We included 11 RCTs with a total of 601 participants. Seven of the 11 trials were small, with fewer than 50 participants. The studies included only adult participants, except for <a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a>, which included one child aged five years, and the two FAST trials, <a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a> and <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a>, which included participants 16 years of age and older. The prevalence of various subtypes of NIIPPU, such as VKH disease, varies widely depending on geographic region, and our review included studies from the USA, Western Europe, Mexico, Chile, Australia, Japan, Saudi Arabia, and India. Notably, no studies from the African subcontinent or which contained majority Black/Afro‐Caribbean participants were included. Two studies had exclusively VKH populations (<a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a>; <a href="./references#CD014831-bbs2-0008" title="JPRN-UMIN000014387. A prospective multicenter comparative clinical trial between corticosteroid pulse therapy vs. combination therapy of oral corticosteroid and cyclosporine on Vogt-Koyanagi-Harada disease. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000014387 (first received 27 June 2014). [CENTRAL: CN-01827271] OnoT , GotoH , SakaiT , NittaF , MizukiN , TakaseH , et al. Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt–Koyanagi–Harada disease. Japanese Journal of Ophthalmology 2021 Oct 24 [Epub ahead of print]. [DOI: 10.1007/s10384-021-00878-w]OnoT , MochizukiM , GotoH , SakaiT , NittaF , MizukiN , et al. A prospective multi-center randomized clinical study comparing steroid-pulse therapy and a combined therapy with oral prednisolone and cyclosporine for new-onset acute Vogt-Koyanagi-Harada disease. Investigative Ophthalmology and Visual Science2020;61(7):3169. [CENTRAL: CN-02179109] [EMBASE: 632697033]">Ono 2021</a>), two had sizable VKH populations (<a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a>; <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a>), and four studies had either no participants with VKH (<a href="./references#CD014831-bbs2-0002" title="DeuterC , EngelmannK , HeiligenhausA , LanzlI , MackensenF , NessT , et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. British Journal of Ophthalmology2018;102(5):647‐53. [CENTRAL: CN-00781196] [DOI: 10.1136/bjophthalmol-2017-310156]EUCTR2009-009998-10-DE. Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009998-10 (first received 2 December 2009). NCT01092533. Myfortic for the treatment of non-infectious intermediate uveitis (MYCUV-IIT02) [Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectious intermediate uveitis - a prospective, controlled randomized multicenter trial]. clinicaltrials.gov/ct2/show/study/NCT01092533 (first received 25 March 2010). ">Deuter 2018</a>; <a href="./references#CD014831-bbs2-0003" title="De VriesJ , BaarsmaG , ZaalM , Boen-TanT , RothovaA , BuitenhuisH , et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. British Journal of Ophthalmology1990;74(6):344‐9. [CENTRAL: CN-00069296] [DOI: 10.1136/bjo.74.6.344]">De Vries 1990</a>; <a href="./references#CD014831-bbs2-0005" title="MurphyC , GreinerK , PlskovaJ , DuncanL , FrostN , ForresterJ , et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Archives of Ophthalmology2005;123(5):634‐41. [CENTRAL: CN-00511918] [DOI: 10.1001/archopht.123.5.634]">Murphy 2005</a>; <a href="./references#CD014831-bbs2-0004" title="ISRCTN46576063. Tacrolimus monotherapy for uveitis [Dual steroid and tacrolimus therapy versus steroid withdrawal and tacrolimus therapy in the treatment of posterior segment intraocular inflammation (uveitis)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN46576063 (first received 16 April 2008). [DOI: https://doi.org/10.1186/ISRCTN46576063]LeeR , GreenwoodR , TaylorH , AmerR , BiesterS , HeissigerovaJ , et al. A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. Ophthalmology2012;119(6):1223‐30. [DOI: 10.1016/j.ophtha.2011.12.030]LeeRW , GreenwoodR , AmerR , BiesterS , PlskovaJ , ForresterJV , et al. Tacrolimus monotherapy versus tacrolimus and prednisone for the maintenance of disease remission in non-infectious posterior segment intraocular inflammation. Investigative Ophthalmology and Visual Science2009;50(13):2024. ">Lee 2012</a>), or a small proportion (<a href="./references#CD014831-bbs2-0006" title="NussenblattRB , PalestineA , ChanCC , FujikawaLS , StevensG , GreenSB . A randomised, double-masked trial of sandimmune vs. prednisolone for endogenous uveitis. American Academy of Ophthalmology1990;112:105. [CENTRAL: CN-00485269] NussenblattRB , PalestineAG , ChanCC , StevensG , MellowSD , GreenSB . Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. American Journal of Ophthalmology1991;112(2):138‐46. [CENTRAL: CN-00077346] [DOI: 10.1016/s0002-9394(14)76692-9]">Nussenblatt 1991</a>). Two studies did not report the proportion of participants with VKH (<a href="./references#CD014831-bbs2-0007" title="NussenblattRB , De SmetMD , RubinB , FreidlinV , WhitcupSM , DavisJ , et al. A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin. American Journal of Ophthalmology1993;115(5):583‐91. [CENTRAL: CN-00093004] [DOI: 10.1016/s0002-9394(14)71454-0]">Nussenblatt 1993</a>; <a href="./references#CD014831-bbs2-0011" title="WiederholtM , KämpeC , HansenLL , HövenerG . Treatment of posterior uveitis with cyclosporin or prednisolone--one-year report of a randomized prospective study [Behandlung der uveitis posterior mit cyclosporin oder prednisolon--jahresbericht über eine randomisierte prospektive studie]. Fortschritte der Ophthalmologie1986;83(3):348‐52. [CENTRAL: CN-00044224] [EMBASE: 1986247564] [PMID: 3527903]">Wiederholt 1986</a>). Subgroup analyses with the VKH patients did not differ from the main analyses, in that frequently the evidence was very uncertain regarding one treatment's superiority over another in terms of safety or efficacy. The high proportion of VKH patients in some included studies makes their results less generalizable to certain parts of the world, with lower rates of VKH, and vice‐versa. </p> <p>In the search, we found few trials which compared various DMARDs head‐to‐head, except for the FAST trials (<a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a>; <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a>), which compared mycophenolate to methotrexate, and the <a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a> study, which compared azathioprine to cyclosporine in combination with a low‐dose oral steroid. The other studies compared a DMARD with or without oral steroid to steroid monotherapy (<a href="./references#CD014831-bbs2-0002" title="DeuterC , EngelmannK , HeiligenhausA , LanzlI , MackensenF , NessT , et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. British Journal of Ophthalmology2018;102(5):647‐53. [CENTRAL: CN-00781196] [DOI: 10.1136/bjophthalmol-2017-310156]EUCTR2009-009998-10-DE. Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009998-10 (first received 2 December 2009). NCT01092533. Myfortic for the treatment of non-infectious intermediate uveitis (MYCUV-IIT02) [Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectious intermediate uveitis - a prospective, controlled randomized multicenter trial]. clinicaltrials.gov/ct2/show/study/NCT01092533 (first received 25 March 2010). ">Deuter 2018</a>; <a href="./references#CD014831-bbs2-0003" title="De VriesJ , BaarsmaG , ZaalM , Boen-TanT , RothovaA , BuitenhuisH , et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. British Journal of Ophthalmology1990;74(6):344‐9. [CENTRAL: CN-00069296] [DOI: 10.1136/bjo.74.6.344]">De Vries 1990</a>; <a href="./references#CD014831-bbs2-0006" title="NussenblattRB , PalestineA , ChanCC , FujikawaLS , StevensG , GreenSB . A randomised, double-masked trial of sandimmune vs. prednisolone for endogenous uveitis. American Academy of Ophthalmology1990;112:105. [CENTRAL: CN-00485269] NussenblattRB , PalestineAG , ChanCC , StevensG , MellowSD , GreenSB . Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. American Journal of Ophthalmology1991;112(2):138‐46. [CENTRAL: CN-00077346] [DOI: 10.1016/s0002-9394(14)76692-9]">Nussenblatt 1991</a>; <a href="./references#CD014831-bbs2-0008" title="JPRN-UMIN000014387. A prospective multicenter comparative clinical trial between corticosteroid pulse therapy vs. combination therapy of oral corticosteroid and cyclosporine on Vogt-Koyanagi-Harada disease. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000014387 (first received 27 June 2014). [CENTRAL: CN-01827271] OnoT , GotoH , SakaiT , NittaF , MizukiN , TakaseH , et al. Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt–Koyanagi–Harada disease. Japanese Journal of Ophthalmology 2021 Oct 24 [Epub ahead of print]. [DOI: 10.1007/s10384-021-00878-w]OnoT , MochizukiM , GotoH , SakaiT , NittaF , MizukiN , et al. A prospective multi-center randomized clinical study comparing steroid-pulse therapy and a combined therapy with oral prednisolone and cyclosporine for new-onset acute Vogt-Koyanagi-Harada disease. Investigative Ophthalmology and Visual Science2020;61(7):3169. [CENTRAL: CN-02179109] [EMBASE: 632697033]">Ono 2021</a>; <a href="./references#CD014831-bbs2-0011" title="WiederholtM , KämpeC , HansenLL , HövenerG . Treatment of posterior uveitis with cyclosporin or prednisolone--one-year report of a randomized prospective study [Behandlung der uveitis posterior mit cyclosporin oder prednisolon--jahresbericht über eine randomisierte prospektive studie]. Fortschritte der Ophthalmologie1986;83(3):348‐52. [CENTRAL: CN-00044224] [EMBASE: 1986247564] [PMID: 3527903]">Wiederholt 1986</a>), a DMARD to the same DMARD plus oral steroid (<a href="./references#CD014831-bbs2-0004" title="ISRCTN46576063. Tacrolimus monotherapy for uveitis [Dual steroid and tacrolimus therapy versus steroid withdrawal and tacrolimus therapy in the treatment of posterior segment intraocular inflammation (uveitis)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN46576063 (first received 16 April 2008). [DOI: https://doi.org/10.1186/ISRCTN46576063]LeeR , GreenwoodR , TaylorH , AmerR , BiesterS , HeissigerovaJ , et al. A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. Ophthalmology2012;119(6):1223‐30. [DOI: 10.1016/j.ophtha.2011.12.030]LeeRW , GreenwoodR , AmerR , BiesterS , PlskovaJ , ForresterJV , et al. Tacrolimus monotherapy versus tacrolimus and prednisone for the maintenance of disease remission in non-infectious posterior segment intraocular inflammation. Investigative Ophthalmology and Visual Science2009;50(13):2024. ">Lee 2012</a>), or two DMARDs with same mechanism of action (<a href="./references#CD014831-bbs2-0005" title="MurphyC , GreinerK , PlskovaJ , DuncanL , FrostN , ForresterJ , et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Archives of Ophthalmology2005;123(5):634‐41. [CENTRAL: CN-00511918] [DOI: 10.1001/archopht.123.5.634]">Murphy 2005</a>; <a href="./references#CD014831-bbs2-0007" title="NussenblattRB , De SmetMD , RubinB , FreidlinV , WhitcupSM , DavisJ , et al. A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin. American Journal of Ophthalmology1993;115(5):583‐91. [CENTRAL: CN-00093004] [DOI: 10.1016/s0002-9394(14)71454-0]">Nussenblatt 1993</a>). Although oral steroids are efficacious and should be viewed as the initial standard of care, there is a clear clinical need for steroid‐sparing medications. Because of the lack of direct comparisons, data are sparse to answer the most clinically relevant question: which DMARD is most effective or safest when compared to other, dissimilar DMARDs? This review provides little practical evidence to the clinician wondering which medication to start as the best first choice, or which medication to choose when an initial DMARD fails. Further studies in which medications are tested head‐to‐head are needed to answer this important clinical question. </p> <p>There was variation in terms of comparator treatments, especially in steroid dosing and tapers, between studies. The length of steroid tapers varied from several weeks to six months, while the amount the dose was decreased and the frequency at which these decreases occurred also differed between studies. There were few instances in which an experimental and control pair were represented by multiple studies; most were single studies without comparable replicates. Studies that compared cyclosporine A also utilized different doses of the medication, with earlier studies (<a href="./references#CD014831-bbs2-0003" title="De VriesJ , BaarsmaG , ZaalM , Boen-TanT , RothovaA , BuitenhuisH , et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. British Journal of Ophthalmology1990;74(6):344‐9. [CENTRAL: CN-00069296] [DOI: 10.1136/bjo.74.6.344]">De Vries 1990</a>; <a href="./references#CD014831-bbs2-0006" title="NussenblattRB , PalestineA , ChanCC , FujikawaLS , StevensG , GreenSB . A randomised, double-masked trial of sandimmune vs. prednisolone for endogenous uveitis. American Academy of Ophthalmology1990;112:105. [CENTRAL: CN-00485269] NussenblattRB , PalestineAG , ChanCC , StevensG , MellowSD , GreenSB . Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. American Journal of Ophthalmology1991;112(2):138‐46. [CENTRAL: CN-00077346] [DOI: 10.1016/s0002-9394(14)76692-9]">Nussenblatt 1991</a>; <a href="./references#CD014831-bbs2-0011" title="WiederholtM , KämpeC , HansenLL , HövenerG . Treatment of posterior uveitis with cyclosporin or prednisolone--one-year report of a randomized prospective study [Behandlung der uveitis posterior mit cyclosporin oder prednisolon--jahresbericht über eine randomisierte prospektive studie]. Fortschritte der Ophthalmologie1986;83(3):348‐52. [CENTRAL: CN-00044224] [EMBASE: 1986247564] [PMID: 3527903]">Wiederholt 1986</a>) treating participants with a higher dose (8 mg to 15 mg/kg/day) than what is typically used today in clinical practice (2 mg to 5 mg/kg/day; <a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a>; <a href="./references#CD014831-bbs2-0005" title="MurphyC , GreinerK , PlskovaJ , DuncanL , FrostN , ForresterJ , et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Archives of Ophthalmology2005;123(5):634‐41. [CENTRAL: CN-00511918] [DOI: 10.1001/archopht.123.5.634]">Murphy 2005</a>), owing to known nephrotoxicity at higher doses (<a href="./references#CD014831-bbs2-0050" title="PalestineAG , Austin HA 3rd, BalowJE , AntonovychTT , SabnisSG , PreussHG , et al. Renal histopathologic alterations in patients treated with cyclosporine for uveitis. New England Journal of Medicine1986;314(20):1293-8. [DOI: 10.1056/NEJM198605153142005]">Palestine 1986</a>). One study specifically addressed cyclosporine A and G toxicity in a dose‐escalation trial (<a href="./references#CD014831-bbs2-0007" title="NussenblattRB , De SmetMD , RubinB , FreidlinV , WhitcupSM , DavisJ , et al. A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin. American Journal of Ophthalmology1993;115(5):583‐91. [CENTRAL: CN-00093004] [DOI: 10.1016/s0002-9394(14)71454-0]">Nussenblatt 1993</a>), which found that higher doses (7.5 mg or 10 mg/kg/day) of both formulations were associated with higher rates of moderately severe renal toxicity and the need for dose reductions. </p> <p>There was a high degree of heterogeneity in how studies defined control of inflammation, relapse, and clinical activity. Because of this, we were unable to make any useful comparisons based on a single, prespecified definition of control of inflammation, and instead based our analyses on how the individual study had defined "control of inflammation." Frequently, several components of this definition were challenging to quantify, such as the number of retinal hemorrhages, retinal vasculitis, or "activity" of retinal or choroidal lesions. Even a two‐step change in the grade of vitreous cell/flare is somewhat subjective between observers. Other activity domains (such as anterior chamber cells, vitreous opacities like 'snowballs', rate of serous retinal detachment, etc.) were frequently included as a part of the study's definition of control of inflammation. This lack of standardization of primary outcome makes it challenging to compare results across studies or group results together in meta‐analyses, a particularly unfortunate situation in a relatively rare condition like NIIPPU, in which studies are frequently small. All studies reported a visual acuity outcome, although a number of different methods were employed, including the ETDRS chart, Snellen tables, Landolt C optotypes, and tumbling Es. Some metric for macular edema was reported by seven studies, but there was a variety in how this was measured (biomicroscopy, optical coherence tomography, or fluorescein angiography), whether macular edema was reported as a change from baseline, as a proportion of participants with resolution, or as a criterion for relapse. The proportion of participants to achieve steroid‐sparing control was not reported by all studies but was generally defined as those on less than or equal to 5 mg to 10 mg/day of oral steroid. Quality of life and vision‐related quality of life metrics were only reported by a few studies using the SF‐36 scale and VFQ or VCM‐1 scales, respectively (<a href="./references#CD014831-bbs2-0005" title="MurphyC , GreinerK , PlskovaJ , DuncanL , FrostN , ForresterJ , et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Archives of Ophthalmology2005;123(5):634‐41. [CENTRAL: CN-00511918] [DOI: 10.1001/archopht.123.5.634]">Murphy 2005</a>; <a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a>; <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a>). No studies reported data on cost‐effectiveness.  </p> <p>Adverse events were not reported in a standardized way across studies: some studies reported the incidence of adverse events over the study period, some reported the proportion or percentage of participants experiencing various adverse events, and some simply listed events which had occurred during the study without clarifying how common the adverse event was. Laboratory cut‐offs varied from study to study, and many adverse events were self‐reported without detailed protocols regarding how self‐reporting was collected and standardized. Because all studies reported the number of participants requiring cessation of medication because of safety or intolerability concerns, and because this number was discrete (participants either had to stop or did not), we utilized this as our main safety metric when considering the risk of bias. We also felt that, on a practical level, this metric may be the most important to clinicians counselling their patients on the risk of adverse events with a new DMARD. </p> <p>In general, follow‐up times for studies ranged widely from three months to over a year. Two studies began their follow‐up period once the participant was quiet on the experimental regimen (<a href="./references#CD014831-bbs2-0002" title="DeuterC , EngelmannK , HeiligenhausA , LanzlI , MackensenF , NessT , et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. British Journal of Ophthalmology2018;102(5):647‐53. [CENTRAL: CN-00781196] [DOI: 10.1136/bjophthalmol-2017-310156]EUCTR2009-009998-10-DE. Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009998-10 (first received 2 December 2009). NCT01092533. Myfortic for the treatment of non-infectious intermediate uveitis (MYCUV-IIT02) [Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectious intermediate uveitis - a prospective, controlled randomized multicenter trial]. clinicaltrials.gov/ct2/show/study/NCT01092533 (first received 25 March 2010). ">Deuter 2018</a>; <a href="./references#CD014831-bbs2-0004" title="ISRCTN46576063. Tacrolimus monotherapy for uveitis [Dual steroid and tacrolimus therapy versus steroid withdrawal and tacrolimus therapy in the treatment of posterior segment intraocular inflammation (uveitis)]. trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN46576063 (first received 16 April 2008). [DOI: https://doi.org/10.1186/ISRCTN46576063]LeeR , GreenwoodR , TaylorH , AmerR , BiesterS , HeissigerovaJ , et al. A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. Ophthalmology2012;119(6):1223‐30. [DOI: 10.1016/j.ophtha.2011.12.030]LeeRW , GreenwoodR , AmerR , BiesterS , PlskovaJ , ForresterJV , et al. Tacrolimus monotherapy versus tacrolimus and prednisone for the maintenance of disease remission in non-infectious posterior segment intraocular inflammation. Investigative Ophthalmology and Visual Science2009;50(13):2024. ">Lee 2012</a>), and then measured for time to relapse, while the others were designed to measure how long it took participants with active disease to achieve control of inflammation on an experimental medication. </p> </section> <section id="CD014831-sec-0132"> <h3 class="title" id="CD014831-sec-0132">Certainty of the evidence</h3> <p>Despite changes from the original protocol to expand the number of qualifying trials by including trials that investigated both pediatric and adult participants, many factors led to the downgrading of the certainty of the evidence to moderate, low or very low. These factors included heterogeneity in study population characteristics, heterogeneity in the underlying causes of NIIPPU, various pharmacologic agents of different formulations and dosages, some of which are no longer in clinical use, heterogeneity in study designs, and small study sizes. Also, we assessed the risk of bias as high in at least one‐third of the studies, with the remaining studies demonstrating at least some concerns in the risk of bias assessment for at least one of the assessed outcomes. </p> </section> <section id="CD014831-sec-0133"> <h3 class="title" id="CD014831-sec-0133">Potential biases in the review process</h3> <p>An Information Specialist assisted with the comprehensive electronic database search of multiple databases, including trial registries. We applied standard Cochrane methods to conduct this review and avoid potential biases associated with the literature search, appraisal, data extraction, analysis, and interpretation. We also performed an additional handsearch of the reference lists of included studies and made frequent contacts with many trial investigators and study authors to obtain additional details regarding study design, analytic methods, and outcome measures where these were lacking or unclear. </p> </section> <section id="CD014831-sec-0134"> <h3 class="title" id="CD014831-sec-0134">Agreements and disagreements with other studies or reviews</h3> <p><a href="./references#CD014831-bbs2-0042" title="KaramM , AlsaifA , Al-NaseemA , HayreA , Al JabbouriA , AldubaikhiA , et al. Mycophenolate versus methotrexate in non-infectious ocular inflammatory disease: a systematic review and meta-analysis. Ocular Immunology and Inflammation 2022 Feb 24 [Epub ahead of print]. [DOI: 10.1080/09273948.2022.2034166]">Karam 2022</a> performed a systematic review and meta‐analysis and compared methotrexate to mycophenolate mofetil for the treatment of all types of non‐infectious uveitis. Similar to our findings, methotrexate had better treatment success compared to mycophenolate for posterior and panuveitis. Interestingly, mycophenolate had a faster median resolution of disease compared to methotrexate, but this included anterior uveitis in the analysis. </p> <p><a href="./references#CD014831-bbs2-0051" title="PatoE , Muñoz-FernándezS , FranciscoF , AbadMA , MaeseJ , Uveitis Working Group from Spanish Society of Rheumatology. Systematic review on the effectiveness of immunosuppressants and biological therapies in the treatment of autoimmune posterior uveitis. Seminars in Arthritis and Rheumatism2011;40(4):314-23. [DOI: 10.1016/j.semarthrit.2010.05.008]">Pato 2011</a> and <a href="./references#CD014831-bbs2-0033" title="Gómez-GómezA , LozaE , RosarioMP , EspinosaG , deMoralesJM , Spanish Society of Ocular Inflammation (SEIOC). Efficacy and safety of immunomodulatory drugs in patients with non-infectious intermediate and posterior uveitis, panuveitis and macular edema: a systematic literature review. Seminars in Arthritis and Rheumatism2020;50(6):1299-306. [DOI: 10.1016/j.semarthrit.2020.08.010]">Gómez‐Gómez 2020</a> performed systematic reviews, while <a href="./references#CD014831-bbs2-0043" title="KnickelbeinJE , KimM , ArgonE , NussenblattRB , SenNH . Comparative efficacy of steroid-sparing therapies for non-infectious uveitis. Expert Review of Ophthalmology2017;12(4):313-9. [DOI: 10.1080/17469899.2017.1319762]">Knickelbein 2017</a> performed only a limited PubMed search. None of these reviews performed a meta‐analysis. <a href="./references#CD014831-bbs2-0033" title="Gómez-GómezA , LozaE , RosarioMP , EspinosaG , deMoralesJM , Spanish Society of Ocular Inflammation (SEIOC). Efficacy and safety of immunomodulatory drugs in patients with non-infectious intermediate and posterior uveitis, panuveitis and macular edema: a systematic literature review. Seminars in Arthritis and Rheumatism2020;50(6):1299-306. [DOI: 10.1016/j.semarthrit.2020.08.010]">Gómez‐Gómez 2020</a> included RCTs and studied non‐anterior, non‐infectious uveitis while <a href="./references#CD014831-bbs2-0051" title="PatoE , Muñoz-FernándezS , FranciscoF , AbadMA , MaeseJ , Uveitis Working Group from Spanish Society of Rheumatology. Systematic review on the effectiveness of immunosuppressants and biological therapies in the treatment of autoimmune posterior uveitis. Seminars in Arthritis and Rheumatism2011;40(4):314-23. [DOI: 10.1016/j.semarthrit.2010.05.008]">Pato 2011</a> included RCTs, uncontrolled masked trials, prospective, and retrospective studies and examined posterior uveitis, anterior uveitis associated with juvenile idiopathic arthritis, and macular edema. Finally, <a href="./references#CD014831-bbs2-0043" title="KnickelbeinJE , KimM , ArgonE , NussenblattRB , SenNH . Comparative efficacy of steroid-sparing therapies for non-infectious uveitis. Expert Review of Ophthalmology2017;12(4):313-9. [DOI: 10.1080/17469899.2017.1319762]">Knickelbein 2017</a> included RCTs and retrospective studies and evaluated treatment effects for all forms of non‐infectious uveitis. Findings from these reviews were similar to ours. </p> <p>The 2018 guidance report from the American Academy of Ophthalmology concluded that mycophenolate mofetil, tacrolimus, cyclosporine, azathioprine, and methotrexate are effective treatments for NIIPPU, but these recommendations were based on findings from studies including RCTs, prospective and retrospective studies, case series, and peer‐reviewed articles, and a meta‐analysis was not performed (<a href="./references#CD014831-bbs2-0029" title="DickAD , RosenbaumJT , Al-DhibiHA , Belfort R Jr, BrézinAP , Fundamentals of Care for Uveitis International Consensus Group. Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative. Ophthalmology2018;125(5):757-73. [DOI: 10.1016/j.ophtha.2017.11.017]">Dick 2018</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD014831-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/urn:x-wiley:14651858:media:CD014831:CD014831-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD014831-fig-0001" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_t/tCD014831-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/full#CD014831-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014831-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/urn:x-wiley:14651858:media:CD014831:CD014831-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: proportion of participants achieving control of inflammation  " data-id="CD014831-fig-0002" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-FIG-02.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_t/tCD014831-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: proportion of participants achieving control of inflammation   </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/full#CD014831-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-FIG-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014831-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/urn:x-wiley:14651858:media:CD014831:CD014831-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: proportion of participants experiencing complications or requiring cessation of medication " data-id="CD014831-fig-0003" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-FIG-03.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_t/tCD014831-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: proportion of participants experiencing complications or requiring cessation of medication  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/full#CD014831-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-FIG-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014831-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/urn:x-wiley:14651858:media:CD014831:CD014831-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison 1: DMARDs versus control, outcome: 1.1 Control of inflammation " data-id="CD014831-fig-0004" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_t/tCD014831-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison 1: DMARDs versus control, outcome: 1.1 Control of inflammation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/full#CD014831-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014831-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/urn:x-wiley:14651858:media:CD014831:CD014831-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison 2: Methotrexate versus mycophenolate, outcome 2.1: Control of inflammation" data-id="CD014831-fig-0005" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_t/tCD014831-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison 2: Methotrexate versus mycophenolate, outcome 2.1: Control of inflammation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/full#CD014831-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014831-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/urn:x-wiley:14651858:media:CD014831:CD014831-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison 2: Methotrexate versus mycophenolate, outcome: 2.10 Proportion of participants experiencing complications or requiring cessation of medication" data-id="CD014831-fig-0006" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_t/tCD014831-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison 2: Methotrexate versus mycophenolate, outcome: 2.10 Proportion of participants experiencing complications or requiring cessation of medication </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/full#CD014831-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014831-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/urn:x-wiley:14651858:media:CD014831:CD014831-FIG-07" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison 3: steroids ± azathioprine versus cyclosporin A, outcome: 3.1 Control of inflammation" data-id="CD014831-fig-0007" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-FIG-07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_t/tCD014831-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison 3: steroids ± azathioprine versus cyclosporin A, outcome: 3.1 Control of inflammation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/full#CD014831-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-FIG-07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014831-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/urn:x-wiley:14651858:media:CD014831:CD014831-FIG-08" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison 3: steroids ± azathioprine versus cyclosporin A, outcome: 3.8 Proportion of participants experiencing complications or requiring cessation of medication" data-id="CD014831-fig-0008" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-FIG-08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_t/tCD014831-FIG-08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Forest plot of comparison 3: steroids ± azathioprine versus cyclosporin A, outcome: 3.8 Proportion of participants experiencing complications or requiring cessation of medication </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/full#CD014831-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-FIG-08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014831-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/urn:x-wiley:14651858:media:CD014831:CD014831-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: DMARDs plus steroid versus steroid monotherapy, Outcome 1: Control of inflammation" data-id="CD014831-fig-0009" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_t/tCD014831-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: DMARDs plus steroid versus steroid monotherapy, Outcome 1: Control of inflammation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references#CD014831-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014831-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/urn:x-wiley:14651858:media:CD014831:CD014831-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: DMARDs plus steroid versus steroid monotherapy, Outcome 2: Control of inflammation: high‐dose cyclosporine A" data-id="CD014831-fig-0010" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_t/tCD014831-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: DMARDs plus steroid versus steroid monotherapy, Outcome 2: Control of inflammation: high‐dose cyclosporine A </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references#CD014831-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014831-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/urn:x-wiley:14651858:media:CD014831:CD014831-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: DMARDs plus steroid versus steroid monotherapy, Outcome 3: Change in BCVA" data-id="CD014831-fig-0011" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_t/tCD014831-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: DMARDs plus steroid versus steroid monotherapy, Outcome 3: Change in BCVA </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references#CD014831-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014831-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/urn:x-wiley:14651858:media:CD014831:CD014831-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: DMARDs plus steroid versus steroid monotherapy, Outcome 4: Change in CMT" data-id="CD014831-fig-0012" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_t/tCD014831-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: DMARDs plus steroid versus steroid monotherapy, Outcome 4: Change in CMT </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references#CD014831-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014831-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/urn:x-wiley:14651858:media:CD014831:CD014831-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: DMARDs plus steroid versus steroid monotherapy, Outcome 5: Proportion of participants experiencing complications or requiring cessation of medication" data-id="CD014831-fig-0013" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_t/tCD014831-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: DMARDs plus steroid versus steroid monotherapy, Outcome 5: Proportion of participants experiencing complications or requiring cessation of medication </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references#CD014831-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014831-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/urn:x-wiley:14651858:media:CD014831:CD014831-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Methotrexate versus mycophenolate, Outcome 1: Control of inflammation" data-id="CD014831-fig-0014" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_t/tCD014831-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Methotrexate versus mycophenolate, Outcome 1: Control of inflammation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references#CD014831-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014831-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/urn:x-wiley:14651858:media:CD014831:CD014831-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Methotrexate versus mycophenolate, Outcome 2: Control of inflammation: subset (VKH patients only)" data-id="CD014831-fig-0015" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_t/tCD014831-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Methotrexate versus mycophenolate, Outcome 2: Control of inflammation: subset (VKH patients only) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references#CD014831-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014831-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/urn:x-wiley:14651858:media:CD014831:CD014831-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Methotrexate versus mycophenolate, Outcome 3: Change in BCVA" data-id="CD014831-fig-0016" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_t/tCD014831-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Methotrexate versus mycophenolate, Outcome 3: Change in BCVA</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references#CD014831-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014831-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/urn:x-wiley:14651858:media:CD014831:CD014831-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Methotrexate versus mycophenolate, Outcome 4: Proportion of participants with confirmed (residual) macular edema" data-id="CD014831-fig-0017" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_t/tCD014831-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Methotrexate versus mycophenolate, Outcome 4: Proportion of participants with confirmed (residual) macular edema </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references#CD014831-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014831-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/urn:x-wiley:14651858:media:CD014831:CD014831-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Methotrexate versus mycophenolate, Outcome 5: Change in central macular thickness" data-id="CD014831-fig-0018" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_t/tCD014831-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Methotrexate versus mycophenolate, Outcome 5: Change in central macular thickness </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references#CD014831-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014831-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/urn:x-wiley:14651858:media:CD014831:CD014831-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Methotrexate versus mycophenolate, Outcome 6: Proportion of participants achieving steroid reduction" data-id="CD014831-fig-0019" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_t/tCD014831-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Methotrexate versus mycophenolate, Outcome 6: Proportion of participants achieving steroid reduction </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references#CD014831-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014831-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/urn:x-wiley:14651858:media:CD014831:CD014831-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Methotrexate versus mycophenolate, Outcome 7: Change in vision‐related quality of life scores" data-id="CD014831-fig-0020" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_t/tCD014831-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Methotrexate versus mycophenolate, Outcome 7: Change in vision‐related quality of life scores </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references#CD014831-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014831-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/urn:x-wiley:14651858:media:CD014831:CD014831-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Methotrexate versus mycophenolate, Outcome 8: Change in general health‐related quality of life scores" data-id="CD014831-fig-0021" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_t/tCD014831-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Methotrexate versus mycophenolate, Outcome 8: Change in general health‐related quality of life scores </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references#CD014831-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014831-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/urn:x-wiley:14651858:media:CD014831:CD014831-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Methotrexate versus mycophenolate, Outcome 9: Proportion of participants experiencing any adverse event" data-id="CD014831-fig-0022" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_t/tCD014831-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Methotrexate versus mycophenolate, Outcome 9: Proportion of participants experiencing any adverse event </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references#CD014831-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014831-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/urn:x-wiley:14651858:media:CD014831:CD014831-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Methotrexate versus mycophenolate, Outcome 10: Proportion of participants experiencing complications or requiring cessation of medication" data-id="CD014831-fig-0023" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_t/tCD014831-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: Methotrexate versus mycophenolate, Outcome 10: Proportion of participants experiencing complications or requiring cessation of medication </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references#CD014831-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014831-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/urn:x-wiley:14651858:media:CD014831:CD014831-CMP-002.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Methotrexate versus mycophenolate, Outcome 11: Proportion of participants experiencing complications or requiring cessation of medication: subset (VKH patients only)" data-id="CD014831-fig-0024" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-002.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_t/tCD014831-CMP-002.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2: Methotrexate versus mycophenolate, Outcome 11: Proportion of participants experiencing complications or requiring cessation of medication: subset (VKH patients only) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references#CD014831-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-002.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014831-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/urn:x-wiley:14651858:media:CD014831:CD014831-CMP-002.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Methotrexate versus mycophenolate, Outcome 12: Proportion of participants experiencing systemic complications" data-id="CD014831-fig-0025" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-002.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_t/tCD014831-CMP-002.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2: Methotrexate versus mycophenolate, Outcome 12: Proportion of participants experiencing systemic complications </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references#CD014831-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-002.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014831-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/urn:x-wiley:14651858:media:CD014831:CD014831-CMP-002.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Methotrexate versus mycophenolate, Outcome 13: Proportion of participants experiencing ocular complications" data-id="CD014831-fig-0026" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-002.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_t/tCD014831-CMP-002.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2: Methotrexate versus mycophenolate, Outcome 13: Proportion of participants experiencing ocular complications </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references#CD014831-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-002.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014831-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/urn:x-wiley:14651858:media:CD014831:CD014831-CMP-002.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Methotrexate versus mycophenolate, Outcome 14: Proportion of participants experiencing ocular complications: subset (VKH patients only)" data-id="CD014831-fig-0027" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-002.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_t/tCD014831-CMP-002.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2: Methotrexate versus mycophenolate, Outcome 14: Proportion of participants experiencing ocular complications: subset (VKH patients only) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references#CD014831-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-002.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014831-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/urn:x-wiley:14651858:media:CD014831:CD014831-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Steroids with or without azathioprine versus cyclosporine A, Outcome 1: Control of inflammation" data-id="CD014831-fig-0028" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_t/tCD014831-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Steroids with or without azathioprine versus cyclosporine A, Outcome 1: Control of inflammation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references#CD014831-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014831-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/urn:x-wiley:14651858:media:CD014831:CD014831-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Steroids with or without azathioprine versus cyclosporine A, Outcome 2: Control of inflammation: high‐dose cyclosporine A" data-id="CD014831-fig-0029" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_t/tCD014831-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Steroids with or without azathioprine versus cyclosporine A, Outcome 2: Control of inflammation: high‐dose cyclosporine A </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references#CD014831-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014831-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/urn:x-wiley:14651858:media:CD014831:CD014831-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Steroids with or without azathioprine versus cyclosporine A, Outcome 3: Change in BCVA" data-id="CD014831-fig-0030" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_t/tCD014831-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Steroids with or without azathioprine versus cyclosporine A, Outcome 3: Change in BCVA </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references#CD014831-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014831-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/urn:x-wiley:14651858:media:CD014831:CD014831-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Steroids with or without azathioprine versus cyclosporine A, Outcome 4: Proportion of participants achieving improvement in visual acuity" data-id="CD014831-fig-0031" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_t/tCD014831-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Steroids with or without azathioprine versus cyclosporine A, Outcome 4: Proportion of participants achieving improvement in visual acuity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references#CD014831-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014831-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/urn:x-wiley:14651858:media:CD014831:CD014831-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Steroids with or without azathioprine versus cyclosporine A, Outcome 5: Proportion of participants with macular edema" data-id="CD014831-fig-0032" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_t/tCD014831-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Steroids with or without azathioprine versus cyclosporine A, Outcome 5: Proportion of participants with macular edema </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references#CD014831-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014831-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/urn:x-wiley:14651858:media:CD014831:CD014831-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Steroids with or without azathioprine versus cyclosporine A, Outcome 6: Proportion of participants achieving steroid reduction" data-id="CD014831-fig-0033" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_t/tCD014831-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Steroids with or without azathioprine versus cyclosporine A, Outcome 6: Proportion of participants achieving steroid reduction </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references#CD014831-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014831-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/urn:x-wiley:14651858:media:CD014831:CD014831-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Steroids with or without azathioprine versus cyclosporine A, Outcome 7: Proportion of participants with any adverse events" data-id="CD014831-fig-0034" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_t/tCD014831-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Steroids with or without azathioprine versus cyclosporine A, Outcome 7: Proportion of participants with any adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references#CD014831-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014831-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/urn:x-wiley:14651858:media:CD014831:CD014831-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Steroids with or without azathioprine versus cyclosporine A, Outcome 8: Proportion of participants experiencing complications or requiring cessation of medication" data-id="CD014831-fig-0035" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_t/tCD014831-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: Steroids with or without azathioprine versus cyclosporine A, Outcome 8: Proportion of participants experiencing complications or requiring cessation of medication </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references#CD014831-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014831-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/urn:x-wiley:14651858:media:CD014831:CD014831-CMP-003.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Steroids with or without azathioprine versus cyclosporine A, Outcome 9: Proportion of participants experiencing systemic complications" data-id="CD014831-fig-0036" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-003.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_t/tCD014831-CMP-003.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3: Steroids with or without azathioprine versus cyclosporine A, Outcome 9: Proportion of participants experiencing systemic complications </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references#CD014831-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-003.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014831-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/urn:x-wiley:14651858:media:CD014831:CD014831-CMP-003.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Steroids with or without azathioprine versus cyclosporine A, Outcome 10: Proportion of participants experiencing ocular complications" data-id="CD014831-fig-0037" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-003.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_t/tCD014831-CMP-003.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3: Steroids with or without azathioprine versus cyclosporine A, Outcome 10: Proportion of participants experiencing ocular complications </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references#CD014831-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-003.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014831-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/urn:x-wiley:14651858:media:CD014831:CD014831-CMP-003.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Steroids with or without azathioprine versus cyclosporine A, Outcome 11: Proportion of participants experiencing ocular complications: high‐dose cyclosporine A" data-id="CD014831-fig-0038" src="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-003.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_t/tCD014831-CMP-003.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3: Steroids with or without azathioprine versus cyclosporine A, Outcome 11: Proportion of participants experiencing ocular complications: high‐dose cyclosporine A </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references#CD014831-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/media/CDSR/CD014831/image_n/nCD014831-CMP-003.11.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD014831-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Non‐biologic disease‐modifying antirheumatic drugs (DMARDs) versus steroid for NIIPPU</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Non‐biologic disease‐modifying antirheumatic drugs (DMARDs) versus steroid for NIIPPU</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> NIIPPU </p> <p><b>Setting:</b> ophthalmology clinics (Netherlands, Germany) </p> <p><b>Intervention:</b> DMARDs (CsA, EC‐MPS plus steroid) </p> <p><b>Comparison:</b> control (placebo plus steroid or steroid alone) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Anticipated absolute effect (95% CI)</b><sup>*</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Relative effect (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Assumed risk with control</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Assumed risk with DMARDs</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants achieving control of inflammation</b> </p> <p>(higher number of events is better)</p> <p>Follow‐up: 0 to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 events per 100 participants</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 events per 100 participants</b> </p> <p>(2 to 100)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.81</b> (95% CI 1.10 to 7.17) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>⊕⊝⊝⊝</b> </p> <p><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One study comparing CsA plus steroid with placebo plus steroid also reported this outcome but used CsA doses no longer in practice (<a href="./references#CD014831-bbs2-0003" title="De VriesJ , BaarsmaG , ZaalM , Boen-TanT , RothovaA , BuitenhuisH , et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. British Journal of Ophthalmology1990;74(6):344‐9. [CENTRAL: CN-00069296] [DOI: 10.1136/bjo.74.6.344]">De Vries 1990</a>); thus, we did not include it in meta‐analysis. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in BCVA</b> </p> <p>(lower logMAR indicate better vision)</p> <p>Follow‐up: 0 to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Right eyes MD ‐0.03 logMAR (95% CI ‐0.96 logMAR to 0.90 logMAR); Left eyes MD ‐0.10 logMAR (95% CI ‐0.27 logMAR to 0.07 logMAR) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82 eyes (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>⊕⊝⊝⊝</b> </p> <p><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants achieving a 2‐line improvement in visual acuity (Snellen chart)</b> </p> <p>(higher scores indicate better vision)</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No data were reported for this outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with confirmed macular edema</b> </p> <p>(lower number of events is better)</p> <p>Follow‐up: 0 to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No data were reported for this outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants achieving steroid‐sparing control</b> </p> <p>(higher number of events is better)</p> <p>Follow‐up: 0 to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No data were reported for this outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants experiencing complications or requiring cessation of medication</b> </p> <p>(lower number of events is better)</p> <p>Follow‐up: 0 to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>⊕⊝⊝⊝</b> </p> <p><b>Very low</b><sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One event reported in DMARDs group (RR 2.61, 95% CI 0.11 to 60.51). Another study reported this outcome but used CsA doses no longer in practice (<a href="./references#CD014831-bbs2-0003" title="De VriesJ , BaarsmaG , ZaalM , Boen-TanT , RothovaA , BuitenhuisH , et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. British Journal of Ophthalmology1990;74(6):344‐9. [CENTRAL: CN-00069296] [DOI: 10.1136/bjo.74.6.344]">De Vries 1990</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).</b> </p> <p><b>BCVA:</b> best‐corrected visual acuity; <b>CI:</b> confidence interval; <b>CsA:</b> cyclosporin A; <b>DMARD</b> : disease‐modifying antirheumatic drug;<b>EC‐MPS:</b> enteric‐coated mycophenolate sodium; <b>logMAR:</b> logarithm of the minimum angle of resolution;<b>MD:</b> mean difference; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SD:</b> standard deviation </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>The Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group grades of evidence:</b> <br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/><b>Very low certainty:</b> we are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded (‐2) for risk of bias (unclear risk of bias for the randomization process, deviations from intended interventions, and high risk of bias overall)<br/><sup>b</sup>Downgraded (‐1) for imprecision (small sample size)<br/><sup>c</sup>Downgraded (‐2) for risk of bias (unclear risk of bias for the randomization process and missing outcome data, and high risk of bias for measurement of outcome, selection of the reported result, and high risk of bias overall) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Non‐biologic disease‐modifying antirheumatic drugs (DMARDs) versus steroid for NIIPPU</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/full#CD014831-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD014831-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Methotrexate versus mycophenolate for NIIPPU</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Mycophenolate versus methotrexate for NIIPPU</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> NIIPPU </p> <p><b>Setting:</b> ophthalmology clinics (India, United States, Australia, India, Mexico, Saudi Arabia) </p> <p><b>Intervention:</b> methotrexate </p> <p><b>Comparison:</b> mycophenolate </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="bottom"> <p><b>Anticipated absolute effect (95% CI)</b><sup>*</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Relative effect (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Assumed risk with mycophenolate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Assumed risk with methotrexate</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants achieving control of inflammation</b><sup>§</sup> </p> <p>(higher number of events is better)</p> <p>Follow‐up: 0 to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>55 events per 100 participants</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 events per 100 participants</b> (55 to 88) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.23</b> (1.01 to 1.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>261 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in BCVA</b> </p> <p>(lower logMAR indicate better vision)</p> <p>Follow‐up: 0 to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean BCVA score across the control group ranged from ‐0.12 to ‐0.19 logMAR</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>The mean logMAR was 0.01 higher (worse) on average</b><br/>(0.04 lower to 0.05 higher logMAR) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>490 eyes (2 RCTs)<sup>ɸ</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants achieving a 2‐line improvement in visual acuity (Snellen chart)</b> </p> <p>(higher scores indicate better vision)</p> <p>Follow‐up: 0 to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No data were reported for this outcome</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with confirmed macular edema</b> </p> <p>(lower number of events is better)</p> <p>Follow‐up: 0 to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>46 events per 100 participant eyes</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 events per 100 participant eyes</b> (9 to 60) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR</b> 0.49 (0.19 to 1.30) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 eyes (1 RCT)<sup>†</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>b,c</sup> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p> </p> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants achieving steroid‐sparing control</b><sup>§</sup> </p> <p>(higher number of events is better)</p> <p>Follow‐up: 0 to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>55 events per 100 participants</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 events per 100 participants</b> (55 to 88) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.23</b> (1.01 to 1.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>261 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants experiencing complications or requiring cessation of medication</b> </p> <p>(lower number of events is better)</p> <p>Follow‐up: 0 to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 events per 100 participants</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 events per 100 participants</b> (3 to 17) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.99</b> (0.43 to 2.27) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>296 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>a,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).</b> </p> <p><b>BCVA:</b> best‐corrected visual acuity; <b>CI:</b> confidence interval; <b>logMAR:</b> logarithm of the minimum angle of resolution;<b>MD:</b> mean difference; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SD:</b> standard deviation; <b>VKH:</b> Vogt‐Koyanagi‐Harada </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>The Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group grades of evidence:</b> <br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/><b>Very low certainty:</b> we are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>§</sup>Study primary outcome of steroid sparing control of inflammation defined as ≤ 0.5 + anterior chamber cells, ≤ 0.5 + vitreous cells, ≤ 0.5 + vitreous haze, and no active retinal or choroidal lesions; ≤ 2 drops of prednisolone acetate 1% a day in both studies and daily prednisolone ≤ 10 mg in one study and ≤ 7.5 mg/day in the other study<br/><sup>ɸ</sup>Visual acuity of uveitic eyes only<br/><sup>†</sup>Subgroup of VKH participants' eyes with macular edema at baseline<br/><br/><sup>a</sup>Downgraded (‐1) for imprecision (small sample size)<br/><sup>b</sup>Downgraded (‐1) for indirectness (single study subgroup of VKH in India)<br/><sup>c</sup>Downgraded (‐2) for serious imprecision (small sample size)<br/><sup>d</sup>Downgraded (‐1) for risk of bias (both studies have some concern for risk of bias in outcome measurement) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Methotrexate versus mycophenolate for NIIPPU</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/full#CD014831-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD014831-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Steroids with or without azathioprine versus cyclosporine A for NIIPPU</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Steroids with or without azathioprine versus cyclosporine A for NIIPPU</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> NIIPPU </p> <p><b>Setting:</b> ophthalmology clinics (Germany, Japan, Chile, USA) </p> <p><b>Intervention:</b> Steroids with or without azathioprine (oral steroids, IV steroids, or azathioprine) </p> <p><b>Comparison:</b> cyclosporine A (CsA) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="bottom"> <p><b>Anticipated absolute effect (95% CI)</b><sup>*</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Relative effect (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>№ of participants</b> <br/><b>(studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="bottom"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Assumed risk with cyclosporine A</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Assumed risk with steroids ± azathioprine</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants achieving control of inflammation</b> </p> <p>(higher number of events is better)</p> <p>Follow‐up: 0 to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>87 events per 100 participants</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>73 events per 100 participants</b> (61 to 88) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.84</b> (0.70 to 1.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112 (2 RCTs)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two other studies reported this outcome but used CsA doses no longer in practice (<a href="./references#CD014831-bbs2-0006" title="NussenblattRB , PalestineA , ChanCC , FujikawaLS , StevensG , GreenSB . A randomised, double-masked trial of sandimmune vs. prednisolone for endogenous uveitis. American Academy of Ophthalmology1990;112:105. [CENTRAL: CN-00485269] NussenblattRB , PalestineAG , ChanCC , StevensG , MellowSD , GreenSB . Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. American Journal of Ophthalmology1991;112(2):138‐46. [CENTRAL: CN-00077346] [DOI: 10.1016/s0002-9394(14)76692-9]">Nussenblatt 1991</a>; <a href="./references#CD014831-bbs2-0011" title="WiederholtM , KämpeC , HansenLL , HövenerG . Treatment of posterior uveitis with cyclosporin or prednisolone--one-year report of a randomized prospective study [Behandlung der uveitis posterior mit cyclosporin oder prednisolon--jahresbericht über eine randomisierte prospektive studie]. Fortschritte der Ophthalmologie1986;83(3):348‐52. [CENTRAL: CN-00044224] [EMBASE: 1986247564] [PMID: 3527903]">Wiederholt 1986</a>).  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in BCVA</b> </p> <p>(lower logMAR indicate better vision)</p> <p>Follow‐up: 0 to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean BCVA score across the CsA group ranged from ‐0.32 to ‐0.21 logMAR</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>The mean logMAR was 0.04 lower (better) on average</b><br/>(‐0.14 to 0.07 logMAR) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91 eyes (2 RCTs)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants achieving a 2‐line improvement in visual acuity (Snellen chart)</b> </p> <p>(higher scores indicate better vision)</p> <p>Follow‐up: 0 to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One study reported this outcome but used CsA doses no longer in practice (<a href="./references#CD014831-bbs2-0011" title="WiederholtM , KämpeC , HansenLL , HövenerG . Treatment of posterior uveitis with cyclosporin or prednisolone--one-year report of a randomized prospective study [Behandlung der uveitis posterior mit cyclosporin oder prednisolon--jahresbericht über eine randomisierte prospektive studie]. Fortschritte der Ophthalmologie1986;83(3):348‐52. [CENTRAL: CN-00044224] [EMBASE: 1986247564] [PMID: 3527903]">Wiederholt 1986</a>).  </p> <p> </p> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with confirmed macular edema</b> </p> <p>(lower number of events is better)</p> <p>Follow‐up: 0 to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One study reported this outcome but used CsA doses no longer in practice</p> <p> (<a href="./references#CD014831-bbs2-0006" title="NussenblattRB , PalestineA , ChanCC , FujikawaLS , StevensG , GreenSB . A randomised, double-masked trial of sandimmune vs. prednisolone for endogenous uveitis. American Academy of Ophthalmology1990;112:105. [CENTRAL: CN-00485269] NussenblattRB , PalestineAG , ChanCC , StevensG , MellowSD , GreenSB . Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. American Journal of Ophthalmology1991;112(2):138‐46. [CENTRAL: CN-00077346] [DOI: 10.1016/s0002-9394(14)76692-9]">Nussenblatt 1991</a>).  </p> <p> </p> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants achieving steroid‐sparing control</b> </p> <p>(higher number of events is better)</p> <p>Follow‐up: 0 to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>78 events per 100 participants</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 events per 100 participants</b> (26 to 97) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.64</b> (0.33 to 1.25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 (1 RCT)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants experiencing complications or requiring cessation of medication</b> </p> <p>(lower number of events is better)</p> <p>Follow‐up: 0 to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 events per 100 participants</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 events per 100 participants</b> (1 to 24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.85</b><br/>(0.21 to 3.45) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91 participants (2 RCTs)<sup>§</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One other study reported this outcome but used CsA doses no longer in practice (<a href="./references#CD014831-bbs2-0006" title="NussenblattRB , PalestineA , ChanCC , FujikawaLS , StevensG , GreenSB . A randomised, double-masked trial of sandimmune vs. prednisolone for endogenous uveitis. American Academy of Ophthalmology1990;112:105. [CENTRAL: CN-00485269] NussenblattRB , PalestineAG , ChanCC , StevensG , MellowSD , GreenSB . Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. American Journal of Ophthalmology1991;112(2):138‐46. [CENTRAL: CN-00077346] [DOI: 10.1016/s0002-9394(14)76692-9]">Nussenblatt 1991</a>).  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).</b> </p> <p><b>BCVA:</b> best‐corrected visual acuity; <b>CI:</b> confidence interval; <b>CsA</b> : cyclosporin A; <b>IV:</b> intravenous<b>logMAR:</b> logarithm of the minimum angle of resolution;<b>MD:</b> mean difference; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>SD:</b> standard deviation; <b>VKH:</b> Vogt‐Koyanagi‐Harada </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>The Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group grades of evidence:</b> <br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/><b>Very low certainty:</b> we are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded (‐2) for risk of bias (one or more studies with unclear or high risk of bias overall, randomization process, deviations from intended interventions)<br/><sup>b</sup>Downgraded (‐1) for imprecision (small sample size)<br/><sup>c</sup>Downgraded (‐1) for indirectness (VKH not representative of all NIIPPU) </p> <p><sup>§</sup>Only VKH participants </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Steroids with or without azathioprine versus cyclosporine A for NIIPPU</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/full#CD014831-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014831-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">DMARDs plus steroid versus steroid monotherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Control of inflammation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Control of inflammation: high‐dose cyclosporine A <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Change in BCVA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Right eyes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Left eyes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Change in CMT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Right eyes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Left eyes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Proportion of participants experiencing complications or requiring cessation of medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">DMARDs plus steroid versus steroid monotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references#CD014831-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014831-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Methotrexate versus mycophenolate</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Control of inflammation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [1.01, 1.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Control of inflammation: subset (VKH patients only) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 VKH patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Change in BCVA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>490</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.04, 0.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Proportion of participants with confirmed (residual) macular edema <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Change in central macular thickness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 Change in central macular thickness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Proportion of participants achieving steroid reduction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [1.01, 1.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.1 Steroid reduction to ≤ 7.5 mg/day oral prednisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.93, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.2 Steroid reduction to ≤ 10 mg/day oral prednisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.95, 2.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Change in vision‐related quality of life scores <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.1 IND‐VFQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.27 [‐2.25, 6.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.2 NEI‐VFQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.20 [‐1.39, 5.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Change in general health‐related quality of life scores <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.1 SF‐36, Physical component summary</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [‐0.48, 2.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.2 SF‐36, Mental component summary</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐2.24, 2.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Proportion of participants experiencing any adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.99, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Proportion of participants experiencing complications or requiring cessation of medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.43, 2.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.11 Proportion of participants experiencing complications or requiring cessation of medication: subset (VKH patients only) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.12 Proportion of participants experiencing systemic complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.1 Elevated AST or ALT (nonserious)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.81 [0.86, 3.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.2 Elevated AST or ALT (serious)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.26, 8.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.3 Abnormal Hb</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.10, 1.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.4 Low leukocyte count</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.06 [0.32, 28.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.5 Elevated creatinine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.06 [0.13, 74.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.13 Proportion of participants experiencing ocular complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13.1 Increased IOP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.50, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13.2 Cataract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.18, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13.3 Hypotony</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.08 [0.47, 35.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.14 Proportion of participants experiencing ocular complications: subset (VKH patients only) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.1 Increased IOP ‐ VKH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.68 [0.39, 113.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.2 Cataract ‐ VKH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.46 [0.31, 95.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.3 Hypotony ‐ VKH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.50 [0.17, 70.14]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Methotrexate versus mycophenolate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references#CD014831-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014831-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Steroids with or without azathioprine versus cyclosporine A</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Control of inflammation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.70, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 IV pulse methylprednisolone for 3 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.63, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 Azathioprine 2 to 3 mg/kg/day </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.69, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Control of inflammation: high‐dose cyclosporine A <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.72, 2.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Change in BCVA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.14, 0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 IV pulse methylprednisolone for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.13, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 Azathioprine 2 to 3 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.11 [‐0.35, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Proportion of participants achieving improvement in visual acuity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.50, 1.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 ETDRS chart</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.49, 1.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.2 Snellen table</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.09, 11.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Proportion of participants with macular edema <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Proportion of participants achieving steroid reduction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Proportion of participants with any adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 Proportion of participants experiencing complications or requiring cessation of medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.21, 3.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.1 IV pulse methylprednisolone for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 2.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.2 Azathioprine 2 to 3 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.38 [0.31, 92.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.9 Proportion of participants experiencing systemic complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.35, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.1 IV pulse methylprednisolone for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.15, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.2 Azathioprine 2 to 3 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.54, 1.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.10 Proportion of participants experiencing ocular complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10.1 Increased IOP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.43, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10.2 Cataract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [0.90, 2.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.11 Proportion of participants experiencing ocular complications: high‐dose cyclosporine A <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.1 Cataract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Steroids with or without azathioprine versus cyclosporine A</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references#CD014831-tbl-0006">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-1"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.1 Control of inflammation</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Deuter 2018</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col8" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed centrally via a web‐based randomisation system for each site by permuted blocks. No information provided about the allocation sequence concealment. Baseline characterisitics differences could be compatable with chance. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study is "open label" with no blinding described. There is no information about deviations in treatment due to trial context. Analysis by intention‐to‐treat (ITT) last observation carried forward (LOCF). Participants appear to be analyzed by assigned group. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data are available for most randomized participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Description not given about determination of change in baseline vitreous haze score. Unblinded outcome assessment could have differed between groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The primary endpoint has multiple assessments (BCVA, vitreous haze, CME by OCT, etc.) with standard scales for each. No information provided about a pre specified analysis plan. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p><a href="./references#CD014831-bbs2-0002" title="DeuterC , EngelmannK , HeiligenhausA , LanzlI , MackensenF , NessT , et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. British Journal of Ophthalmology2018;102(5):647‐53. [CENTRAL: CN-00781196] [DOI: 10.1136/bjophthalmol-2017-310156]EUCTR2009-009998-10-DE. Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009998-10 (first received 2 December 2009). NCT01092533. Myfortic for the treatment of non-infectious intermediate uveitis (MYCUV-IIT02) [Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectious intermediate uveitis - a prospective, controlled randomized multicenter trial]. clinicaltrials.gov/ct2/show/study/NCT01092533 (first received 25 March 2010). ">Deuter 2018</a> was judged to have a potentially high risk of bias based on concerns regarding bias in the measurement of the outcome (open lable, lack of second unblinded outcome assessor), along with some concerns about bias arising from the randomization process, deviations from intended interventions, and selection of the reported result. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.1 Control of inflammation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references#riskOfBias2Table-1">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-2"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.2 Control of inflammation: high‐dose cyclosporine A</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>De Vries 1990</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information on method of allocation concealment. There are few differences between groups and could be due to chance. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and treating investigator were blinded to treatment assignment. The ITT analysis with exclusions for ocular side effects and protocol noncompliance is probably appropriate. Impact is balanced between treatment groups (three participants from each group). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Efficacy data are not available for 6/27 participants but is similar between groups (3/13 vs 3/14). There are differences between text and figures on how drop‐outs may be handled, but any missing data is unlikely to depend on the true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The blinded outcome assessor used appropriate predefined inflammatory activity score.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is no information provided about statistical analysis plans. It is unlikely that the result could be selected from multiple measurements or analyses. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns regarding risk of bias were identified for the efficacy outcome in <a href="./references#CD014831-bbs2-0003" title="De VriesJ , BaarsmaG , ZaalM , Boen-TanT , RothovaA , BuitenhuisH , et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. British Journal of Ophthalmology1990;74(6):344‐9. [CENTRAL: CN-00069296] [DOI: 10.1136/bjo.74.6.344]">De Vries 1990</a>. The study was largely assessed to have low risk of bias in most domains; however, there were some concerns regarding the randomization process as there was no description given of allocation concealment, and in selection of the reported result, as information about a statistical analysis plan was not provided. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.2 Control of inflammation: high‐dose cyclosporine A</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references#riskOfBias2Table-2">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-3"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.5 Proportion of participants experiencing complications or requiring cessation of medication</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Deuter 2018</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col10" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed centrally via a web‐based randomisation system for each site by permuted blocks. No information provided about the allocation sequence concealment. Baseline characterisitics differences could be compatable with chance. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study "open label" with no blinding described. There is no information about deviations in treatment due to trial context. Analysis described as ITT. Discontinuation due to adverse events included all participants. Participants appear to be analyzed by assigned group. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data is missing for 3/44 (6.8%) participants. Patients who were experiencing severe side effects may been lost to follow up. If there are missing data from later assessments for these patients, the missingness in the outcome could influence the true rate of serious side effects. It is unlikely this occured. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients and obervers were not blinded and this could have influenced their perception of adverse events. In addition, follow up visits were variable which could have also influenced adverse event reporting/detection. Adverse event that caused discontinuation was a laboratory test. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information is provided about a statistical analysis plan. No information provided about pre‐determined cutoffs or scales used for adverse events. Adverse events reported in per patient‐years; this may have been one of several eligible analyses. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p><a href="./references#CD014831-bbs2-0002" title="DeuterC , EngelmannK , HeiligenhausA , LanzlI , MackensenF , NessT , et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. British Journal of Ophthalmology2018;102(5):647‐53. [CENTRAL: CN-00781196] [DOI: 10.1136/bjophthalmol-2017-310156]EUCTR2009-009998-10-DE. Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009998-10 (first received 2 December 2009). NCT01092533. Myfortic for the treatment of non-infectious intermediate uveitis (MYCUV-IIT02) [Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectious intermediate uveitis - a prospective, controlled randomized multicenter trial]. clinicaltrials.gov/ct2/show/study/NCT01092533 (first received 25 March 2010). ">Deuter 2018</a> was judged to be at possibly high risk of bias in the safety outcome because of concerns in selection of the reported result, as no information was provided about pre‐determined cutoffs or scales used for adverse events. There were some concerns about risk of bias in the other domains for this outcome. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.5 Proportion of participants experiencing complications or requiring cessation of medication</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references#riskOfBias2Table-3">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-4"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.1 Control of inflammation</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Rathinam 2014</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized by program generated permuted, block randomization by principle statistician. Baseline characteristics were similar; statistically significantly differences could be from chance based on the number of characteristics. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and study coordinators were not masked. No clear evidence of deviations from the intended intervention that arose because of the study protocol. All complete case analysis and ITT analysis with regression‐based multiple imputation. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There were 6/35 and 7/32 participants excluded for not receiving the intervention, loss to follow‐up, or dropout. A complete case analysis and additional regression‐based multiple imputation ITT analysis were performed. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Study ophthalmologists were blinded and measured AC cells according the SUN guidelines, vitreous cells were graded according to a scale from the Multicenter Uveitis Steroid Treatment trial, vitreous haze assessed by the NEI scoring system, which are somewhat subjective but scaled. Activity of retinal/choroidal lesions judged by the treating ophthalmologist and is more subjective. Observers were blinded and while inter‐observer variability may have occurred, it is unlikely that intra‐observer measurements differed based on intervention groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information provided about a pre‐specified analysis plan. The time points of 5 and 6 month visits are not clearly clinically relevant. No evidence of multiple eligible outcome measurements although time points of 5 and 6 months are not clearly clinically relevant. No evidence of multiple eligible analyses of data. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p><a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a> was judged to have some concerns in risk of bias in efficacy outcome becuase of concerns regarding bias in selection of the reported result. No pre‐specified analysis plan was reported. The other 4 domains were judged to be at low risk of bias in this study. </p> </td> </tr> <tr class="study-data"> <td> <p>Rathinam 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Block randomization with varying block sizes only known to the biostatistician. Individuals with access to randomization list and study coordinators enrolling participants are separate. Baseline demographics and clinical characteristics were similar between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All participants and study coordinators were unmasked to treatment assignment after enrolment; study drugs are different in appearance and must be administered on different weekly schedules. Deviations from protocol interventions were detailed and may not be due to trial context. All patients with a 6 month visit or who were declared as having early treatment failure were analyzed according to their randomization group. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There were 22 participants (10%) were lost to follow‐up; 194 patients (96 in the methotrexate group and 98 in the mycophenolate group) had complete information for the primary outcome. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Pre‐defined grading scale for grading vitreous haze, etc., with reporting of inter‐observer variation for several time points. Unlikely to have variability between intervention groups as same site assessor; between sites may differ. Outcome assessors were masked to treatment group. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Final analysis did match pre‐specified, published statistical analysis plan. Multiple measurements and types included in treatment success definition. The outcome domain is a known adaptation of established SUN criteria. Pre specified analyses are reported as outlined and post hoc are stated. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A low risk of bias was determined for <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a> in the efficacy outcome measure. All domains for this outcome were considered at low risk of bias, with no concerns identified for the randomization process, outcome measurement, or reporting of the result. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.1 Control of inflammation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references#riskOfBias2Table-4">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-5"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.10 Proportion of participants experiencing complications or requiring cessation of medication</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Rathinam 2014</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized by program generated permuted, block randomization by principle statistician. Baseline characteristics were similar; statistically significantly differences could be from chance based on the number of characteristics. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients and study coordinators were not masked. No clear evidence of deviations from the intended intervention that arose because of the study protocol. An additional intention‐to‐treat analysis was conducted using regression based multiple‐imputation, all 80 patients were included. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There were 6/35 and 7/32 participants excluded for not receiving the intervention, loss to follow‐up, or dropout. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Serious and non serious adverse events were ascertained at each visit by the coordinator and ophthalmologist. Information about methodology of collecting these outcomes is not provided but is likely appropriate for laboratory values; more concerns arise from subjective, patient‐reported measures like headache/fatigue. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information is provided about a pre‐specified analysis plan, although frequency of adverse events is listed as a "prespecified secondary outcome". Total adverse events over the entire study period are reported and do not seem to have been influenced by multiple eligible outcome measurements within this outcome domain. There is no evidence of multiple eligible analysis of these data. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Most domains for the safety outcome in the <a href="./references#CD014831-bbs2-0009" title="NCT01232920. First-line antimetabolites as steroid-sparing treatment uveitis pilot trial. clinicaltrials.gov/ct2/show/NCT01232920 (first received 2 November 2010). [CENTRAL: CN-02032098] NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality-of-life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. American Journal of Ophthalmology2017;179:10‐17. [CENTRAL: CN-01374518] [DOI: 10.1016/j.ajo.2017.04.003]NiemeyerKM , GonzalesJA , RathinamSR , BabuM , ThundikandyR , KanakathA , et al. Quality of life outcomes from a randomized controlled trial comparing methotrexate to mycophenolate mofetil for noninfectious uveitis. Investigative Ophthalmology and Visual Science2017;58(8):2174. [CENTRAL: CN-01616554] [EMBASE: 621489608]RathinamSR , BabuM , ThundikandyR , KanakathA , NardoneN , EsterbergE , et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology2014;121(10):1863‐70. [CENTRAL: CN-01053754] [DOI: 10.1016/j.ophtha.2014.04.023]ShenE , RathinamSR , BabuM , BrowneE , WeinribR , PorcoT , et al. Uveitic macular edema outcomes: results of a randomized controlled trial. Clinical and Translational Science2014;7(3):236. [CENTRAL: CN-01049997] [DOI: 10.1111/cts.12171] [EMBASE: 71734851]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeS , et al. Outcomes of vogt-koyanagi-harada disease from a randomized clinical trial of antimetabolite therapies. Investigative Ophthalmology and Visual Science2016;57(12):1899. [CENTRAL: CN-01377043] [EMBASE: 616083527]ShenE , RathinamSR , BabuM , KanakathA , ThundikandyR , LeeSM , et al. Outcomes of vogt-koyanagi-harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. American Journal of Ophthalmology2016;168:279‐86. [CENTRAL: CN-01177618] [DOI: 10.1016/j.ajo.2016.06.004]">Rathinam 2014</a> study were judged to be at low risk of bias. However, overall the study is judged to be at some risk of bias because of concerns in the measurement of the safety outcome; information about methodology for collection of subjective, patient‐reported issues with tolerability/safety is not provided. </p> </td> </tr> <tr class="study-data"> <td> <p>Rathinam 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Block randomization with varying block sizes only known to the biostatistician. Individuals with access to randomization list and study coordinators enrolling participants are separate. Baseline demographics and clinical characteristics were similar between the two groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All participants and study coordinators were not masked to treatment assignment after enrolment; study drugs are different in appearance and must be administered on different weekly schedules. Deviations from protocol interventions were detailed and may not be due to trial context. All patients with a 6 month visit or who were declared as having early treatment failure were analyzed according to their randomization group. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>AEs reported in trial registry include all participants in both arms (MTX 107/107 vs MM 109/109). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Defined laboratory abnormalities are not inappropriate. Participant reported measures have varying subjectivity (e.g., mood or dizziness). Participants were not masked to treatment assignment. It is not clear if the safety outcome assessors were blinded in the same manner as the efficacy outcome assessments. There is the potential for diagnostic detection bias for the non‐study visits outlined for this outcome assessor. The AEs seem equal between groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Final analysis did match pre‐specified, published statistical analysis plan. There are multiple possible eligible analyses but those beyond the pre‐specified are reported as post hoc. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The safety outcome in <a href="./references#CD014831-bbs2-0010" title="CTRI 2017/09/009699. Immunosuppresants comparison for UVEITIS [First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13782 (first received 9 November 2017). JabsDA . Antimetabolite therapy for uveitis: methotrexate or mycophenolate?JAMA Ophthalmology2019;137(12):1449‐51. [CENTRAL: CN-02136445] [DOI: 10.1001/jamaophthalmol.2019.3964] [PMID: 31503274]JabsDA . Stratification clarification for methods for randomized clinical trials - reply. JAMA Ophthalmology2020;138(7):801. [DOI: 10.1001/jamaophthalmol.2020.1864] [PMID: 32437500]KellyNK , ChattopadhyayA , RathinamSR , GonzalesJA , ThundikandyR , KanakathA , et al. Health- and vision-related quality of life in a randomized controlled trial comparing methotrexate and mycophenolate mofetil for uveitis. Ophthalmology2021;128(9):1337-45. [CENTRAL: CN-02268128] [DOI: 10.1016/j.ophtha.2021.02.024] [PMID: 33675850]KongCL , KellyNK , SundararajanM , RathinamSR , GonzalesJA , ThundikandyR , et al. Comparison of CD4 counts with mycophenolate mofetil versus methotrexate from the first-line antimetabolites as steroid-sparing treatment (FAST) uveitis trial. Ocular Immunology and Inflammation2020;30(1):1-5. [CENTRAL: CN-02161428] [DOI: 10.1080/09273948.2020.1774906] [PMID: 32779952]NCT01829295. First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial. clinicaltrials.gov/ct2/show/NCT01829295 (first received 11 April 2013). [CENTRAL: CN-01541548] PorcoTC , KimE , AcharyaNR . Stratification clarification for methods for randomized clinical trials. JAMA Ophthalmology2020;138(7):800-1. [DOI: 10.1001/jamaophthalmol.2020.1551] [PMID: 32437493]RathinamSR , GonzalesJA , ThundikandyR , KanakathA , MuruganSB , VedhanayakiR , et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA2019;322(10):936‐45. [CENTRAL: CN-01990886] [DOI: 10.1001/jama.2019.12618] [PMID: 31503307]">Rathinam 2019</a> was judged to be at low risk of bias for 4 out of 5 domains; however, there were some concerns in measurement of the outcome domain which rendered an overall judgement of some concerns of bias. There was judged to be potential for diagnostic detection bias for adverse events, especially subjective adverse events such as dizziness, as patients were not masked to treatment assignment, and it is not clear if safety outcome assessors were blinded in the same way as efficacy outcome assessors. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.10 Proportion of participants experiencing complications or requiring cessation of medication</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references#riskOfBias2Table-5">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-6"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.1 Control of inflammation</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.1.1 IV pulse methylprednisolone for 3 days </b> </p> </td> </tr> <tr class="study-data"> <td> <p>Ono 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomization for all sites performed at single data center and "numbered container method" noted for concealment. There do not appear to be substantial differences between groups at baseline. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Treating clinicians and participants were not masked to treatment. No detailed protocol of acceptable non intervention treatments was provided, however the reported topical steroid use and changes to intervention protocol are reported. Analysis is described as "missing values were treated as missing" for this outcome. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Almost all participants (70 / 72) had outcome data reported.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Validated outcome measurements used for primary outcome and unlikely to differ between groups. Efficacy outcome measurements performed by masked assessors. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No detailed information about prespecified analysis plan. There are multiple possible measures included in the composite outcome. There are multiple possible analyses for each measure to contribute to the final effect measure. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p><a href="./references#CD014831-bbs2-0008" title="JPRN-UMIN000014387. A prospective multicenter comparative clinical trial between corticosteroid pulse therapy vs. combination therapy of oral corticosteroid and cyclosporine on Vogt-Koyanagi-Harada disease. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000014387 (first received 27 June 2014). [CENTRAL: CN-01827271] OnoT , GotoH , SakaiT , NittaF , MizukiN , TakaseH , et al. Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt–Koyanagi–Harada disease. Japanese Journal of Ophthalmology 2021 Oct 24 [Epub ahead of print]. [DOI: 10.1007/s10384-021-00878-w]OnoT , MochizukiM , GotoH , SakaiT , NittaF , MizukiN , et al. A prospective multi-center randomized clinical study comparing steroid-pulse therapy and a combined therapy with oral prednisolone and cyclosporine for new-onset acute Vogt-Koyanagi-Harada disease. Investigative Ophthalmology and Visual Science2020;61(7):3169. [CENTRAL: CN-02179109] [EMBASE: 632697033]">Ono 2021</a> was judged to be at some risk of bias for the efficacy measure. Four out of 5 domains were considered at low risk of bias. There were some concerns in the selection of the reported result, as there was not information included about a prespecified analysis plan and multiple possible measures were included in the composite outcome, introducing the possibility of multiple analyses for each measure contributing to the final effect measure. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.1.2 Azathioprine 2 to 3 mg/kg/day </b> </p> </td> </tr> <tr class="study-data"> <td> <p>Cuchacovich 2010</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants treatment groups randomized with a table of random, computer‐generated numbers. Allocation concealment is not detailed. The authors note that age may be a source of bias. The small study size means differences in baseline characteristics could be due to chance alone. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and intervention providers were not masked. In the AZA group, CsA was added to AZA for 3 participants and 2 participants were switched to other IMTs (cyclophosphamide, mycophenolate) after reactivation. In the CsA arm, 2 participants had AZA added after reactivation. These deviations following reactivation are likely to influence the outcome especially since they are not balanced between groups. Participants are analyzed in the group they were assigned to at randomization. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All participant data appear available.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Inflammatory score, anterior chamber Tyndall and flare, and vitreous haze were measured using published scales. Outcomes were assessed at specific times by an independent ophthalmologist, not passively collected. Measurements unlikely to differ between groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information provided about a pre‐specified statistical analysis plan. The outcome "improvement in inflammation" is a composite of multiple assessments with differing scales and subjectivity. Though are multiple possible combinations for this analysis. There is no evidence the results was selected from multiple measurements or analyses. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The efficacy outcome in <a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a> was judged to have high risk of bias because of concerns with deviations from intended interventions, as patients were allowed to receive additional IMTs, including the experimental medication from the opposite group. There were also some concerns with the randomization process and the selection of the reported result. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.1 Control of inflammation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references#riskOfBias2Table-6">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-7"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.2 Control of inflammation: high‐dose cyclosporine A</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Nussenblatt 1991</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information provided about how patients were randomized with allocation concealed. Baseline demographics are not provided; diagnosis of randomized participants is fairly similar between groups. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The prednisolone was prepared into a liquid solution that had the taste and consistency of the cyclosporine liquid preparation. This made it impossible for the patients to konw which drug they were taking on the basis of physical characteristics of the two preparations.<br/>Patients were observed at monthly intervals by two masked observers. </p> <p>No information provided on whether an intent‐to‐treat analysis was done, but all patients randomized to each group appear to have been analyzed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>28 per group, however only 15 with vitreal haze in Cyclosporine A group and 13 with vitreal haze in the prednisolone group as denominators </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Vitreal haze was measured by two mased observers who had to agree.</p> <p>Observers were masked and had to agree.</p> <p>Assessors were blinded.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information provided about a statistical analysis plan.</p> <p>No evidence of multiple eligible outcome measurements used.</p> <p>No evidence of muliple eligible anlayses of the data.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>[same as 3.1]</p> </td> </tr> <tr class="study-data"> <td> <p>Wiederholt 1986</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col10" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No detailed information is provided about randomization procedure. The allocation sequence was concealed using sealed envelopes that determine randomized treatment group. Baseline differences with so few participants may be due to chance alone. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Modes of therapy delivery differed (liquid versus tablet form). The study is not described as masked or blinded. </p> <p>A detailed protocol is not provided. There are interventions, such as vitrectomy, that may have been deviations or acceptable (e.g. participant 3 had vitrectomy at 3 months). </p> <p>All participants are included in analyses by their assigned group with detailed information.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for all participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All visual acuity measurements were carried out under standardized conditions by a ward doctor who was not involved in the study, and the inflammatory activity of uveitis was determined using a previously introduced scheme by two investigators involved in the study. </p> <p>Outcome assessment for inflammation required two assessors and was scheduled at specific intervals. </p> <p>Outcome assessors for inflammatory activity were not blinded.</p> <p>Somewhat subjective scaling scoring could have been influenced by the knowledge of treatment, but this is not likely as both observers would have had to be influenced similarly. </p> <p>It is not clear that the outcome was influenced.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No information provided about a statistical analysis plan.</p> <p>Definitions of relapse and success not laid out, multiple time points at which a patient could be declared a relapse seem possible. </p> <p>Results of some participants are reported over 12 months and others go to 18 months and a 3 month vs 12 month comparision provided. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>[same as 3.1]</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.2 Control of inflammation: high‐dose cyclosporine A</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references#riskOfBias2Table-7">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-8"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.8 Proportion of participants experiencing complications or requiring cessation of medication</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.8.1 IV pulse methylprednisolone for 3 days</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Ono 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomization for all sites performed at single data center and "numbered container method" noted for concealment. There do not appear to be substantial differences between groups at baseline. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Treating clinicians and participants were not masked to treatment. No detailed protocol of acceptable non intervention treatments was provided, however the reported topical steroid use and changes to intervention protocol are reported. Analysis is described as "missing values were treated as missing" for this outcome. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Almost all participants (70/72) had outcome data reported.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Combination of clinical and participants reported AEs. Possible diagnostic detection bias if passive collection of AE data. Ophthalmologists monitoring safety was not masked. Stopping rules for serious adverse events not described; if the decision to stop treatment because of serious AEs is decided by the unmasked treating ophthalmologist, the outcome is determined by the intervention provider. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No SAP or protocol for comparison to results in report. The results is in line with the Methods section. Lab safety threshold for d/c are reported on fixed scales combined with reported AEs that could be selected. Protocol for assessors' stopping is not described. Comparing to the Methods section, it does not appear that the results was selected. No SAP for comparison. The analyses outlined for labs and reported AEs do not appear to have been selected. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p><a href="./references#CD014831-bbs2-0008" title="JPRN-UMIN000014387. A prospective multicenter comparative clinical trial between corticosteroid pulse therapy vs. combination therapy of oral corticosteroid and cyclosporine on Vogt-Koyanagi-Harada disease. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000014387 (first received 27 June 2014). [CENTRAL: CN-01827271] OnoT , GotoH , SakaiT , NittaF , MizukiN , TakaseH , et al. Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt–Koyanagi–Harada disease. Japanese Journal of Ophthalmology 2021 Oct 24 [Epub ahead of print]. [DOI: 10.1007/s10384-021-00878-w]OnoT , MochizukiM , GotoH , SakaiT , NittaF , MizukiN , et al. A prospective multi-center randomized clinical study comparing steroid-pulse therapy and a combined therapy with oral prednisolone and cyclosporine for new-onset acute Vogt-Koyanagi-Harada disease. Investigative Ophthalmology and Visual Science2020;61(7):3169. [CENTRAL: CN-02179109] [EMBASE: 632697033]">Ono 2021</a> was judged to have some concerns of bias in the safety outcome. Measurement of the outcome and selection of the reported result were both felt to have some risk of bias. Stopping rules for serious AEs were not described, the safety assessor was not blinded, and no statistical analysis plan provided were some of the reasons for this determination. The other domains were judged to be of low risk of bias. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.8.2 Azathioprine 2 to 3 mg/kg/day</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Cuchacovich 2010</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col8" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants treatment groups randomized with a table of random, computer‐generated numbers. Allocation concealment is not detailed. The authors note that age may be a source of bias. The small study size means differences in baseline characteristics could be due to chance alone. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and intervention providers were not masked. In the AZA group, CsA was added to AZA for 3 participants and 2 participants were switched to other IMTs (cyclophosphamide, mycophenolate) after reactivation. In the CsA arm, 2 participants had AZA added after reactivation. These deviations following reactivation are likely to influence the outcome especially since they are not balanced between groups. Participants are analyzed in the group they were assigned to at randomization. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All participant data appear available.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Passive collection of participant reported adverse events could result in diagnostic detection bias. Patients and investigators were not blinded, some adverse events were self‐reported, and criteria for requiring cessation of a medication are not described; therefore the measurement of this outcome could have been influenced by the observers' and/or participants' biases. The outcome reflects decisions made by the intervention provider (treatment termination). </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No pre‐specified statistical analysis plan available for comparison. There is no information about the multiple systematic AEs assessed for the outcome results; discrepency between tables and text regarding neurologic sequelae indicates other AEs may have been assessed. No evidence of results selected from multiple eligible analyses. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p><a href="./references#CD014831-bbs2-0001" title="CuchacovichM , SolanesF , DíazG , CermenatiT , AvilaS , VerdaguerJ , et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease. Ocular Immunology and Inflammation2010;18(3):200‐7. [CENTRAL: CN-00781196] [DOI: 10.3109/09273941003587541]">Cuchacovich 2010</a> was judged to be at high risk of bias for the safety outcome measure, with some concerns arising from the randomization process and selection of the reported result, and a high risk of bias determined for the measurement of outcome and deviations from intended intervention domains. This arose because of lack of blinding, self‐reported safety outcomes, without pre‐specified criteria for requiring cessation of the medication, as well as discrepancies between data reported in text and tables which suggested other AEs may have been assessed. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.8 Proportion of participants experiencing complications or requiring cessation of medication</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014831.pub2/references#riskOfBias2Table-8">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD014831.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD014831-note-0011">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD014831-note-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD014831-note-0009">Français</a> </li> <li class="section-language"> <a class="" href="ko#CD014831-note-0008">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD014831-note-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD014831-note-0006">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014831\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014831\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014831\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014831\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014831\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014831\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014831\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014831\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014831\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014831\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014831\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014831\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014831\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014831\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014831\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014831\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014831\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014831\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PMzGcYGP&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014831.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD014831.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD014831.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD014831.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014831.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719194030"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD014831.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719194034"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD014831.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918de2cabe139368',t:'MTc0MDcxOTE5NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 